

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
20 March 2003 (20.03.2003)(10) International Publication Number
WO 03/022222 A2(51) International Patent Classification⁷:

A61K

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.

(21) International Application Number: PCT/US02/28870

(22) International Filing Date:

11 September 2002 (11.09.2002)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

09/953,611 13 September 2001 (13.09.2001) US

(71) Applicant: ISIS PHARMACEUTICALS, INC.
[US/US]; 2292 Faraday Avenue, Carlsbad, CA 92008 (US).

(72) Inventors: WARD, Donna, T.; 41349 Magnolia Street, Murrieta, CA 92562 (US). WATT, Andrew, T.; 1500 Shadowridge Drive, Apartment 154, Vista, CA 92083 (US).

(74) Agents: LICATA, Jane, Massey et al.; Licata & Tyrel P.C., 66 E. Main Street, Marlton, NJ 08053 (US).

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CI, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 03/022222 A2

(54) Title: ANTISENSE MODULATION OF PROTEIN KINASE R EXPRESSION

(57) Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Protein Kinase R. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Protein Kinase R. Methods of using these compounds for modulation of Protein Kinase R expression and for treatment of diseases associated with expression of Protein Kinase R are provided.

5

ANTISENSE MODULATION OF PROTEIN KINASE R EXPRESSION**FIELD OF THE INVENTION**

10 The present invention provides compositions and methods for modulating the expression of Protein Kinase R. In particular, this invention relates to compounds, particularly oligonucleotides, specifically hybridizable with nucleic acids encoding Protein Kinase R. Such compounds have been shown to
15 modulate the expression of Protein Kinase R.

BACKGROUND OF THE INVENTION

In the family of extracellular cytokines, interferons are glycoprotein signaling molecules that are secreted in response
20 to viral infection. Interferon synthesis is induced by the presence of RNA with double stranded character, which is a common intermediate in the replication of many viruses. Interferons bind to cell-surface receptors and stimulate an antiviral, antiproliferative, immunomodulatory response in host
25 cells by inhibiting the replication of both RNA and DNA viruses and by activating the transcription of more than three-hundred interferon-stimulated genes (de Veer et al., *J. Leukoc. Biol.*, 2001, 69, 912-920).

30 Interferon induces the synthesis of antiviral 2'5'-oligoadenylate synthetases, enzymes that catalyze the production of an unusual nucleotide compound, pppA(2',5'A)_n. These 2',5'-oligoadenylates then bind and activate a latent ribonuclease, RNase L, which degrades viral and cellular mRNA and ribosomal RNA, thereby halting protein synthesis (de Veer et al., *J. Leukoc. Biol.*, 2001, 69, 912-920).

35 Serving to prevent viral replication and infection, or to silence transposon hopping in the germline, is a natural biological process called double-stranded RNA-induced gene silencing, or RNA interference (RNAi). RNAi is a process in

-2-

which double-stranded RNA (dsRNA) corresponding to the sense and antisense sequence of an endogenous mRNA is introduced into a cell, and the cognate mRNA is degraded and the gene silenced (Bass, *Cell*, 2000, 101, 235-238; Montgomery and Fire, *Trends Genet.*, 1998, 14, 255-258).

Interferons also induce the production of a serine/threonine kinase, Protein Kinase R (also known as PKR, PRKR, interferon-induced double-stranded RNA-activated p68 kinase, DAI, dsI, and P1/eIF2 α protein kinase). Protein kinase R plays an important role in the anti-viral response mediated by interferons, and is activated following infection by influenza virus, adenovirus, hepatitis C virus, and human immunoodeficiency virus type 1 (HIV-1) (Balachandran et al., *Embo J.*, 1998, 17, 6888-6902).

In the presence of double-stranded RNA (dsRNA), Protein Kinase R autophosphorylates, which activates its enzymatic activity, and Protein Kinase R then catalyzes phosphorylation of its substrates. Substrates for Protein Kinase R include the alpha subunit of eukaryotic protein synthesis initiation factor 2 (eIF-2 α), nuclear factor-kappa B (NF- κ B), and B56 α (the regulatory subunit of human protein phosphatase 2A). These substrates act in two separate dsRNA-triggered antiviral programs involving the production of antiviral interferons and other alarmone cytokines and the expression of antiapoptotic genes (Iordanov et al., *Mol. Cell. Biol.*, 2001, 21, 61-72; Xu and Williams, *Mol. Cell. Biol.*, 2000, 20, 5285-5299).

The phosphorylation of eIF-2 α inhibits the factor at the initiation stage of translation. Because eIF-2 α regulates protein synthesis in interferon-treated and virus-infected cells, Protein Kinase R is a central component of the interferon-induced antiviral response, and may play an important role in the control of cell growth and differentiation in uninfected cells (Kuhen et al., *Gene*, 1996, 178, 191-193).

Protein kinase R was first isolated as lambda phage and P1 phage clones from a human genomic library (Kuhen et al., *Gene*, 1996, 178, 191-193) and the organization of the regulatory and catalytic subdomains of the human and mouse gene products was found to be remarkably conserved (Kuhen et al., *Genomics*, 1996,

-3-

36, 197-201). By fluorescence *in situ* hybridization, the human Protein Kinase R gene was localized to the 2p21 chromosomal locus, and the mouse gene was mapped to chromosome 17 (band E2) (Barber et al., *Genomics*, 1993, 16, 765-767). Clusters of 5 nonrandom breakpoints, translocations, and other alterations near the 2p21 region of the human chromosome are associated with lipomas, large cell lymphomas, immunoblastic lymphomas, T cell leukemias, myelodysplastic syndrome, primary congenital glaucoma, and acute myeloid leukemia (Barber et al., *Genomics*, 10 1993, 16, 765-767; Sarfarazi et al., *Genomics*, 1995, 30, 171-177).

Homodimerization is required to activate Protein Kinase R, and heterodimerization between Protein Kinase R and other dsRNA-binding proteins can inhibit its kinase activity. One dsRNA-15 binding protein, p74, interacts with both Protein Kinase R and with a catalytically defective mutant of Protein Kinase R, and modulates cell growth (Coolidge and Patton, *Nucleic Acids Res.*, 2000, 28, 1407-1417).

In hepatitis C virus infections, most viral isolates are 20 resistant to treatment with interferon, and the virus is believed to have mechanisms of circumventing the antiviral effect of interferon. One such mechanism involves the hepatitis C virus envelope protein, E2, which bears a sequence identical to phosphorylation sites in Protein Kinase R and in the Protein 25 Kinase R target, eIF-2 α . The viral E2 protein inhibits Protein Kinase R activity and blocks its inhibitory effect on protein synthesis and cell growth (Taylor et al., *Science*, 1999, 285, 107-110).

Another potential outcome of Protein Kinase R inhibition by 30 hepatitis C viral protein E2 is the promotion of cell growth, which may contribute to the development of hepatitis C virus-associated hepatocellular carcinoma (He et al., *J. Virol.*, 2001, 75, 5090-5098).

Protein kinase R has also been proposed to play a role in 35 the induction of cell death. Apoptosis, or programmed cell death, occurs in response to cellular stresses such as growth factor deprivation, UV light, inflammatory cytokine production, and viral infection. Apoptosis is also induced in murine 3T3 L1 cells by overexpression of wild type Protein Kinase R when

-4-

treated with dsRNA. Conversely, overexpression of a catalytically inactive dominant-negative mutant Protein Kinase R causes malignant transformation and resistance to apoptosis, indicating the importance of this kinase in regulation of 5 cellular proliferation (Balachandran et al., *Embo J.*, 1998, 17, 6888-6902).

Mice with a targeted deletion in the Protein Kinase R gene develop normally with no phenotypic defects, but have an impaired antiviral response upon dsRNA or interferon treatment, 10 and murine embryonic fibroblasts (MEFs) derived from these Protein Kinase R null mice are less sensitive to apoptotic stimuli than MEFs obtained from isogenic normal mice (Der et al., *Proc. Natl. Acad. Sci. U. S. A.*, 1997, 94, 3279-3283). These mice are also more susceptible to infection by influenza 15 virus, which may result from a failure to halt protein synthesis and an increase in viral replication, from a reduction of apoptosis (allowing the virus to replicate to higher levels during infection), or from a defect in Protein Kinase R-mediated stimulation of the immune system (de Veer et al., *J. Leukoc. Biol.*, 2001, 69, 912-920).

The pharmacological modulation of Protein Kinase R activity and/or expression is therefore believed to be an appropriate point of therapeutic intervention in viral infections, in pathological conditions such as cancer, in diseases affected by 25 the misregulation of apoptotic pathways, as well as a target for the functional elucidation and/or the regulation of alternate RNA processing mechanisms such as RNAi.

Antisense-mediated inhibition of Protein Kinase R has been utilized as a tool to elucidate mechanisms of the interferon 30 signal transduction pathway. The vaccinia virus has been used to infect cultured African green monkey kidney (BSC-40) cells, causing induction of the expression of an antisense mRNA transcript of Protein Kinase R, demonstrating that Protein Kinase R potently inhibits protein synthesis (Lee et al., *Virology*, 1993, 192, 380-385). Similarly, an eukaryotic 35 expression vector was used to stably transform U-937 cells and inhibit expression of Protein Kinase R with antisense mRNA transcripts of the cDNA (Der and Lau, *Proc. Natl. Acad. Sci. U. S. A.*, 1995, 92, 8841-8845).

Disclosed and claimed in PCT Publication WO 97/08292 are methods for production of viral vaccines comprising infection of a cell culture deficient in Protein Kinase R activity, wherein said cells are obtained by transfection with or culturing cells 5 in the presence of a Protein Kinase R antisense polynucleotide (Lau, 1997).

An antisense oligonucleotide, 19 nucleotides in length, was used to show that Protein Kinase R has an essential role in mediating the induction of apoptosis by tumor necrosis factor 10 (TNF) (Yeung et al., *Proc. Natl. Acad. Sci. U. S. A.*, 1996, 93, 12451-12455).

A phosphorothioate antisense oligonucleotide, 18 nucleotides in length, complementary to the 5' end of the mRNA transcript, was used to show that inhibition of expression of 15 Protein Kinase R blocked the induction of several immediate early genes (Mundschau and Faller, *J. Biol. Chem.*, 1995, 270, 3100-3106).

Because Protein Kinase R is activated by dsRNA, chimeric antisense oligonucleotides have been designed based on the 20 binding site for 2',5'-oligoadenylates, 55-73 nucleotides down from the start codon of the Protein Kinase R mRNA (Cramer et al., *Bioorg. Med. Chem. Lett.*, 1999, 9, 1049-1054; Deb et al., *J. Immunol.*, 2001, 166, 6170-6180; Maitra et al., *J. Biol. Chem.*, 1995, 270, 15071-15075; Maran et al., *Science*, 1994, 265, 25 789-792; Xiao et al., *J. Med. Chem.*, 1997, 40, 1195-1200; Xiao et al., *J. Med. Chem.*, 1998, 41, 1531-1539). For example, the chimeric antisense oligonucleotide 5'-S_p(A2'_p), A-linker-GTACTACTCCCTGCTTCTG-3'-3' tail(dC)-5' was used to show that 30 Protein Kinase R is required for interferon gamma signaling to NF-κB (Deb et al., *J. Immunol.*, 2001, 166, 6170-6180).

Disclosed and claimed in US Patent 5,677,289 is an improvement in a method wherein an antisense oligonucleotide complementary to a target strand of mRNA is administered to a mammal, wherein the mammal is human, to reduce or inhibit the 35 activity of the mRNA, the improvement comprising attaching an activator of ribonuclease L to an oligonucleotide, wherein the activator is an antisense oligonucleotide complementary to the Protein Kinase R mRNA (Torrence et al., 1997).

Disclosed and claimed in US Patent 5,837,503 is a

-6-

recombinant vector containing a cassette for transcription by RNA polymerase III, into which an oligonucleotide has been inserted, and used as a medicinal product. In one embodiment of the invention, the inserted oligonucleotide includes nucleotides 5 encoding an antisense molecule that inhibits Protein Kinase R (Doglio et al., 1998).

However, these strategies are untested as therapeutic protocols, and currently, there are no known therapeutic agents which effectively inhibit the synthesis of Protein Kinase R. 10 Consequently, the need for additional agents capable of effectively inhibiting Protein Kinase R function remains.

Antisense technology is emerging as an effective means for reducing the expression of specific gene products and may therefore prove to be uniquely useful in a number of 15 therapeutic, diagnostic, and research applications for the modulation of Protein Kinase R expression.

The present invention provides compositions and methods for modulating Protein Kinase R expression.

20 SUMMARY OF THE INVENTION

The present invention is directed to compounds, particularly antisense oligonucleotides, which are targeted to a nucleic acid encoding Protein Kinase R, and which modulate the expression of Protein Kinase R. Pharmaceutical and other 25 compositions comprising the compounds of the invention are also provided. Further provided are methods of modulating the expression of Protein Kinase R in cells or tissues comprising contacting said cells or tissues with one or more of the antisense compounds or compositions of the invention. Further 30 provided are methods of treating an animal, particularly a human, suspected of having or being prone to a disease or condition associated with expression of Protein Kinase R by administering a therapeutically or prophylactically effective amount of one or more of the antisense compounds or compositions 35 of the invention.

DETAILED DESCRIPTION OF THE INVENTION

The present invention employs oligomeric compounds, particularly antisense oligonucleotides, for use in modulating

the function of nucleic acid molecules encoding Protein Kinase R, ultimately modulating the amount of Protein Kinase R produced. This is accomplished by providing antisense compounds which specifically hybridize with one or more nucleic acids 5 encoding Protein Kinase R. As used herein, the terms "target nucleic acid" and "nucleic acid encoding Protein Kinase R" encompass DNA encoding Protein Kinase R, RNA (including pre-mRNA and mRNA) transcribed from such DNA, and also cDNA derived from such RNA. The specific hybridization of an oligomeric compound 10 with its target nucleic acid interferes with the normal function of the nucleic acid. This modulation of function of a target nucleic acid by compounds which specifically hybridize to it is generally referred to as "antisense". The functions of DNA to be interfered with include replication and transcription. The 15 functions of RNA to be interfered with include all vital functions such as, for example, translocation of the RNA to the site of protein translation, translation of protein from the RNA, splicing of the RNA to yield one or more mRNA species, and catalytic activity which may be engaged in or facilitated by the 20 RNA. The overall effect of such interference with target nucleic acid function is modulation of the expression of Protein Kinase R. In the context of the present invention, "modulation" means either an increase (stimulation) or a decrease (inhibition) in the expression of a gene. In the context of the 25 present invention, inhibition is the preferred form of modulation of gene expression and mRNA is a preferred target.

It is preferred to target specific nucleic acids for antisense. "Targeting" an antisense compound to a particular nucleic acid, in the context of this invention, is a multistep 30 process. The process usually begins with the identification of a nucleic acid sequence whose function is to be modulated. This may be, for example, a cellular gene (or mRNA transcribed from the gene) whose expression is associated with a particular disorder or disease state, or a nucleic acid molecule from an 35 infectious agent. In the present invention, the target is a nucleic acid molecule encoding Protein Kinase R. The targeting process also includes determination of a site or sites within this gene for the antisense interaction to occur such that the desired effect, e.g., detection or modulation of expression of

-8-

the protein, will result. Within the context of the present invention, a preferred intragenic site is the region encompassing the translation initiation or termination codon of the open reading frame (ORF) of the gene. Since, as is known in the art, the translation initiation codon is typically 5'-AUG (in transcribed mRNA molecules; 5'-ATG in the corresponding DNA molecule), the translation initiation codon is also referred to as the "AUG codon," the "start codon" or the "AUG start codon". A minority of genes have a translation initiation codon having the RNA sequence 5'-GUG, 5'-UUG or 5'-CUG, and 5'-AUA, 5'-ACG and 5'-CUG have been shown to function in vivo. Thus, the terms "translation initiation codon" and "start codon" can encompass many codon sequences, even though the initiator amino acid in each instance is typically methionine (in eukaryotes) or formylmethionine (in prokaryotes). It is also known in the art that eukaryotic and prokaryotic genes may have two or more alternative start codons, any one of which may be preferentially utilized for translation initiation in a particular cell type or tissue, or under a particular set of conditions. In the context of the invention, "start codon" and "translation initiation codon" refer to the codon or codons that are used in vivo to initiate translation of an mRNA molecule transcribed from a gene encoding Protein Kinase R, regardless of the sequence(s) of such codons.

It is also known in the art that a translation termination codon (or "stop codon") of a gene may have one of three sequences, i.e., 5'-UAA, 5'-UAG and 5'-UGA (the corresponding DNA sequences are 5'-TAA, 5'-TAG and 5'-TGA, respectively). The terms "start codon region" and "translation initiation codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation initiation codon. Similarly, the terms "stop codon region" and "translation termination codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation termination codon.

The open reading frame (ORF) or "coding region," which is known in the art to refer to the region between the translation

initiation codon and the translation termination codon, is also a region which may be targeted effectively. Other target regions include the 5' untranslated region (5'UTR), known in the art to refer to the portion of an mRNA in the 5' direction from the translation initiation codon, and thus including nucleotides between the 5' cap site and the translation initiation codon of an mRNA or corresponding nucleotides on the gene, and the 3' untranslated region (3'UTR), known in the art to refer to the portion of an mRNA in the 3' direction from the translation termination codon, and thus including nucleotides between the translation termination codon and 3' end of an mRNA or corresponding nucleotides on the gene. The 5' cap of an mRNA comprises an N7-methylated guanosine residue joined to the 5'-most residue of the mRNA via a 5'-5' triphosphate linkage. The 5' cap region of an mRNA is considered to include the 5' cap structure itself as well as the first 50 nucleotides adjacent to the cap. The 5' cap region may also be a preferred target region.

Although some eukaryotic mRNA transcripts are directly translated, many contain one or more regions, known as "introns," which are excised from a transcript before it is translated. The remaining (and therefore translated) regions are known as "exons" and are spliced together to form a continuous mRNA sequence. mRNA splice sites, i.e., intron-exon junctions, may also be preferred target regions, and are particularly useful in situations where aberrant splicing is implicated in disease, or where an overproduction of a particular mRNA splice product is implicated in disease. Aberrant fusion junctions due to rearrangements or deletions are also preferred targets. It has also been found that introns can also be effective, and therefore preferred, target regions for antisense compounds targeted, for example, to DNA or pre-mRNA.

Once one or more target sites have been identified, oligonucleotides are chosen which are sufficiently complementary to the target, i.e., hybridize sufficiently well and with sufficient specificity, to give the desired effect.

In the context of this invention, "hybridization" means hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary

-10-

nucleoside or nucleotide bases. For example, adenine and thymine are complementary nucleobases which pair through the formation of hydrogen bonds. "Complementary," as used herein, refers to the capacity for precise pairing between two nucleotides. For example, if a nucleotide at a certain position of an oligonucleotide is capable of hydrogen bonding with a nucleotide at the same position of a DNA or RNA molecule, then the oligonucleotide and the DNA or RNA are considered to be complementary to each other at that position. The oligonucleotide and the DNA or RNA are complementary to each other when a sufficient number of corresponding positions in each molecule are occupied by nucleotides which can hydrogen bond with each other. Thus, "specifically hybridizable" and "complementary" are terms which are used to indicate a sufficient degree of complementarity or precise pairing such that stable and specific binding occurs between the oligonucleotide and the DNA or RNA target. It is understood in the art that the sequence of an antisense compound need not be 100% complementary to that of its target nucleic acid to be specifically hybridizable. An antisense compound is specifically hybridizable when binding of the compound to the target DNA or RNA molecule interferes with the normal function of the target DNA or RNA to cause a loss of utility, and there is a sufficient degree of complementarity to avoid non-specific binding of the antisense compound to non-target sequences under conditions in which specific binding is desired, i.e., under physiological conditions in the case of in vivo assays or therapeutic treatment, and in the case of in vitro assays, under conditions in which the assays are performed.

Antisense and other compounds of the invention which hybridize to the target and inhibit expression of the target are identified through experimentation, and the sequences of these compounds are hereinbelow identified as preferred embodiments of the invention. The target sites to which these preferred sequences are complementary are hereinbelow referred to as "active sites" and are therefore preferred sites for targeting. Therefore another embodiment of the invention encompasses compounds which hybridize to these active sites.

Antisense compounds are commonly used as research reagents

-11-

and diagnostics. For example, antisense oligonucleotides, which are able to inhibit gene expression with exquisite specificity, are often used by those of ordinary skill to elucidate the function of particular genes. Antisense compounds are also 5 used, for example, to distinguish between functions of various members of a biological pathway. Antisense modulation has, therefore, been harnessed for research use.

For use in kits and diagnostics, the antisense compounds of the present invention, either alone or in combination with other 10 antisense compounds or therapeutics, can be used as tools in differential and/or combinatorial analyses to elucidate expression patterns of a portion or the entire complement of genes expressed within cells and tissues.

Expression patterns within cells or tissues treated with 15 one or more antisense compounds are compared to control cells or tissues not treated with antisense compounds and the patterns produced are analyzed for differential levels of gene expression as they pertain, for example, to disease association, signaling pathway, cellular localization, expression level, size, 20 structure or function of the genes examined. These analyses can be performed on stimulated or unstimulated cells and in the presence or absence of other compounds which affect expression patterns.

Examples of methods of gene expression analysis known in 25 the art include DNA arrays or microarrays (Brazma and Vilo, *FEBS Lett.*, 2000, 480, 17-24; Celis, et al., *FEBS Lett.*, 2000, 480, 2-16), SAGE (serial analysis of gene expression) (Madden, et al., *Drug Discov. Today*, 2000, 5, 415-425), READS (restriction enzyme 30 amplification of digested cDNAs) (Prashar and Weissman, *Methods Enzymol.*, 1999, 303, 258-72), TOGA (total gene expression analysis) (Sutcliffe, et al., *Proc. Natl. Acad. Sci. U. S. A.*, 2000, 97, 1976-81), protein arrays and proteomics (Celis, et al., *FEBS Lett.*, 2000, 480, 2-16; Jungblut, et al., *Electrophoresis*, 1999, 20, 2100-10), expressed sequence tag 35 (EST) sequencing (Celis, et al., *FEBS Lett.*, 2000, 480, 2-16; Larsson, et al., *J. Biotechnol.*, 2000, 80, 143-57), subtractive RNA fingerprinting (SuRF) (Fuchs, et al., *Anal. Biochem.*, 2000, 286, 91-98; Larson, et al., *Cytometry*, 2000, 41, 203-208), subtractive cloning, differential display (DD) (Jurecic and

-12-

Belmont, *Curr. Opin. Microbiol.*, 2000, 3, 316-21), comparative genomic hybridization (Carulli, et al., *J. Cell Biochem. Suppl.*, 1998, 31, 286-96), FISH (fluorescent in situ hybridization) techniques (Going and Gusterson, *Eur. J. Cancer*, 1999, 35, 1895-904) and mass spectrometry methods (reviewed in (To, *Comb. Chem. High Throughput Screen*, 2000, 3, 235-41).

The specificity and sensitivity of antisense is also harnessed by those of skill in the art for therapeutic uses. Antisense oligonucleotides have been employed as therapeutic 10 moieties in the treatment of disease states in animals and man. Antisense oligonucleotide drugs, including ribozymes, have been safely and effectively administered to humans and numerous clinical trials are presently underway. It is thus established 15 that oligonucleotides can be useful therapeutic modalities that can be configured to be useful in treatment regimes for treatment of cells, tissues and animals, especially humans.

In the context of this invention, the term "oligonucleotide" refers to an oligomer or polymer of 20 ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or mimetics thereof. This term includes oligonucleotides composed of naturally-occurring nucleobases, sugars and covalent internucleoside (backbone) linkages as well as oligonucleotides having non-naturally-occurring portions which function 25 similarly. Such modified or substituted oligonucleotides are often preferred over native forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for nucleic acid target and increased stability in the presence of nucleases.

While antisense oligonucleotides are a preferred form of 30 antisense compound, the present invention comprehends other oligomeric antisense compounds, including but not limited to oligonucleotide mimetics such as are described below. The antisense compounds in accordance with this invention preferably comprise from about 8 to about 50 nucleobases (i.e. from about 8 35 to about 50 linked nucleosides). Particularly preferred antisense compounds are antisense oligonucleotides, even more preferably those comprising from about 12 to about 30 nucleobases. Antisense compounds include ribozymes, external guide sequence (EGS) oligonucleotides (oligozymes), and other

-13-

short catalytic RNAs or catalytic oligonucleotides which hybridize to the target nucleic acid and modulate its expression.

As is known in the art, a nucleoside is a base-sugar combination. The base portion of the nucleoside is normally a heterocyclic base. The two most common classes of such heterocyclic bases are the purines and the pyrimidines. Nucleotides are nucleosides that further include a phosphate group covalently linked to the sugar portion of the nucleoside. For those nucleosides that include a pentofuranosyl sugar, the phosphate group can be linked to either the 2', 3' or 5' hydroxyl moiety of the sugar. In forming oligonucleotides, the phosphate groups covalently link adjacent nucleosides to one another to form a linear polymeric compound. In turn the respective ends of this linear polymeric structure can be further joined to form a circular structure, however, open linear structures are generally preferred. Within the oligonucleotide structure, the phosphate groups are commonly referred to as forming the internucleoside backbone of the oligonucleotide. The normal linkage or backbone of RNA and DNA is a 3' to 5' phosphodiester linkage.

Specific examples of preferred antisense compounds useful in this invention include oligonucleotides containing modified backbones or non-natural internucleoside linkages. As defined in this specification, oligonucleotides having modified backbones include those that retain a phosphorus atom in the backbone and those that do not have a phosphorus atom in the backbone. For the purposes of this specification, and as sometimes referenced in the art, modified oligonucleotides that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides.

Preferred modified oligonucleotide backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates, 5'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, selenophosphates and

-14-

boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein one or more internucleotide linkages is a 3' to 3', 5' to 5' or 2' to 2' linkage. Preferred oligonucleotides having inverted

5 polarity comprise a single 3' to 3' linkage at the 3'-most internucleotide linkage i.e. a single inverted nucleoside residue which may be abasic (the nucleobase is missing or has a hydroxyl group in place thereof). Various salts, mixed salts and free acid forms are also included.

10 Representative United States patents that teach the preparation of the above phosphorus-containing linkages include, but are not limited to, U.S.: 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 15 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; 5,194,599; 5,565,555; 5,527,899; 5,721,218; 5,672,697 and 5,625,050, certain of which are commonly owned with this application, and each of which is herein incorporated by 20 reference.

Preferred modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; 25 methylene formacetyl and thioformacetyl backbones; riboacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH₂ component parts.

30

35 Representative United States patents that teach the preparation of the above oligonucleosides include, but are not limited to, U.S.: 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307;

-15-

5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240;
5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312;
5,633,360; 5,677,437; 5,792,608; 5,646,269 and 5,677,439,
certain of which are commonly owned with this application, and
5 each of which is herein incorporated by reference.

In other preferred oligonucleotide mimetics, both the sugar and the internucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups. The base units are maintained for hybridization with an appropriate nucleic acid target compound. One such oligomeric compound, an oligonucleotide mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar-backbone of an oligonucleotide is replaced with an amide containing backbone, in particular an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone.

Representative United States patents that teach the preparation of PNA compounds include, but are not limited to, U.S.:
20 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference. Further teaching of PNA compounds can be found in Nielsen et al., *Science*, 1991, 254, 1497-1500.

Most preferred embodiments of the invention are oligonucleotides with phosphorothioate backbones and 25 oligonucleosides with heteroatom backbones, and in particular -CH₂-NH-O-CH₂-, -CH₂-N(CH₃)-O-CH₂- [known as a methylene (methylimino) or MMI backbone], -CH₂-O-N(CH₃)-CH₂-, -CH₂-N(CH₃)-N(CH₃)-CH₂- and -O-N(CH₃)-CH₂-CH₂- [wherein the native phosphodiester backbone is represented as -O-P-O-CH₂-] of the 30 above referenced U.S. patent 5,489,677, and the amide backbones of the above referenced U.S. patent 5,602,240. Also preferred are oligonucleotides having morpholino backbone structures of the above-referenced U.S. patent 5,034,506.

Modified oligonucleotides may also contain one or more 35 substituted sugar moieties. Preferred oligonucleotides comprise one of the following at the 2' position: OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted C₁ to C₁₀ alkyl or C₂ to C₁₀ alkenyl and alkynyl.

-16-

Particularly preferred are $O[(CH_2)_nO]_mCH_3$, $O(CH_2)_nOCH_3$, $O(CH_2)_nNH_2$, $O(CH_2)_nCH_3$, $O(CH_2)_nONH_2$, and $O(CH_2)_nON[(CH_2)_nCH_3]_2$, where n and m are from 1 to about 10. Other preferred oligonucleotides comprise one of the following at the 2' position: C₁ to C₁₀ lower alkyl, 5 substituted lower alkyl, alkenyl, alkynyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH₃, OCN, Cl, Br, CN, CF₃, OCF₃, SOCH₃, SO₂CH₃, NO₂, N₃, NH₂, heterocycloalkyl, heterocycloalkaryl, 10 aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties. A preferred modification includes 2'-methoxyethoxy (2'-O-CH₂CH₂OCH₃, also known as 2'-O-(2-methoxyethyl) or 2'-MOE) 15 (Martin et al., *Helv. Chim. Acta*, 1995, 78, 486-504) i.e., an alkoxyalkoxy group. A further preferred modification includes 2'-dimethylaminoxyethoxy, i.e., a $O(CH_2)_2ON(CH_3)_2$ group, also known as 2'-DMAOE, as described in examples hereinbelow, and 2'-dimethylaminoethoxyethoxy (also known in the art as 2'-O- 20 dimethylaminoethoxyethyl or 2'-DMAEOE), i.e., 2'-O-CH₂-O-CH₂-N(CH₃)₂, also described in examples hereinbelow.

A further preferred modification includes Locked Nucleic Acids (LNAs) in which the 2'-hydroxyl group is linked to the 3' or 4' carbon atom of the sugar ring thereby forming a bicyclic 25 sugar moiety. The linkage is preferably a methylene (-CH₂-) group bridging the 2' oxygen atom and the 4' carbon atom wherein n is 1 or 2. LNAs and preparation thereof are described in WO 98/39352 and WO 99/14226.

Other preferred modifications include 2'-methoxy (2'-O-CH₃), 30 2'-aminopropoxy (2'-OCH₂CH₂CH₂NH₂), 2'-allyl (2'-CH₂-CH=CH₂), 2'-O-allyl (2'-O-CH₂-CH=CH₂) and 2'-fluoro (2'-F). The 2' modification may be in the arabino (up) position or ribo (down) position. A preferred 2'-arabino modification is 2'-F. Similar modifications may also be made at other positions on the 35 oligonucleotide, particularly the 3' position of the sugar on the 3' terminal nucleotide or in 2'-5' linked oligonucleotides and the 5' position of 5' terminal nucleotide. Oligonucleotides may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. Representative United States

-17-

patents that teach the preparation of such modified sugar structures include, but are not limited to, U.S.: 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; 5,792,747; and 5,700,920, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference in its entirety.

10 Oligonucleotides may also include nucleobase (often referred to in the art simply as "base") modifications or substitutions. As used herein, "unmodified" or "natural" nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and 15 uracil (U). Modified nucleobases include other synthetic and natural nucleobases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl (-C≡C-CH₃) uracil and cytosine and other alkynyl derivatives of pyrimidine bases, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted 20 adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 2-F-adenine, 2-amino-adenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine. Further 25 modified nucleobases include tricyclic pyrimidines such as phenoxazine cytidine (1H-pyrimido[5,4-b][1,4]benzoxazin-2(3H)-one), phenothiazine cytidine (1H-pyrimido[5,4-b][1,4]benzothiazin-2(3H)-one), G-clamps such as a substituted phenoxazine cytidine (e.g. 9-(2-aminoethoxy)-H-pyrimido[5,4-b][1,4]benzoxazin-2(3H)-one), carbazole cytidine (2H-pyrimido[4,5-b]indol-2-one), pyridoindole cytidine (H-pyrido[3',2':4,5]pyrrolo[2,3-d]pyrimidin-2-one). Modified nucleobases may also include those in which the purine or pyrimidine base is replaced with other heterocycles, for example 30 35

-18-

7-deaza-adenine, 7-deazaguanosine, 2-aminopyridine and 2-pyridone. Further nucleobases include those disclosed in United States Patent No. 3,687,808, those disclosed in *The Concise Encyclopedia Of Polymer Science And Engineering*, pages 858-859, 5 Kroschwitz, J.I., ed. John Wiley & Sons, 1990, those disclosed by Englisch et al., *Angewandte Chemie*, International Edition, 1991, 30, 613, and those disclosed by Sanghvi, Y.S., Chapter 15, *Antisense Research and Applications*, pages 289-302, Crooke, S.T. and Lebleu, B., ed., CRC Press, 1993. Certain of these 10 nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds of the invention. These include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine 15 substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2°C (Sanghvi, Y.S., Crooke, S.T. and Lebleu, B., eds., *Antisense Research and Applications*, CRC Press, Boca Raton, 1993, pp. 276-278) and are presently preferred base 20 substitutions, even more particularly when combined with 2'-O-methoxyethyl sugar modifications.

Representative United States patents that teach the preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include, but are not limited to, the above noted U.S. 3,687,808, as well as U.S.: 25 4,845,205; 5,130,302; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121; 5,596,091; 5,614,617; 5,645,985; 5,830,653; 5,763,588; 6,005,096; and 30 5,681,941, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference, and United States patent 5,750,692, which is commonly owned with the instant application and also herein incorporated by reference.

Another modification of the oligonucleotides of the 35 invention involves chemically linking to the oligonucleotide one or more moieties or conjugates which enhance the activity, cellular distribution or cellular uptake of the oligonucleotide. The compounds of the invention can include conjugate groups covalently bound to functional groups such as primary or

secondary hydroxyl groups. Conjugate groups of the invention include intercalators, reporter molecules, polyamines, polyamides, polyethylene glycols, polyethers, groups that enhance the pharmacodynamic properties of oligomers, and groups that enhance the pharmacokinetic properties of oligomers.

5 Typical conjugates groups include cholesterol, lipids, phospholipids, biotin, phenazine, folate, phenanthridine, anthraquinone, acridine, fluoresceins, rhodamines, coumarins, and dyes. Groups that enhance the pharmacodynamic properties, in 10 the context of this invention, include groups that improve oligomer uptake, enhance oligomer resistance to degradation, and/or strengthen sequence-specific hybridization with RNA. Groups that enhance the pharmacokinetic properties, in the 15 context of this invention, include groups that improve oligomer uptake, distribution, metabolism or excretion. Representative conjugate groups are disclosed in International Patent Application PCT/US92/09196, filed October 23, 1992 the entire disclosure of which is incorporated herein by reference.

Conjugate moieties include but are not limited to lipid moieties 20 such as a cholesterol moiety (Letsinger et al., *Proc. Natl. Acad. Sci. USA*, 1989, 86, 6553-6556), cholic acid (Manoharan et al., *Bioorg. Med. Chem. Lett.*, 1994, 4, 1053-1060), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., *Ann. N.Y. Acad. Sci.*, 1992, 660, 306-309; Manoharan et al., *Bioorg. Med. Chem. Lett.*, 1993, 3, 2765-2770), a thiocholesterol (Oberhauser et al., *Nucl. Acids Res.*, 1992, 20, 533-538), an aliphatic chain, e.g., 25 dodecandiol or undecyl residues (Saison-Behmoaras et al., *EMBO J.*, 1991, 10, 1111-1118; Kabanov et al., *FEBS Lett.*, 1990, 259, 327-330; Svinarchuk et al., *Biochimie*, 1993, 75, 49-54), a 30 phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., *Tetrahedron Lett.*, 1995, 36, 3651-3654; Shea et al., *Nucl. Acids Res.*, 1990, 18, 3777-3783), a polyamine or a 35 polyethylene glycol chain (Manoharan et al., *Nucleosides & Nucleotides*, 1995, 14, 969-973), or adamantane acetic acid (Manoharan et al., *Tetrahedron Lett.*, 1995, 36, 3651-3654), a palmityl moiety (Mishra et al., *Biochim. Biophys. Acta*, 1995, 1264, 229-237), or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke et al., *J. Pharmacol. Exp. Ther.*,

-20-

1996, 277, 923-937. Oligonucleotides of the invention may also be conjugated to active drug substances, for example, aspirin, warfarin, phenylbutazone, ibuprofen, suprofen, fensufen, ketoprofen, (S)-(+)-pranoprofen, carprofen, dansylsarcosine, 5 2,3,5-triiodobenzoic acid, flufenamic acid, folinic acid, a benzothiadiazide, chlorothiazide, a diazepine, indomethacin, a barbiturate, a cephalosporin, a sulfa drug, an antidiabetic, an antibacterial or an antibiotic. Oligonucleotide-drug conjugates and their preparation are described in United States Patent 10 Application 09/334,130 (filed June 15, 1999) which is incorporated herein by reference in its entirety.

Representative United States patents that teach the preparation of such oligonucleotide conjugates include, but are not limited to, U.S.: 4,828,979; 4,948,882; 5,218,105; 15 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717; 5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 20 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241; 5,391,723; 5,416,203; 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481; 25 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and 5,688,941, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference.

It is not necessary for all positions in a given compound 30 to be uniformly modified, and in fact more than one of the aforementioned modifications may be incorporated in a single compound or even at a single nucleoside within an oligonucleotide. The present invention also includes antisense compounds which are chimeric compounds. "Chimeric" antisense 35 compounds or "chimeras," in the context of this invention, are antisense compounds, particularly oligonucleotides, which contain two or more chemically distinct regions, each made up of at least one monomer unit, i.e., a nucleotide in the case of an oligonucleotide compound. These oligonucleotides typically

-21-

contain at least one region wherein the oligonucleotide is modified so as to confer upon the oligonucleotide increased resistance to nuclease degradation, increased cellular uptake, and/or increased binding affinity for the target nucleic acid.

5 An additional region of the oligonucleotide may serve as a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. By way of example, RNase H is a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of oligonucleotide inhibition of gene expression. Consequently, comparable results can often be obtained with shorter oligonucleotides when chimeric oligonucleotides are used, compared to phosphorothioate deoxyoligonucleotides hybridizing to the same target region.

10 15 Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art.

Chimeric antisense compounds of the invention may be formed as composite structures of two or more oligonucleotides, modified oligonucleotides, oligonucleosides and/or oligonucleotide mimetics as described above. Such compounds have also been referred to in the art as hybrids or gapmers. Representative United States patents that teach the preparation of such hybrid structures include, but are not limited to, U.S.: 25 5,013,830; 5,149,797; 5,220,007; 5,256,775; 5,366,878; 5,403,711; 5,491,133; 5,565,350; 5,623,065; 5,652,355; 5,652,356; and 5,700,922, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference in its entirety.

30 The antisense compounds used in accordance with this invention may be conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors including, for example, Applied Biosystems (Foster City, CA). Any other means for such synthesis known in the art may additionally or alternatively be employed. It is well known to use similar techniques to prepare oligonucleotides such as the phosphorothioates and alkylated derivatives.

35 The antisense compounds of the invention are synthesized in

-22-

vitro and do not include antisense compositions of biological origin, or genetic vector constructs designed to direct the in vivo synthesis of antisense molecules.

The compounds of the invention may also be admixed,

5 encapsulated, conjugated or otherwise associated with other molecules, molecule structures or mixtures of compounds, as for example, liposomes, receptor targeted molecules, oral, rectal, topical or other formulations, for assisting in uptake, distribution and/or absorption. Representative United States
10 patents that teach the preparation of such uptake, distribution and/or absorption assisting formulations include, but are not limited to, U.S.: 5,108,921; 5,354,844; 5,416,016; 5,459,127; 5,521,291; 5,543,158; 5,547,932; 5,583,020; 5,591,721; 4,426,330; 4,534,899; 5,013,556; 5,108,921; 5,213,804;
15 5,227,170; 5,264,221; 5,356,633; 5,395,619; 5,416,016; 5,417,978; 5,462,854; 5,469,854; 5,512,295; 5,527,528; 5,534,259; 5,543,152; 5,556,948; 5,580,575; and 5,595,756, each
of which is herein incorporated by reference.

The antisense compounds of the invention encompass any
20 pharmaceutically acceptable salts, esters, or salts of such esters, or any other compound which, upon administration to an animal including a human, is capable of providing (directly or indirectly) the biologically active metabolite or residue thereof. Accordingly, for example, the disclosure is also drawn
25 to prodrugs and pharmaceutically acceptable salts of the compounds of the invention, pharmaceutically acceptable salts of such prodrugs, and other bioequivalents.

The term "prodrug" indicates a therapeutic agent that is prepared in an inactive form that is converted to an active form
30 (i.e., drug) within the body or cells thereof by the action of endogenous enzymes or other chemicals and/or conditions. In particular, prodrug versions of the oligonucleotides of the invention are prepared as SATE [(S-acetyl-2-thioethyl) phosphate] derivatives according to the methods disclosed in WO 93/24510 to Gosselin et al., published December 9, 1993 or in WO 35 94/26764 and U.S. 5,770,713 to Imbach et al.

The term "pharmaceutically acceptable salts" refers to physiologically and pharmaceutically acceptable salts of the compounds of the invention: i.e., salts that retain the desired

-23-

biological activity of the parent compound and do not impart undesired toxicological effects thereto.

Pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Examples of metals used as cations are sodium, potassium, magnesium, calcium, and the like. Examples of suitable amines are N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine (see, for example, Berge et al., "Pharmaceutical Salts," *J. of Pharma Sci.*, 1977, 66, 1-19). The base addition salts of said acidic compounds are prepared by contacting the free acid form with a sufficient amount of the desired base to produce the salt in the conventional manner. The free acid form may be regenerated by contacting the salt form with an acid and isolating the free acid in the conventional manner. The free acid forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free acid for purposes of the present invention. As used herein, a "pharmaceutical addition salt" includes a pharmaceutically acceptable salt of an acid form of one of the components of the compositions of the invention. These include organic or inorganic acid salts of the amines. Preferred acid salts are the hydrochlorides, acetates, salicylates, nitrates and phosphates. Other suitable pharmaceutically acceptable salts are well known to those skilled in the art and include basic salts of a variety of inorganic and organic acids, such as, for example, with inorganic acids, such as for example hydrochloric acid, hydrobromic acid, sulfuric acid or phosphoric acid; with organic carboxylic, sulfonic, sulfo or phospho acids or N-substituted sulfamic acids, for example acetic acid, propionic acid, glycolic acid, succinic acid, maleic acid, hydroxymaleic acid, methylmaleic acid, fumaric acid, malic acid, tartaric acid, lactic acid, oxalic acid, gluconic acid, glucaric acid, glucuronic acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, salicylic acid, 4-aminosalicylic acid, 2-phenoxybenzoic acid, 2-acetoxybenzoic acid, embonic acid, nicotinic acid or isonicotinic acid; and with amino acids, such

-24-

as the 20 alpha-amino acids involved in the synthesis of proteins in nature, for example glutamic acid or aspartic acid, and also with phenylacetic acid, methanesulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, 5 ethane-1,2-disulfonic acid, benzenesulfonic acid, 4-methylbenzenesulfonic acid, naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic acid, 2- or 3-phosphoglycerate, glucose-6-phosphate, N-cyclohexylsulfamic acid (with the formation of cyclamates), or with other acid organic compounds, 10 such as ascorbic acid. Pharmaceutically acceptable salts of compounds may also be prepared with a pharmaceutically acceptable cation. Suitable pharmaceutically acceptable cations are well known to those skilled in the art and include alkaline, alkaline earth, ammonium and quaternary ammonium cations. 15 Carbonates or hydrogen carbonates are also possible.

For oligonucleotides, preferred examples of pharmaceutically acceptable salts include but are not limited to (a) salts formed with cations such as sodium, potassium, ammonium, magnesium, calcium, polyamines such as spermine and 20 spermidine, etc.; (b) acid addition salts formed with inorganic acids, for example hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like; (c) salts formed with organic acids such as, for example, acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric 25 acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid, palmitic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acid, polygalacturonic acid, and the like; and (d) salts formed from 30 elemental anions such as chlorine, bromine, and iodine.

The antisense compounds of the present invention can be utilized for diagnostics, therapeutics, prophylaxis and as research reagents and kits. For therapeutics, an animal, preferably a human, suspected of having a disease or disorder 35 which can be treated by modulating the expression of Protein Kinase R is treated by administering antisense compounds in accordance with this invention. The compounds of the invention can be utilized in pharmaceutical compositions by adding an effective amount of an antisense compound to a suitable

-25-

pharmaceutically acceptable diluent or carrier. Use of the antisense compounds and methods of the invention may also be useful prophylactically, e.g., to prevent or delay infection, inflammation or tumor formation, for example.

5 The antisense compounds of the invention are useful for research and diagnostics, because these compounds hybridize to nucleic acids encoding Protein Kinase R, enabling sandwich and other assays to easily be constructed to exploit this fact. Hybridization of the antisense oligonucleotides of the invention
10 with a nucleic acid encoding Protein Kinase R can be detected by means known in the art. Such means may include conjugation of an enzyme to the oligonucleotide, radiolabelling of the oligonucleotide or any other suitable detection means. Kits using such detection means for detecting the level of Protein
15 Kinase R in a sample may also be prepared.

The present invention also includes pharmaceutical compositions and formulations which include the antisense compounds of the invention. The pharmaceutical compositions of the present invention may be administered in a number of ways
20 depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic and to mucous membranes including vaginal and rectal delivery), pulmonary, e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer;
25 intratracheal, intranasal, epidermal and transdermal), oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration. Oligonucleotides with at
30 least one 2'-O-methoxyethyl modification are believed to be particularly useful for oral administration.

Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable. Coated condoms, gloves and the like may also be useful. Preferred topical formulations include those in which the oligonucleotides of the invention are in admixture with a

-26-

topical delivery agent such as lipids, liposomes, fatty acids, fatty acid esters, steroids, chelating agents and surfactants. Preferred lipids and liposomes include neutral (e.g. dioleoylphosphatidyl DOPE ethanolamine, dimyristoylphosphatidyl 5 choline DMPC, distearoylphosphatidyl choline) negative (e.g. dimyristoylphosphatidyl glycerol DMPG) and cationic (e.g. dioleoyltetramethylaminopropyl DOTAP and dioleoylphosphatidyl ethanolamine DOTMA). Oligonucleotides of the invention may be encapsulated within liposomes or may form complexes thereto, in 10 particular to cationic liposomes. Alternatively, oligonucleotides may be complexed to lipids, in particular to cationic lipids. Preferred fatty acids and esters include but are not limited arachidonic acid, oleic acid, eicosanoic acid, lauric acid, caprylic acid, capric acid, myristic acid, palmitic 15 acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein, dilaurin, glyceryl 1-monocaprate, 1-dodecylazacycloheptan-2-one, an acylcarnitine, an acylcholine, or a C₁-10 alkyl ester (e.g. isopropylmyristate IPM), monoglyceride, diglyceride or pharmaceutically acceptable salt 20 thereof. Topical formulations are described in detail in United States patent application 09/315,298 filed on May 20, 1999 which is incorporated herein by reference in its entirety.

Compositions and formulations for oral administration include powders or granules, microparticulates, 25 nanoparticulates, suspensions or solutions in water or non-aqueous media, capsules, gel capsules, sachets, tablets or minitablets. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders may be desirable. Preferred oral formulations are those in which oligonucleotides 30 of the invention are administered in conjunction with one or more penetration enhancers surfactants and chelators. Preferred surfactants include fatty acids and/or esters or salts thereof, bile acids and/or salts thereof. Preferred bile acids/salts include chenodeoxycholic acid (CDCA) and 35 ursodeoxychenodeoxycholic acid (UDCA), cholic acid, dehydrocholic acid, deoxycholic acid, glucholic acid, glycholic acid, glycodeoxycholic acid, taurocholic acid, taurodeoxycholic acid, sodium tauro-24,25-dihydro-fusidate, sodium glycodihydrofusidate,. Preferred fatty acids include arachidonic

acid, undecanoic acid, oleic acid, lauric acid, caprylic acid, capric acid, myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein, dilaurin, glyceryl 1-monocaprate, 1-dodecylazacycloheptan-2-one, 5 an acylcarnitine, an acylcholine, or a monoglyceride, a diglyceride or a pharmaceutically acceptable salt thereof (e.g. sodium). Also preferred are combinations of penetration enhancers, for example, fatty acids/salts in combination with bile acids/salts. A particularly preferred combination is the 10 sodium salt of lauric acid, capric acid and UDCA. Further penetration enhancers include polyoxyethylene-9-lauryl ether, polyoxyethylene-20-cetyl ether. Oligonucleotides of the invention may be delivered orally in granular form including sprayed dried particles, or complexed to form micro or 15 nanoparticles. Oligonucleotide complexing agents include poly-amino acids; polyimines; polyacrylates; polyalkylacrylates, polyoxethanes, polyalkylcyanoacrylates; cationized gelatins, albumins, starches, acrylates, polyethyleneglycols (PEG) and starches; polyalkylcyanoacrylates; DEAE-derivatized polyimines, 20 pollulans, celluloses and starches. Particularly preferred complexing agents include chitosan, N-trimethylchitosan, poly-L-lysine, polyhistidine, polyornithine, polyspermines, protamine, polyvinylpyridine, polythiodiethylamino-methylethylene P(TDAE), polyaminostyrene (e.g. p-amino), poly(methylcyanoacrylate), 25 poly(ethylcyanoacrylate), poly(butylcyanoacrylate), poly(isobutylcyanoacrylate), poly(isohexylcyanoacrylate), DEAE-methacrylate, DEAE-hexylacrylate, DEAE-acrylamide, DEAE-albumin and DEAE-dextran, polymethylacrylate, polyhexylacrylate, poly(D,L-lactic acid), poly(DL-lactic-co-glycolic acid (PLGA), 30 alginate, and polyethyleneglycol (PEG). Oral formulations for oligonucleotides and their preparation are described in detail in United States applications 08/886,829 (filed July 1, 1997), 09/108,673 (filed July 1, 1998), 09/256,515 (filed February 23, 1999), 09/082,624 (filed May 21, 1998) and 09/315,298 (filed 35 May 20, 1999) each of which is incorporated herein by reference in their entirety.

Compositions and formulations for parenteral, intrathecal or intraventricular administration may include sterile aqueous solutions which may also contain buffers, diluents and other

-28-

suitable additives such as, but not limited to, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients.

Pharmaceutical compositions of the present invention 5 include, but are not limited to, solutions, emulsions, and liposome-containing formulations. These compositions may be generated from a variety of components that include, but are not limited to, preformed liquids, self-emulsifying solids and self-emulsifying semisolids.

10 The pharmaceutical formulations of the present invention, which may conveniently be presented in unit dosage form, may be prepared according to conventional techniques well known in the pharmaceutical industry. Such techniques include the step of bringing into association the active ingredients with the 15 pharmaceutical carrier(s) or excipient(s). In general the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

20 The compositions of the present invention may be formulated into any of many possible dosage forms such as, but not limited to, tablets, capsules, gel capsules, liquid syrups, soft gels, suppositories, and enemas. The compositions of the present invention may also be formulated as suspensions in aqueous, non-25 aqueous or mixed media. Aqueous suspensions may further contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

30 In one embodiment of the present invention the pharmaceutical compositions may be formulated and used as foams. Pharmaceutical foams include formulations such as, but not limited to, emulsions, microemulsions, creams, jellies and liposomes. While basically similar in nature these formulations vary in the components and the consistency of the final product. 35 The preparation of such compositions and formulations is generally known to those skilled in the pharmaceutical and formulation arts and may be applied to the formulation of the compositions of the present invention.

Emulsions

The compositions of the present invention may be prepared and formulated as emulsions. Emulsions are typically heterogenous systems of one liquid dispersed in another in the 5 form of droplets usually exceeding 0.1 μm in diameter. (Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Bunker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199; Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Bunker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., 10 Volume 1, p. 245; Block in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Bunker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 2, p. 335; Higuchi et al., in *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, PA, 1985, p. 301). Emulsions are often biphasic systems comprising of two 15 immiscible liquid phases intimately mixed and dispersed with each other. In general, emulsions may be either water-in-oil (w/o) or of the oil-in-water (o/w) variety. When an aqueous phase is finely divided into and dispersed as minute droplets into a bulk oily phase the resulting composition is called a 20 water-in-oil (w/o) emulsion. Alternatively, when an oily phase is finely divided into and dispersed as minute droplets into a bulk aqueous phase the resulting composition is called an oil-in-water (o/w) emulsion. Emulsions may contain additional components in addition to the dispersed phases and the active 25 drug which may be present as a solution in either the aqueous phase, oily phase or itself as a separate phase. Pharmaceutical excipients such as emulsifiers, stabilizers, dyes, and anti-oxidants may also be present in emulsions as needed. Pharmaceutical emulsions may also be multiple emulsions that are 30 comprised of more than two phases such as, for example, in the case of oil-in-water-in-oil (o/w/o) and water-in-oil-in-water (w/o/w) emulsions. Such complex formulations often provide certain advantages that simple binary emulsions do not. Multiple emulsions in which individual oil droplets of an o/w 35 emulsion enclose small water droplets constitute a w/o/w emulsion. Likewise a system of oil droplets enclosed in globules of water stabilized in an oily continuous provides an o/w/o emulsion.

-30-

Emulsions are characterized by little or no thermodynamic stability. Often, the dispersed or discontinuous phase of the emulsion is well dispersed into the external or continuous phase and maintained in this form through the means of emulsifiers or the viscosity of the formulation. Either of the phases of the emulsion may be a semisolid or a solid, as is the case of emulsion-style ointment bases and creams. Other means of stabilizing emulsions entail the use of emulsifiers that may be incorporated into either phase of the emulsion. Emulsifiers may broadly be classified into four categories: synthetic surfactants, naturally occurring emulsifiers, absorption bases, and finely dispersed solids (Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Bunker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).

Synthetic surfactants, also known as surface active agents, have found wide applicability in the formulation of emulsions and have been reviewed in the literature (Rieger, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Bunker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Bunker (Eds.), Marcel Dekker, Inc., New York, N.Y., 1988, volume 1, p. 199). Surfactants are typically amphiphilic and comprise a hydrophilic and a hydrophobic portion. The ratio of the hydrophilic to the hydrophobic nature of the surfactant has been termed the hydrophile/lipophile balance (HLB) and is a valuable tool in categorizing and selecting surfactants in the preparation of formulations. Surfactants may be classified into different classes based on the nature of the hydrophilic group: nonionic, anionic, cationic and amphoteric (Rieger, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Bunker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285).

Naturally occurring emulsifiers used in emulsion formulations include lanolin, beeswax, phosphatides, lecithin and acacia. Absorption bases possess hydrophilic properties such that they can soak up water to form w/o emulsions yet retain their semisolid consistencies, such as anhydrous lanolin and hydrophilic petrolatum. Finely divided solids have also been used as good emulsifiers especially in combination with

-31-

surfactants and in viscous preparations. These include polar inorganic solids, such as heavy metal hydroxides, nonswelling clays such as bentonite, attapulgite, hectorite, kaolin, montmorillonite, colloidal aluminum silicate and colloidal

5 magnesium aluminum silicate, pigments and nonpolar solids such as carbon or glyceryl tristearate.

A large variety of non-emulsifying materials are also included in emulsion formulations and contribute to the properties of emulsions. These include fats, oils, waxes, fatty acids, fatty alcohols, fatty esters, humectants, hydrophilic colloids, preservatives and antioxidants (Block, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Bunker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger 15 and Bunker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).

Hydrophilic colloids or hydrocolloids include naturally occurring gums and synthetic polymers such as polysaccharides (for example, acacia, agar, alginic acid, carrageenan, guar gum, 20 karaya gum, and tragacanth), cellulose derivatives (for example, carboxymethylcellulose and carboxypropylcellulose), and synthetic polymers (for example, carbomers, cellulose ethers, and carboxyvinyl polymers). These disperse or swell in water to form colloidal solutions that stabilize emulsions by forming 25 strong interfacial films around the dispersed-phase droplets and by increasing the viscosity of the external phase.

Since emulsions often contain a number of ingredients such as carbohydrates, proteins, sterols and phosphatides that may readily support the growth of microbes, these formulations often 30 incorporate preservatives. Commonly used preservatives included in emulsion formulations include methyl paraben, propyl paraben, quaternary ammonium salts, benzalkonium chloride, esters of p-hydroxybenzoic acid, and boric acid. Antioxidants are also commonly added to emulsion formulations to prevent deterioration 35 of the formulation. Antioxidants used may be free radical scavengers such as tocopherols, alkyl gallates, butylated hydroxyanisole, butylated hydroxytoluene, or reducing agents such as ascorbic acid and sodium metabisulfite, and antioxidant synergists such as citric acid, tartaric acid, and lecithin.

-32-

The application of emulsion formulations via dermatological, oral and parenteral routes and methods for their manufacture have been reviewed in the literature (Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Bunker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Emulsion formulations for oral delivery have been very widely used because of reasons of ease of formulation, efficacy from an absorption and bioavailability standpoint. (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Bunker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Bunker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Mineral-oil base laxatives, oil-soluble vitamins and high fat nutritive preparations are among the materials that have commonly been administered orally as o/w emulsions.

In one embodiment of the present invention, the compositions of oligonucleotides and nucleic acids are formulated as microemulsions. A microemulsion may be defined as a system of water, oil and amphiphile which is a single optically isotropic and thermodynamically stable liquid solution (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Bunker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Typically microemulsions are systems that are prepared by first dispersing an oil in an aqueous surfactant solution and then adding a sufficient amount of a fourth component, generally an intermediate chain-length alcohol to form a transparent system. Therefore, microemulsions have also been described as thermodynamically stable, isotropically clear dispersions of two immiscible liquids that are stabilized by interfacial films of surface-active molecules (Leung and Shah, in: *Controlled Release of Drugs: Polymers and Aggregate Systems*, Rosoff, M., Ed., 1989, VCH Publishers, New York, pages 185-215). Microemulsions commonly are prepared via a combination of three to five components that include oil, water, surfactant, cosurfactant and electrolyte. Whether the microemulsion is of the water-in-oil (w/o) or an oil-in-water (o/w) type is dependent on the properties of the oil and surfactant used and on the structure and geometric packing of the polar heads and

-33-

hydrocarbon tails of the surfactant molecules (Schott, in *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, PA, 1985, p. 271).

The phenomenological approach utilizing phase diagrams has 5 been extensively studied and has yielded a comprehensive knowledge, to one skilled in the art, of how to formulate microemulsions (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Bunker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245; Block, in *Pharmaceutical 10 Dosage Forms*, Lieberman, Rieger and Bunker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335). Compared to conventional emulsions, microemulsions offer the advantage of solubilizing water-insoluble drugs in a formulation of thermodynamically stable droplets that are formed spontaneously.

15 Surfactants used in the preparation of microemulsions include, but are not limited to, ionic surfactants, non-ionic surfactants, Brij 96, polyoxyethylene oleyl ethers, polyglycerol fatty acid esters, tetraglycerol monolaurate (ML310), tetraglycerol monooleate (MO310), hexaglycerol monooleate 20 (PO310), hexaglycerol pentaoleate (PO500), decaglycerol monocaprate (MCA750), decaglycerol monooleate (MO750), decaglycerol sequioleate (SO750), decaglycerol decaoleate (DAO750), alone or in combination with cosurfactants. The cosurfactant, usually a short-chain alcohol such as ethanol, 1- 25 propanol, and 1-butanol, serves to increase the interfacial fluidity by penetrating into the surfactant film and consequently creating a disordered film because of the void space generated among surfactant molecules. Microemulsions may, however, be prepared without the use of cosurfactants and 30 alcohol-free self-emulsifying microemulsion systems are known in the art. The aqueous phase may typically be, but is not limited to, water, an aqueous solution of the drug, glycerol, PEG300, PEG400, polyglycerols, propylene glycols, and derivatives of ethylene glycol. The oil phase may include, but is not limited 35 to, materials such as Captex 300, Captex 355, Capmul MCM, fatty acid esters, medium chain (C8-C12) mono, di, and tri-glycerides, polyoxyethylated glyceryl fatty acid esters, fatty alcohols, polyglycolized glycerides, saturated polyglycolized C8-C10 glycerides, vegetable oils and silicone oil.

-34-

Microemulsions are particularly of interest from the standpoint of drug solubilization and the enhanced absorption of drugs. Lipid based microemulsions (both o/w and w/o) have been proposed to enhance the oral bioavailability of drugs, including 5 peptides (Constantinides et al., *Pharmaceutical Research*, **1994**, 11, 1385-1390; Ritschel, *Meth. Find. Exp. Clin. Pharmacol.*, **1993**, 13, 205). Microemulsions afford advantages of improved drug solubilization, protection of drug from enzymatic hydrolysis, possible enhancement of drug absorption due to 10 surfactant-induced alterations in membrane fluidity and permeability, ease of preparation, ease of oral administration over solid dosage forms, improved clinical potency, and decreased toxicity (Constantinides et al., *Pharmaceutical Research*, **1994**, 11, 1385; Ho et al., *J. Pharm. Sci.*, **1996**, 85, 15 138-143). Often microemulsions may form spontaneously when their components are brought together at ambient temperature. This may be particularly advantageous when formulating thermolabile drugs, peptides or oligonucleotides. Microemulsions have also been effective in the transdermal 20 delivery of active components in both cosmetic and pharmaceutical applications. It is expected that the microemulsion compositions and formulations of the present invention will facilitate the increased systemic absorption of oligonucleotides and nucleic acids from the gastrointestinal 25 tract, as well as improve the local cellular uptake of oligonucleotides and nucleic acids within the gastrointestinal tract, vagina, buccal cavity and other areas of administration.

Microemulsions of the present invention may also contain additional components and additives such as sorbitan 30 monostearate (Grill 3), Labrasol, and penetration enhancers to improve the properties of the formulation and to enhance the absorption of the oligonucleotides and nucleic acids of the present invention. Penetration enhancers used in the microemulsions of the present invention may be classified as 35 belonging to one of five broad categories - surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, **1991**, p. 92). Each of these classes has been discussed above.

Liposomes

There are many organized surfactant structures besides microemulsions that have been studied and used for the formulation of drugs. These include monolayers, micelles, bilayers and vesicles. Vesicles, such as liposomes, have attracted great interest because of their specificity and the duration of action they offer from the standpoint of drug delivery. As used in the present invention, the term "liposome" means a vesicle composed of amphiphilic lipids arranged in a spherical bilayer or bilayers.

Liposomes are unilamellar or multilamellar vesicles which have a membrane formed from a lipophilic material and an aqueous interior. The aqueous portion contains the composition to be delivered. Cationic liposomes possess the advantage of being able to fuse to the cell wall. Non-cationic liposomes, although not able to fuse as efficiently with the cell wall, are taken up by macrophages *in vivo*.

In order to cross intact mammalian skin, lipid vesicles must pass through a series of fine pores, each with a diameter less than 50 nm, under the influence of a suitable transdermal gradient. Therefore, it is desirable to use a liposome which is highly deformable and able to pass through such fine pores.

Further advantages of liposomes include; liposomes obtained from natural phospholipids are biocompatible and biodegradable; liposomes can incorporate a wide range of water and lipid soluble drugs; liposomes can protect encapsulated drugs in their internal compartments from metabolism and degradation (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Important considerations in the preparation of liposome formulations are the lipid surface charge, vesicle size and the aqueous volume of the liposomes.

Liposomes are useful for the transfer and delivery of active ingredients to the site of action. Because the liposomal membrane is structurally similar to biological membranes, when liposomes are applied to a tissue, the liposomes start to merge with the cellular membranes. As the merging of the liposome and

-36-

cell progresses, the liposomal contents are emptied into the cell where the active agent may act.

Liposomal formulations have been the focus of extensive investigation as the mode of delivery for many drugs. There is 5 growing evidence that for topical administration, liposomes present several advantages over other formulations. Such advantages include reduced side-effects related to high systemic absorption of the administered drug, increased accumulation of the administered drug at the desired target, and the ability to 10 administer a wide variety of drugs, both hydrophilic and hydrophobic, into the skin.

Several reports have detailed the ability of liposomes to deliver agents including high-molecular weight DNA into the skin. Compounds including analgesics, antibodies, hormones and 15 high-molecular weight DNAs have been administered to the skin. The majority of applications resulted in the targeting of the upper epidermis.

Liposomes fall into two broad classes. Cationic liposomes are positively charged liposomes which interact with the 20 negatively charged DNA molecules to form a stable complex. The positively charged DNA/liposome complex binds to the negatively charged cell surface and is internalized in an endosome. Due to the acidic pH within the endosome, the liposomes are ruptured, releasing their contents into the cell cytoplasm (Wang *et al.*, 25 *Biochem. Biophys. Res. Commun.*, 1987, 147, 980-985).

Liposomes which are pH-sensitive or negatively-charged, 30 entrap DNA rather than complex with it. Since both the DNA and the lipid are similarly charged, repulsion rather than complex formation occurs. Nevertheless, some DNA is entrapped within the aqueous interior of these liposomes. pH-sensitive liposomes have been used to deliver DNA encoding the thymidine kinase gene to cell monolayers in culture. Expression of the exogenous gene was detected in the target cells (Zhou *et al.*, *Journal of Controlled Release*, 1992, 19, 269-274).

35 One major type of liposomal composition includes phospholipids other than naturally-derived phosphatidylcholine. Neutral liposome compositions, for example, can be formed from dimyristoyl phosphatidylcholine (DMPC) or dipalmitoyl phosphatidylcholine (DPPC). Anionic liposome compositions

-37-

generally are formed from dimyristoyl phosphatidylglycerol, while anionic fusogenic liposomes are formed primarily from dioleoyl phosphatidylethanolamine (DOPE). Another type of liposomal composition is formed from phosphatidylcholine (PC) such as, for example, soybean PC, and egg PC. Another type is formed from mixtures of phospholipid and/or phosphatidylcholine and/or cholesterol.

Several studies have assessed the topical delivery of liposomal drug formulations to the skin. Application of liposomes containing interferon to guinea pig skin resulted in a reduction of skin herpes sores while delivery of interferon via other means (e.g. as a solution or as an emulsion) were ineffective (Weiner et al., *Journal of Drug Targeting*, 1992, 2, 405-410). Further, an additional study tested the efficacy of interferon administered as part of a liposomal formulation to the administration of interferon using an aqueous system, and concluded that the liposomal formulation was superior to aqueous administration (du Plessis et al., *Antiviral Research*, 1992, 18, 259-265).

Non-ionic liposomal systems have also been examined to determine their utility in the delivery of drugs to the skin, in particular systems comprising non-ionic surfactant and cholesterol. Non-ionic liposomal formulations comprising Novasome™ I (glyceryl dilaurate/cholesterol/polyoxyethylene-10-stearyl ether) and Novasome™ II (glyceryl distearate/cholesterol/polyoxyethylene-10-stearyl ether) were used to deliver cyclosporin-A into the dermis of mouse skin. Results indicated that such non-ionic liposomal systems were effective in facilitating the deposition of cyclosporin-A into different layers of the skin (Hu et al. *S.T.P.Pharma. Sci.*, 1994, 4, 6, 466).

Liposomes also include "sterically stabilized" liposomes, a term which, as used herein, refers to liposomes comprising one or more specialized lipids that, when incorporated into liposomes, result in enhanced circulation lifetimes relative to liposomes lacking such specialized lipids. Examples of sterically stabilized liposomes are those in which part of the vesicle-forming lipid portion of the liposome (A) comprises one

or more glycolipids, such as monosialoganglioside G_{M1}, or (B) is derivatized with one or more hydrophilic polymers, such as a polyethylene glycol (PEG) moiety. While not wishing to be bound by any particular theory, it is thought in the art that, at 5 least for sterically stabilized liposomes containing gangliosides, sphingomyelin, or PEG-derivatized lipids, the enhanced circulation half-life of these sterically stabilized liposomes derives from a reduced uptake into cells of the reticuloendothelial system (RES) (Allen *et al.*, *FEBS Letters*, 10 **1987**, 223, 42; Wu *et al.*, *Cancer Research*, **1993**, 53, 3765).

Various liposomes comprising one or more glycolipids are known in the art. Papahadjopoulos *et al.* (*Ann. N.Y. Acad. Sci.*, **1987**, 507, 64) reported the ability of monosialoganglioside G_{M1}, galactocerebroside sulfate and phosphatidylinositol to improve 15 blood half-lives of liposomes. These findings were expounded upon by Gabizon *et al.* (*Proc. Natl. Acad. Sci. U.S.A.*, **1988**, 85, 6949). U.S. Patent No. 4,837,028 and WO 88/04924, both to Allen *et al.*, disclose liposomes comprising (1) sphingomyelin and (2) the ganglioside G_{M1} or a galactocerebroside sulfate ester. U.S. 20 Patent No. 5,543,152 (Webb *et al.*) discloses liposomes comprising sphingomyelin. Liposomes comprising 1,2-sn-dimyristoylphosphatidylcholine are disclosed in WO 97/13499 (Lim *et al.*).

Many liposomes comprising lipids derivatized with one or 25 more hydrophilic polymers, and methods of preparation thereof, are known in the art. Sunamoto *et al.* (*Bull. Chem. Soc. Jpn.*, **1980**, 53, 2778) described liposomes comprising a nonionic detergent, 2C₁₂15G, that contains a PEG moiety. Illum *et al.* (*FEBS Lett.*, **1984**, 167, 79) noted that hydrophilic coating of 30 polystyrene particles with polymeric glycols results in significantly enhanced blood half-lives. Synthetic phospholipids modified by the attachment of carboxylic groups of polyalkylene glycols (e.g., PEG) are described by Sears (U.S. Patent Nos. 4,426,330 and 4,534,899). Klibanov *et al.* (*FEBS Lett.*, **1990**, 268, 235) described experiments demonstrating that 35 liposomes comprising phosphatidylethanolamine (PE) derivatized with PEG or PEG stearate have significant increases in blood circulation half-lives. Blume *et al.* (*Biochimica et Biophysica Acta*, **1990**, 1029, 91) extended such observations to other PEG-

-39-

derivatized phospholipids, e.g., DSPE-PEG, formed from the combination of distearoylphosphatidylethanolamine (DSPE) and PEG. Liposomes having covalently bound PEG moieties on their external surface are described in European Patent No. EP 0 445

5 131 B1 and WO 90/04384 to Fisher. Liposome compositions containing 1-20 mole percent of PE derivatized with PEG, and methods of use thereof, are described by Woodle et al. (U.S. Patent Nos. 5,013,556 and 5,356,633) and Martin et al. (U.S. Patent No. 5,213,804 and European Patent No. EP 0 496 813 B1).

10 Liposomes comprising a number of other lipid-polymer conjugates are disclosed in WO 91/05545 and U.S. Patent No. 5,225,212 (both to Martin et al.) and in WO 94/20073 (Zalipsky et al.). Liposomes comprising PEG-modified ceramide lipids are described in WO 96/10391 (Choi et al.). U.S. Patent Nos. 5,540,935

15 (Miyazaki et al.) and 5,556,948 (Tagawa et al.) describe PEG-containing liposomes that can be further derivatized with functional moieties on their surfaces.

A limited number of liposomes comprising nucleic acids are known in the art. WO 96/40062 to Thierry et al. discloses methods for encapsulating high molecular weight nucleic acids in liposomes. U.S. Patent No. 5,264,221 to Tagawa et al. discloses protein-bonded liposomes and asserts that the contents of such liposomes may include an antisense RNA. U.S. Patent No. 5,665,710 to Rahman et al. describes certain methods of encapsulating oligodeoxynucleotides in liposomes. WO 97/04787 to Love et al. discloses liposomes comprising antisense oligonucleotides targeted to the raf gene.

Transfersomes are yet another type of liposomes, and are highly deformable lipid aggregates which are attractive candidates for drug delivery vehicles. Transfersomes may be described as lipid droplets which are so highly deformable that they are easily able to penetrate through pores which are smaller than the droplet. Transfersomes are adaptable to the environment in which they are used, e.g. they are self-optimizing (adaptive to the shape of pores in the skin), self-repairing, frequently reach their targets without fragmenting, and often self-loading. To make transfersomes it is possible to add surface edge-activators, usually surfactants, to a standard liposomal composition. Transfersomes have been used to deliver

-40-

serum albumin to the skin. The transfersome-mediated delivery of serum albumin has been shown to be as effective as subcutaneous injection of a solution containing serum albumin.

Surfactants find wide application in formulations such as 5 emulsions (including microemulsions) and liposomes. The most common way of classifying and ranking the properties of the many different types of surfactants, both natural and synthetic, is by the use of the hydrophile/lipophile balance (HLB). The nature of the hydrophilic group (also known as the "head") 10 provides the most useful means for categorizing the different surfactants used in formulations (Rieger, in *Pharmaceutical Dosage Forms*, Marcel Dekker, Inc., New York, NY, 1988, p. 285).

If the surfactant molecule is not ionized, it is classified as a nonionic surfactant. Nonionic surfactants find wide 15 application in pharmaceutical and cosmetic products and are usable over a wide range of pH values. In general their HLB values range from 2 to about 18 depending on their structure. Nonionic surfactants include nonionic esters such as ethylene glycol esters, propylene glycol esters, glyceryl esters, 20 polyglyceryl esters, sorbitan esters, sucrose esters, and ethoxylated esters. Nonionic alkanolamides and ethers such as fatty alcohol ethoxylates, propoxylated alcohols, and ethoxylated/propoxylated block polymers are also included in this class. The polyoxyethylene surfactants are the most 25 popular members of the nonionic surfactant class.

If the surfactant molecule carries a negative charge when it is dissolved or dispersed in water, the surfactant is classified as anionic. Anionic surfactants include carboxylates 30 such as soaps, acyl lactylates, acyl amides of amino acids, esters of sulfuric acid such as alkyl sulfates and ethoxylated alkyl sulfates, sulfonates such as alkyl benzene sulfonates, acyl isethionates, acyl taurates and sulfosuccinates, and phosphates. The most important members of the anionic surfactant class are the alkyl sulfates and the soaps.

35 If the surfactant molecule carries a positive charge when it is dissolved or dispersed in water, the surfactant is classified as cationic. Cationic surfactants include quaternary ammonium salts and ethoxylated amines. The quaternary ammonium salts are the most used members of this class.

-41-

If the surfactant molecule has the ability to carry either a positive or negative charge, the surfactant is classified as amphoteric. Amphoteric surfactants include acrylic acid derivatives, substituted alkylamides, N-alkylbetaines and phosphatides.

The use of surfactants in drug products, formulations and in emulsions has been reviewed (Rieger, in *Pharmaceutical Dosage Forms*, Marcel Dekker, Inc., New York, NY, 1988, p. 285).

10 Penetration Enhancers

In one embodiment, the present invention employs various penetration enhancers to effect the efficient delivery of nucleic acids, particularly oligonucleotides, to the skin of animals. Most drugs are present in solution in both ionized and 15 nonionized forms. However, usually only lipid soluble or lipophilic drugs readily cross cell membranes. It has been discovered that even non-lipophilic drugs may cross cell membranes if the membrane to be crossed is treated with a penetration enhancer. In addition to aiding the diffusion of 20 non-lipophilic drugs across cell membranes, penetration enhancers also enhance the permeability of lipophilic drugs.

Penetration enhancers may be classified as belonging to one of five broad categories, i.e., surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants (Lee 25 et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p.92). Each of the above mentioned classes of penetration enhancers are described below in greater detail.

Surfactants: In connection with the present invention, 30 surfactants (or "surface-active agents") are chemical entities which, when dissolved in an aqueous solution, reduce the surface tension of the solution or the interfacial tension between the aqueous solution and another liquid, with the result that absorption of oligonucleotides through the mucosa is enhanced. 35 In addition to bile salts and fatty acids, these penetration enhancers include, for example, sodium lauryl sulfate, polyoxyethylene-9-lauryl ether and polyoxyethylene-20-cetyl ether) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier*

-42-

Systems, 1991, p.92); and perfluorochemical emulsions, such as FC-43. Takahashi et al., *J. Pharm. Pharmacol.*, 1988, 40, 252).

Fatty acids: Various fatty acids and their derivatives which act as penetration enhancers include, for example, oleic acid, lauric acid, capric acid (n-decanoic acid), myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein (1-monooleoyl-rac-glycerol), dilaurin, caprylic acid, arachidonic acid, glycerol 1-monocaprate, 1-dodecylazacycloheptan-2-one, acylcarnitines, 10 acylcholines, C₁₋₁₀ alkyl esters thereof (e.g., methyl, isopropyl and t-butyl), and mono- and di-glycerides thereof (i.e., oleate, laurate, caprate, myristate, palmitate, stearate, linoleate, etc.) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p.92; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7, 1-33; El Hariri et al., *J. Pharm. Pharmacol.*, 1992, 44, 651-654).

Bile salts: The physiological role of bile includes the facilitation of dispersion and absorption of lipids and fat-soluble vitamins (Brunton, Chapter 38 in: Goodman & Gilman's *The Pharmacological Basis of Therapeutics*, 9th Ed., Hardman et al. Eds., McGraw-Hill, New York, 1996, pp. 934-935). Various natural bile salts, and their synthetic derivatives, act as penetration enhancers. Thus the term "bile salts" includes any of the naturally occurring components of bile as well as any of their synthetic derivatives. The bile salts of the invention include, for example, cholic acid (or its pharmaceutically acceptable sodium salt, sodium cholate), dehydrocholic acid (sodium dehydrocholate), deoxycholic acid (sodium deoxycholate), 25 glucolic acid (sodium glucolate), glycholic acid (sodium glycocholate), glycodeoxycholic acid (sodium glycodeoxycholate), taurocholic acid (sodium taurocholate), taurodeoxycholic acid (sodium taurodeoxycholate), chenodeoxycholic acid (sodium chenodeoxycholate), ursodeoxycholic acid (UDCA), sodium tauro-30 24,25-dihydro-fusidate (STDHF), sodium glycidihydrofusidate and polyoxyethylene-9-lauryl ether (POE) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, page 92; Swinyard, Chapter 39 In: *Remington's Pharmaceutical Sciences*, 18th Ed., Gennaro, ed., Mack Publishing Co., Easton, PA, 1990,

-43-

pages 782-783; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7, 1-33; Yamamoto et al., *J. Pharm. Exp. Ther.*, 1992, 263, 25; Yamashita et al., *J. Pharm. Sci.*, 1990, 79, 579-583).

5

Chelating Agents: Chelating agents, as used in connection with the present invention, can be defined as compounds that remove metallic ions from solution by forming complexes therewith, with the result that absorption of oligonucleotides 10 through the mucosa is enhanced. With regards to their use as penetration enhancers in the present invention, chelating agents have the added advantage of also serving as DNase inhibitors, as most characterized DNA nucleases require a divalent metal ion for catalysis and are thus inhibited by chelating agents 15 (Jarrett, *J. Chromatogr.*, 1993, 618, 315-339). Chelating agents of the invention include but are not limited to disodium ethylenediaminetetraacetate (EDTA), citric acid, salicylates (e.g., sodium salicylate, 5-methoxysalicylate and homovanilate), N-acyl derivatives of collagen, laureth-9 and N-amino acyl 20 derivatives of beta-diketones (enamines) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, page 92; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7, 1-33; Buur et al., *J. Control Rel.*, 1990, 14, 43-51).

25 Non-chelating non-surfactants: As used herein, non-chelating non-surfactant penetration enhancing compounds can be defined as compounds that demonstrate insignificant activity as chelating agents or as surfactants but that nonetheless enhance absorption of oligonucleotides through the alimentary mucosa 30 (Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7, 1-33). This class of penetration enhancers include, for example, unsaturated cyclic ureas, 1-alkyl- and 1-alkenylazacyclo-alkanone derivatives (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, page 92); and 35 non-steroidal anti-inflammatory agents such as diclofenac sodium, indomethacin and phenylbutazone (Yamashita et al., *J. Pharm. Pharmacol.*, 1987, 39, 621-626).

Agents that enhance uptake of oligonucleotides at the cellular level may also be added to the pharmaceutical and other

-44-

compositions of the present invention. For example, cationic lipids, such as lipofectin (Junichi et al, U.S. Patent No. 5,705,188), cationic glycerol derivatives, and polycationic molecules, such as polylysine (Lollo et al., PCT Application WO 5 97/30731), are also known to enhance the cellular uptake of oligonucleotides.

Other agents may be utilized to enhance the penetration of the administered nucleic acids, including glycols such as ethylene glycol and propylene glycol, pyrrols such as 2-pyrrol, 10 azones, and terpenes such as limonene and menthone.

Carriers

Certain compositions of the present invention also incorporate carrier compounds in the formulation. As used 15 herein, "carrier compound" or "carrier" can refer to a nucleic acid, or analog thereof, which is inert (i.e., does not possess biological activity *per se*) but is recognized as a nucleic acid by *in vivo* processes that reduce the bioavailability of a nucleic acid having biological activity by, for example, 20 degrading the biologically active nucleic acid or promoting its removal from circulation. The coadministration of a nucleic acid and a carrier compound, typically with an excess of the latter substance, can result in a substantial reduction of the amount of nucleic acid recovered in the liver, kidney or other 25 extracirculatory reservoirs, presumably due to competition between the carrier compound and the nucleic acid for a common receptor. For example, the recovery of a partially phosphorothioate oligonucleotide in hepatic tissue can be reduced when it is coadministered with polyinosinic acid, 30 dextran sulfate, polycytidic acid or 4-acetamido-4'isothiocyanostilbene-2,2'-disulfonic acid (Miyao et al., *Antisense Res. Dev.*, 1995, 5, 115-121; Takakura et al., *Antisense & Nucl. Acid Drug Dev.*, 1996, 6, 177-183).

35 Excipients

In contrast to a carrier compound, a "pharmaceutical carrier" or "excipient" is a pharmaceutically acceptable solvent, suspending agent or any other pharmacologically inert vehicle for delivering one or more nucleic acids to an animal.

-45-

The excipient may be liquid or solid and is selected, with the planned manner of administration in mind, so as to provide for the desired bulk, consistency, etc., when combined with a nucleic acid and the other components of a given pharmaceutical composition. Typical pharmaceutical carriers include, but are not limited to, binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose, etc.); fillers (e.g., lactose and other sugars, microcrystalline cellulose, pectin, gelatin, calcium sulfate, ethyl cellulose, polyacrylates or calcium hydrogen phosphate, etc.); lubricants (e.g., magnesium stearate, talc, silica, colloidal silicon dioxide, stearic acid, metallic stearates, hydrogenated vegetable oils, corn starch, polyethylene glycols, sodium benzoate, sodium acetate, etc.); disintegrants (e.g., starch, sodium starch glycolate, etc.); and wetting agents (e.g., sodium lauryl sulphate, etc.).

Pharmaceutically acceptable organic or inorganic excipient suitable for non-parenteral administration which do not deleteriously react with nucleic acids can also be used to formulate the compositions of the present invention. Suitable pharmaceutically acceptable carriers include, but are not limited to, water, salt solutions, alcohols, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.

Formulations for topical administration of nucleic acids may include sterile and non-sterile aqueous solutions, non-aqueous solutions in common solvents such as alcohols, or solutions of the nucleic acids in liquid or solid oil bases. The solutions may also contain buffers, diluents and other suitable additives. Pharmaceutically acceptable organic or inorganic excipients suitable for non-parenteral administration which do not deleteriously react with nucleic acids can be used.

Suitable pharmaceutically acceptable excipients include, but are not limited to, water, salt solutions, alcohol, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.

Other Components

The compositions of the present invention may additionally contain other adjunct components conventionally found in pharmaceutical compositions, at their art-established usage levels. Thus, for example, the compositions may contain additional, compatible, pharmaceutically-active materials such as, for example, antipruritics, astringents, local anesthetics or anti-inflammatory agents, or may contain additional materials useful in physically formulating various dosage forms of the compositions of the present invention, such as dyes, flavoring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers. However, such materials, when added, should not unduly interfere with the biological activities of the components of the compositions of the present invention.

The formulations can be sterilized and, if desired, mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings and/or aromatic substances and the like which do not deleteriously interact with the nucleic acid(s) of the formulation.

Aqueous suspensions may contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

Certain embodiments of the invention provide pharmaceutical compositions containing (a) one or more antisense compounds and (b) one or more other chemotherapeutic agents which function by a non-antisense mechanism. Examples of such chemotherapeutic agents include but are not limited to daunorubicin, daunomycin, dactinomycin, doxorubicin, epirubicin, idarubicin, esorubicin, bleomycin, mafosfamide, ifosfamide, cytosine arabinoside, bis-chloroethylnitrosurea, busulfan, mitomycin C, actinomycin D, mithramycin, prednisone, hydroxyprogesterone, testosterone, tamoxifen, dacarbazine, procarbazine, hexamethylmelamine, pentamethylmelamine, mitoxantrone, amsacrine, chlorambucil, methylcyclohexylnitrosurea, nitrogen mustards, melphalan, cyclophosphamide, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-azacytidine, hydroxyurea, deoxycoformycin, 4-hydroxyperoxycyclophosphoramide, 5-fluorouracil (5-FU), 5-

-47-

fluorodeoxyuridine (5-FUDR), methotrexate (MTX), colchicine, taxol, vincristine, vinblastine, etoposide (VP-16), trimetrexate, irinotecan, topotecan, gemcitabine, teniposide, cisplatin and diethylstilbestrol (DES). See, generally, *The Merck Manual of Diagnosis and Therapy*, 15th Ed. 1987, pp. 1206-1228, Berkow et al., eds., Rahway, N.J. When used with the compounds of the invention, such chemotherapeutic agents may be used individually (e.g., 5-FU and oligonucleotide), sequentially (e.g., 5-FU and oligonucleotide for a period of time followed by MTX and oligonucleotide), or in combination with one or more other such chemotherapeutic agents (e.g., 5-FU, MTX and oligonucleotide, or 5-FU, radiotherapy and oligonucleotide). Anti-inflammatory drugs, including but not limited to nonsteroidal anti-inflammatory drugs and corticosteroids, and antiviral drugs, including but not limited to ribivirin, vidarabine, acyclovir and ganciclovir, may also be combined in compositions of the invention. See, generally, *The Merck Manual of Diagnosis and Therapy*, 15th Ed., Berkow et al., eds., 1987, Rahway, N.J., pages 2499-2506 and 46-49, respectively). Other non-antisense chemotherapeutic agents are also within the scope of this invention. Two or more combined compounds may be used together or sequentially.

In another related embodiment, compositions of the invention may contain one or more antisense compounds, particularly oligonucleotides, targeted to a first nucleic acid and one or more additional antisense compounds targeted to a second nucleic acid target. Numerous examples of antisense compounds are known in the art. Two or more combined compounds may be used together or sequentially.

The formulation of therapeutic compositions and their subsequent administration is believed to be within the skill of those in the art. Dosing is dependent on severity and responsiveness of the disease state to be treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of the disease state is achieved. Optimal dosing schedules can be calculated from measurements of drug accumulation in the body of the patient. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates. Optimum dosages may

-48-

vary depending on the relative potency of individual oligonucleotides, and can generally be estimated based on EC₅₀s found to be effective in in vitro and in vivo animal models. In general, dosage is from 0.01 ug to 100 g per kg of body weight, 5 and may be given once or more daily, weekly, monthly or yearly, or even once every 2 to 20 years. Persons of ordinary skill in the art can easily estimate repetition rates for dosing based on measured residence times and concentrations of the drug in bodily fluids or tissues. Following successful treatment, it 10 may be desirable to have the patient undergo maintenance therapy to prevent the recurrence of the disease state, wherein the oligonucleotide is administered in maintenance doses, ranging from 0.01 ug to 100 g per kg of body weight, once or more daily, to once every 20 years.

15 While the present invention has been described with specificity in accordance with certain of its preferred embodiments, the following examples serve only to illustrate the invention and are not intended to limit the same.

EXAMPLES**Example 1****5 Nucleoside Phosphoramidites for Oligonucleotide Synthesis
Deoxy and 2'-alkoxy amidites**

2'-Deoxy and 2'-methoxy beta-cyanoethyldiisopropyl phosphoramidites were purchased from commercial sources (e.g. Chemgenes, Needham MA or Glen Research, Inc. Sterling VA).

10 Other 2'-O-alkoxy substituted nucleoside amidites are prepared as described in U.S. Patent 5,506,351, herein incorporated by reference. For oligonucleotides synthesized using 2'-alkoxy amidites, the standard cycle for unmodified oligonucleotides was utilized, except the wait step after pulse delivery of tetrazole

15 and base was increased to 360 seconds.

Oligonucleotides containing 5-methyl-2'-deoxycytidine (5-Me-C) nucleotides were synthesized according to published methods [Sanghvi, et. al., *Nucleic Acids Research*, **1993**, 21, 3197-3203] using commercially available phosphoramidites (Glen 20 Research, Sterling VA or ChemGenes, Needham MA).

2'-Fluoro amidites**2'-Fluorodeoxyadenosine amidites**

2'-fluoro oligonucleotides were synthesized as described 25 previously [Kawasaki, et. al., *J. Med. Chem.*, **1993**, 36, 831-841] and United States patent 5,670,633, herein incorporated by reference. Briefly, the protected nucleoside N6-benzoyl-2'-deoxy-2'-fluoroadenosine was synthesized utilizing commercially available 9-beta-D-arabinofuranosyladenine as starting material 30 and by modifying literature procedures whereby the 2'-alpha-fluoro atom is introduced by a S_N2-displacement of a 2'-beta-trityl group. Thus N6-benzoyl-9-beta-D-arabinofuranosyladenine was selectively protected in moderate yield as the 3',5'-ditetrahydropyranyl (THP) intermediate. Deprotection of the THP 35 and N6-benzoyl groups was accomplished using standard methodologies and standard methods were used to obtain the 5'-dimethoxytrityl-(DMT) and 5'-DMT-3'-phosphoramidite intermediates.

-50-

2'-Fluorodeoxyguanosine

The synthesis of 2'-deoxy-2'-fluoroguanosine was accomplished using tetraisopropylidiloxanyl (TPDS) protected 9-beta-D-arabinofuranosylguanine as starting material, and 5 conversion to the intermediate diisobutyryl-arabinofuranosylguanosine. Deprotection of the TPDS group was followed by protection of the hydroxyl group with THP to give diisobutyryl di-THP protected arabinofuranosylguanine. Selective O-deacylation and triflation was followed by treatment 10 of the crude product with fluoride, then deprotection of the THP groups. Standard methodologies were used to obtain the 5'-DMT- and 5'-DMT-3'-phosphoramidites.

2'-Fluorouridine

15 Synthesis of 2'-deoxy-2'-fluorouridine was accomplished by the modification of a literature procedure in which 2,2'-anhydro-1-beta-D-arabinofuranosyluracil was treated with 70% hydrogen fluoride-pyridine. Standard procedures were used to obtain the 5'-DMT and 5'-DMT-3' phosphoramidites.

20

2'-Fluorodeoxycytidine

2'-deoxy-2'-fluorocytidine was synthesized via amination of 2'-deoxy-2'-fluorouridine, followed by selective protection to give N4-benzoyl-2'-deoxy-2'-fluorocytidine. Standard procedures 25 were used to obtain the 5'-DMT and 5'-DMT-3' phosphoramidites.

2'-O-(2-Methoxyethyl) modified amidites

2'-O-Methoxyethyl-substituted nucleoside amidites are prepared as follows, or alternatively, as per the methods of 30 Martin, P., *Helvetica Chimica Acta*, 1995, 78, 486-504.

2,2'-Anhydro[1-(beta-D-arabinofuranosyl)-5-methyluridine]

5-Methyluridine (ribosylthymine, commercially available through Yamasa, Choshi, Japan) (72.0 g, 0.279 M), diphenyl-35 carbonate (90.0 g, 0.420 M) and sodium bicarbonate (2.0 g, 0.024 M) were added to DMF (300 mL). The mixture was heated to reflux, with stirring, allowing the evolved carbon dioxide gas to be released in a controlled manner. After 1 hour, the slightly darkened solution was concentrated under reduced

-51-

pressure. The resulting syrup was poured into diethylether (2.5 L), with stirring. The product formed a gum. The ether was decanted and the residue was dissolved in a minimum amount of methanol (ca. 400 mL). The solution was poured into fresh ether (2.5 L) to yield a stiff gum. The ether was decanted and the gum was dried in a vacuum oven (60°C at 1 mm Hg for 24 h) to give a solid that was crushed to a light tan powder (57 g, 85% crude yield). The NMR spectrum was consistent with the structure, contaminated with phenol as its sodium salt (ca. 5%). The material was used as is for further reactions (or it can be purified further by column chromatography using a gradient of methanol in ethyl acetate (10-25%) to give a white solid, mp 222-4°C).

15 **2'-O-Methoxyethyl-5-methyluridine**

2,2'-Anhydro-5-methyluridine (195 g, 0.81 M), tris(2-methoxyethyl)borate (231 g, 0.98 M) and 2-methoxyethanol (1.2 L) were added to a 2 L stainless steel pressure vessel and placed in a pre-heated oil bath at 160°C. After heating for 48 hours at 155-160°C, the vessel was opened and the solution evaporated to dryness and triturated with MeOH (200 mL). The residue was suspended in hot acetone (1 L). The insoluble salts were filtered, washed with acetone (150 mL) and the filtrate evaporated. The residue (280 g) was dissolved in CH₃CN (600 mL) and evaporated. A silica gel column (3 kg) was packed in CH₂Cl₂/acetone/MeOH (20:5:3) containing 0.5% Et₃NH. The residue was dissolved in CH₂Cl₂ (250 mL) and adsorbed onto silica (150 g) prior to loading onto the column. The product was eluted with the packing solvent to give 160 g (63%) of product. Additional material was obtained by reworking impure fractions.

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine

2'-O-Methoxyethyl-5-methyluridine (160 g, 0.506 M) was co-evaporated with pyridine (250 mL) and the dried residue dissolved in pyridine (1.3 L). A first aliquot of dimethoxytrityl chloride (94.3 g, 0.278 M) was added and the mixture stirred at room temperature for one hour. A second aliquot of dimethoxytrityl chloride (94.3 g, 0.278 M) was added

-52-

and the reaction stirred for an additional one hour. Methanol (170 mL) was then added to stop the reaction. HPLC showed the presence of approximately 70% product. The solvent was evaporated and triturated with CH₃CN (200 mL). The residue was dissolved in CHCl₃ (1.5 L) and extracted with 2x500 mL of saturated NaHCO₃, and 2x500 mL of saturated NaCl. The organic phase was dried over Na₂SO₄, filtered and evaporated. 275 g of residue was obtained. The residue was purified on a 3.5 kg silica gel column, packed and eluted with EtOAc/hexane/acetone (5:5:1) containing 0.5% Et₃NH. The pure fractions were evaporated to give 164 g of product. Approximately 20 g additional was obtained from the impure fractions to give a total yield of 183 g (57%).

15 **3'-O-Acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine**

20 2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine (106 g, 0.167 M), DMF/pyridine (750 mL of a 3:1 mixture prepared from 562 mL of DMF and 188 mL of pyridine) and acetic anhydride (24.38 mL, 0.258 M) were combined and stirred at room temperature for 24 hours. The reaction was monitored by TLC by first quenching the TLC sample with the addition of MeOH. Upon completion of the reaction, as judged by TLC, MeOH (50 mL) was added and the mixture evaporated at 35°C. The residue was dissolved in CHCl₃ (800 mL) and extracted with 2x200 mL of saturated sodium bicarbonate and 2x200 mL of saturated NaCl. The water layers were back extracted with 200 mL of CHCl₃. The combined organics were dried with sodium sulfate and evaporated to give 122 g of residue (approx. 90% product). The residue was purified on a 3.5 kg silica gel column and eluted using EtOAc/hexane (4:1). Pure product fractions were evaporated to yield 96 g (84%). An additional 1.5 g was recovered from later fractions.

35 **3'-O-Acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyl-4-triazoleuridine**

A first solution was prepared by dissolving 3'-O-acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine (96 g, 0.144 M) in CH₃CN (700 mL) and set aside. Triethylamine (189 mL, 1.44

-53-

M) was added to a solution of triazole (90 g, 1.3 M) in CH₃CN (1 L), cooled to -5°C and stirred for 0.5 h using an overhead stirrer. POCl₅ was added dropwise, over a 30 minute period, to the stirred solution maintained at 0-10°C, and the resulting mixture stirred for an additional 2 hours. The first solution was added dropwise, over a 45 minute period, to the latter solution. The resulting reaction mixture was stored overnight in a cold room. Salts were filtered from the reaction mixture and the solution was evaporated. The residue was dissolved in EtOAc (1 L) and the insoluble solids were removed by filtration. The filtrate was washed with 1x300 mL of NaHCO₃, and 2x300 mL of saturated NaCl, dried over sodium sulfate and evaporated. The residue was triturated with EtOAc to give the title compound.

15 **2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine**

A solution of 3'-O-acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyl-4-triazoleuridine (103 g, 0.141 M) in dioxane (500 mL) and NH₃OH (30 mL) was stirred at room temperature for 2 hours. The dioxane solution was evaporated and the residue azeotroped with MeOH (2x200 mL). The residue was dissolved in MeOH (300 mL) and transferred to a 2 liter stainless steel pressure vessel. MeOH (400 mL) saturated with NH₃ gas was added and the vessel heated to 100°C for 2 hours (TLC showed complete conversion). The vessel contents were evaporated to dryness and the residue was dissolved in EtOAc (500 mL) and washed once with saturated NaCl (200 mL). The organics were dried over sodium sulfate and the solvent was evaporated to give 85 g (95%) of the title compound.

30 **N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyl-cytidine**

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine (85 g, 0.134 M) was dissolved in DMF (800 mL) and benzoic anhydride (37.2 g, 0.165 M) was added with stirring. After stirring for 3 hours, TLC showed the reaction to be approximately 95% complete. The solvent was evaporated and the residue azeotroped with MeOH (200 mL). The residue was dissolved in CHCl₃ (700 mL) and extracted with saturated NaHCO₃ (2x300 mL) and saturated NaCl

-54-

(2x300 mL), dried over MgSO₄, and evaporated to give a residue (96 g). The residue was chromatographed on a 1.5 kg silica column using EtOAc/hexane (1:1) containing 0.5% Et₃NH as the eluting solvent. The pure product fractions were evaporated to give 90

5 g (90%) of the title compound.

N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyl-cytidine-3'-amidite

N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyl-cytidine (74 g, 0.10 M) was dissolved in CH₂Cl₂ (1 L). Tetrazole diisopropylamine (7.1 g) and 2-cyanoethoxy-tetra(isopropyl)-phosphite (40.5 mL, 0.123 M) were added with stirring, under a nitrogen atmosphere. The resulting mixture was stirred for 20 hours at room temperature (TLC showed the reaction to be 95% complete). The reaction mixture was extracted with saturated NaHCO₃ (1x300 mL) and saturated NaCl (3x300 mL). The aqueous washes were back-extracted with CH₂Cl₂ (300 mL), and the extracts were combined, dried over MgSO₄, and concentrated. The residue obtained was chromatographed on a 1.5 kg silica column using EtOAc/hexane (3:1) as the eluting solvent. The pure fractions were combined to give 90.6 g (87%) of the title compound.

2'-O-(Aminooxyethyl) nucleoside amidites and 2'-O-(dimethylaminooxyethyl) nucleoside amidites

25

2'-(Dimethylaminooxyethoxy) nucleoside amidites

2'-(Dimethylaminooxyethoxy) nucleoside amidites [also known in the art as 2'-O-(dimethylaminooxyethyl) nucleoside amidites] are prepared as described in the following paragraphs.

30 Adenosine, cytidine and guanosine nucleoside amidites are prepared similarly to the thymidine (5-methyluridine) except the exocyclic amines are protected with a benzoyl moiety in the case of adenosine and cytidine and with isobutyryl in the case of guanosine.

35

5'-O-tert-Butyldiphenylsilyl-0²-2'-anhydro-5-methyluridine

O²-2'-anhydro-5-methyluridine (Pro. Bio. Sint., Varese, Italy, 100.0g, 0.416 mmol), dimethylaminopyridine (0.66g, 0.013eq, 0.0054mmol) were dissolved in dry pyridine (500 ml) at

-55-

ambient temperature under an argon atmosphere and with mechanical stirring. *tert*-Butyldiphenylchlorosilane (125.8g, 119.0mL, 1.1eq, 0.458mmol) was added in one portion. The reaction was stirred for 16 h at ambient temperature. TLC (Rf 5 0.22, ethyl acetate) indicated a complete reaction. The solution was concentrated under reduced pressure to a thick oil. This was partitioned between dichloromethane (1 L) and saturated sodium bicarbonate (2x1 L) and brine (1 L). The organic layer was dried over sodium sulfate and concentrated under reduced 10 pressure to a thick oil. The oil was dissolved in a 1:1 mixture of ethyl acetate and ethyl ether (600mL) and the solution was cooled to -10°C. The resulting crystalline product was collected by filtration, washed with ethyl ether (3x200 mL) and dried (40°C, 15 1mm Hg, 24 h) to 149g (74.8%) of white solid. TLC and NMR were consistent with pure product.

**5'-O-*tert*-Butyldiphenylsilyl-2'-O-(2-hydroxyethyl)-5-
methyluridine**

20 In a 2 L stainless steel, unstirred pressure reactor was added borane in tetrahydrofuran (1.0 M, 2.0 eq, 622 mL). In the fume hood and with manual stirring, ethylene glycol (350 mL, excess) was added cautiously at first until the evolution of hydrogen gas subsided. 5'-O-*tert*-Butyldiphenylsilyl-0²-2'-anhydro-5-methyluridine (149 g, 0.311 mol) and sodium 25 bicarbonate (0.074 g, 0.003 eq) were added with manual stirring. The reactor was sealed and heated in an oil bath until an internal temperature of 160 °C was reached and then maintained for 16 h (pressure < 100 psig). The reaction vessel was cooled 30 to ambient and opened. TLC (Rf 0.67 for desired product and Rf 0.82 for ara-T side product, ethyl acetate) indicated about 70% conversion to the product. In order to avoid additional side product formation, the reaction was stopped, concentrated under reduced pressure (10 to 1mm Hg) in a warm water bath (40-100°C) 35 with the more extreme conditions used to remove the ethylene glycol. [Alternatively, once the low boiling solvent is gone, the remaining solution can be partitioned between ethyl acetate and water. The product will be in the organic phase.] The residue was purified by column chromatography (2kg silica gel,

-56-

ethyl acetate-hexanes gradient 1:1 to 4:1). The appropriate fractions were combined, stripped and dried to product as a white crisp foam (84g, 50%), contaminated starting material (17.4g) and pure reusable starting material 20g. The yield 5 based on starting material less pure recovered starting material was 58%. TLC and NMR were consistent with 99% pure product.

2'-O-([2-phthalimidoxy)ethyl]-5'-t-butyldiphenylsilyl-5-methyluridine

10 5'-O-tert-Butyldiphenylsilyl-2'-O-(2-hydroxyethyl)-5-methyluridine (20g, 36.98mmol) was mixed with triphenylphosphine (11.63g, 44.36mmol) and N-hydroxyphthalimide (7.24g, 44.36mmol). It was then dried over P_2O_5 under high vacuum for two days at 40°C. The reaction mixture was flushed with argon and dry THF 15 (369.8mL, Aldrich, sure seal bottle) was added to get a clear solution. Diethyl-azodicarboxylate (6.98mL, 44.36mmol) was added dropwise to the reaction mixture. The rate of addition is maintained such that resulting deep red coloration is just discharged before adding the next drop. After the addition was 20 complete, the reaction was stirred for 4 hrs. By that time TLC showed the completion of the reaction (ethylacetate:hexane, 60:40). The solvent was evaporated in vacuum. Residue obtained was placed on a flash column and eluted with ethyl acetate:hexane (60:40), to get 2'-O-([2-phthalimidoxy)ethyl]-5'-t-butyldiphenylsilyl-5-methyluridine as white foam (21.819 g, 25 86%).

5'-O-tert-butyldiphenylsilyl-2'-O-[(2-formadoximinoxy)ethyl]-5-methyluridine

30 2'-O-([2-phthalimidoxy)ethyl]-5'-t-butyldiphenylsilyl-5-methyluridine (3.1g, 4.5mmol) was dissolved in dry CH_2Cl_2 (4.5mL) and methylhydrazine (300mL, 4.64mmol) was added dropwise at -10°C to 0°C. After 1 h the mixture was filtered, the filtrate was washed with ice cold CH_2Cl_2 , and the combined organic phase was 35 washed with water, brine and dried over anhydrous Na_2SO_4 . The solution was concentrated to get 2'-O-(aminoxyethyl) thymidine, which was then dissolved in MeOH (67.5mL). To this formaldehyde (20% aqueous solution, w/w, 1.1 eq.) was added and the resulting

-57-

mixture was stirred for 1 h. Solvent was removed under vacuum; residue chromatographed to get 5'-O-tert-butyldiphenylsilyl-2'-O-[(2-formadoximinoxy) ethyl]-5-methyluridine as white foam (1.95 g, 78%).

5

5'-O-tert-Butyldiphenylsilyl-2'-O-[N,N-dimethylaminoxyethyl]-5-methyluridine

5'-O-tert-butyldiphenylsilyl-2'-O-[(2-formadoximinoxy)ethyl]-5-methyluridine (1.77g, 3.12mmol) was dissolved in a solution of 1M pyridinium p-toluenesulfonate (PPTS) in dry MeOH (30.6mL). Sodium cyanoborohydride (0.39g, 6.13mmol) was added to this solution at 10°C under inert atmosphere. The reaction mixture was stirred for 10 minutes at 10°C. After that the reaction vessel was removed from the ice bath and stirred at room temperature for 2 h, the reaction monitored by TLC (5% MeOH in CH₂Cl₂). Aqueous NaHCO₃ solution (5%, 10mL) was added and extracted with ethyl acetate (2x20mL). Ethyl acetate phase was dried over anhydrous Na₂SO₄, evaporated to dryness. Residue was dissolved in a solution of 1M PPTS in MeOH (30.6mL). Formaldehyde (20% w/w, 30mL, 3.37mmol) was added and the reaction mixture was stirred at room temperature for 10 minutes. Reaction mixture cooled to 10°C in an ice bath, sodium cyanoborohydride (0.39g, 6.13mmol) was added and reaction mixture stirred at 10°C for 10 minutes. After 10 minutes, the reaction mixture was removed from the ice bath and stirred at room temperature for 2 hrs. To the reaction mixture 5% NaHCO₃ (25mL) solution was added and extracted with ethyl acetate (2x25mL). Ethyl acetate layer was dried over anhydrous Na₂SO₄ and evaporated to dryness. The residue obtained was purified by flash column chromatography and eluted with 5% MeOH in CH₂Cl₂ to get 5'-O-tert-butyldiphenylsilyl-2'-O-[N,N-dimethylaminoxyethyl]-5-methyluridine as a white foam (14.6g, 80%).

35 **2'-O-(dimethylaminoxyethyl)-5-methyluridine**

Triethylamine trihydrofluoride (3.91mL, 24.0mmol) was dissolved in dry THF and triethylamine (1.67mL, 12mmol, dry, kept over KOH). This mixture of triethylamine-2HF was then

-58-

added to 5'-O-*tert*-butyldiphenylsilyl-2'-O-[N,N-dimethylaminoxyethyl]-5-methyluridine (1.40g, 2.4mmol) and stirred at room temperature for 24 hrs. Reaction was monitored by TLC (5% MeOH in CH₂Cl₂). Solvent was removed under vacuum and 5 the residue placed on a flash column and eluted with 10% MeOH in CH₂Cl₂ to get 2'-O-(dimethylaminoxyethyl)-5-methyluridine (766mg, 92.5%).

5'-O-DMT-2'-O-(dimethylaminoxyethyl)-5-methyluridine

10 2'-O-(dimethylaminoxyethyl)-5-methyluridine (750mg, 2.17mmol) was dried over P₂O₅ under high vacuum overnight at 40°C. It was then co-evaporated with anhydrous pyridine (20mL). The residue obtained was dissolved in pyridine (11mL) under argon atmosphere. 4-dimethylaminopyridine (26.5mg, 2.60mmol), 4,4'-15 dimethoxytrityl chloride (880mg, 2.60mmol) was added to the mixture and the reaction mixture was stirred at room temperature until all of the starting material disappeared. Pyridine was removed under vacuum and the residue chromatographed and eluted with 10% MeOH in CH₂Cl₂ (containing a few drops of pyridine) to 20 get 5'-O-DMT-2'-O-(dimethylaminoxyethyl)-5-methyluridine (1.13g, 80%).

5'-O-DMT-2'-O-(2-N,N-dimethylaminoxyethyl)-5-methyluridine-3'-[(2-cyanoethyl)-N,N-disopropylphosphoramidite]

25 5'-O-DMT-2'-O-(dimethylaminoxyethyl)-5-methyluridine (1.08g, 1.67mmol) was co-evaporated with toluene (20mL). To the residue N,N-diisopropylamine tetrazonide (0.29g, 1.67mmol) was added and dried over P₂O₅ under high vacuum overnight at 40°C. 30 Then the reaction mixture was dissolved in anhydrous acetonitrile (8.4mL) and 2-cyanoethyl-N,N,N',N'-tetraisopropylphosphoramidite (2.12mL, 6.08mmol) was added. The reaction mixture was stirred at ambient temperature for 4 hrs under inert atmosphere. The progress of the reaction was 35 monitored by TLC (hexane:ethyl acetate 1:1). The solvent was evaporated, then the residue was dissolved in ethyl acetate (70mL) and washed with 5% aqueous NaHCO₃ (40mL). Ethyl acetate layer was dried over anhydrous Na₂SO₄ and concentrated. Residue

-59-

obtained was chromatographed (ethyl acetate as eluent) to get 5'-O-DMT-2'-O-(2-N,N-dimethylaminoxyethyl)-5-methyluridine-3'-(2-cyanoethyl)-N,N-diisopropylphosphoramidite] as a foam (1.04g, 74.9%).

5

2'-(Aminooxyethoxy) nucleoside amidites

2'-(Aminooxyethoxy) nucleoside amidites [also known in the art as 2'-O-(aminooxyethyl) nucleoside amidites] are prepared as described in the following paragraphs. Adenosine, cytidine and 10 thymidine nucleoside amidites are prepared similarly.

N2-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine-3'-(2-cyanoethyl)-N,N-diisopropylphosphoramidite]

15 The 2'-O-aminooxyethyl guanosine analog may be obtained by selective 2'-O-alkylation of diaminopurine riboside. Multigram quantities of diaminopurine riboside may be purchased from Schering AG (Berlin) to provide 2'-O-(2-ethylacetyl) diaminopurine riboside along with a minor amount of the 3'-O- 20 isomer. 2'-O-(2-ethylacetyl) diaminopurine riboside may be resolved and converted to 2'-O-(2-ethylacetyl)guanosine by treatment with adenosine deaminase. (McGee, D. P. C., Cook, P. D., Guinosso, C. J., WO 94/02501 A1 940203.) Standard protection procedures should afford 2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine and 2-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine which may be reduced to provide 2-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-hydroxyethyl)-5'-O-(4,4'-dimethoxytrityl)guanosine. As before the hydroxyl group 25 may be displaced by N-hydroxypthalimide via a Mitsunobu reaction, and the protected nucleoside may phosphitylated as usual to yield 2-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-[(2-phthalmidoxy)ethyl]-5'-O-(4,4'-dimethoxytrityl)guanosine-3'-(2-cyanoethyl)-N,N-diisopropylphosphoramidite].

35

2'-dimethylaminoethoxyethoxy (2'-DMAEOE) nucleoside amidites

2'-dimethylaminoethoxyethoxy nucleoside amidites (also known in the art as 2'-O-dimethylaminoethoxyethyl, i.e., 2'-O-

-60-

CH₂-O-CH₂-N(CH₃)₂, or 2'-DMAEOE nucleoside amidites) are prepared as follows. Other nucleoside amidites are prepared similarly.

2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine

5 2[2-(Dimethylamino)ethoxy]ethanol (Aldrich, 6.66 g, 50 mmol) is slowly added to a solution of borane in tetrahydrofuran (1 M, 10 mL, 10 mmol) with stirring in a 100 mL bomb. Hydrogen gas evolves as the solid dissolves. O²⁻, 2'-anhydro-5-methyluridine (1.2 g, 5 mmol), and sodium bicarbonate (2.5 mg) 10 are added and the bomb is sealed, placed in an oil bath and heated to 155°C for 26 hours. The bomb is cooled to room temperature and opened. The crude solution is concentrated and the residue partitioned between water (200 mL) and hexanes (200 mL). The excess phenol is extracted into the hexane layer. The 15 aqueous layer is extracted with ethyl acetate (3x200 mL) and the combined organic layers are washed once with water, dried over anhydrous sodium sulfate and concentrated. The residue is columned on silica gel using methanol/methylene chloride 1:20 (which has 2% triethylamine) as the eluent. As the column 20 fractions are concentrated a colorless solid forms which is collected to give the title compound as a white solid.

5'-O-dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine

25 To 0.5 g (1.3 mmol) of 2'-O-[2(2-N,N-dimethylamino-ethoxy)ethyl]-5-methyl uridine in anhydrous pyridine (8 mL), triethylamine (0.36 mL) and dimethoxytrityl chloride (DMT-Cl, 0.87 g, 2 eq.) are added and stirred for 1 hour. The reaction 30 mixture is poured into water (200 mL) and extracted with CH₂Cl₂ (2x200 mL). The combined CH₂Cl₂ layers are washed with saturated NaHCO₃ solution, followed by saturated NaCl solution and dried over anhydrous sodium sulfate. Evaporation of the solvent followed by silica gel chromatography using MeOH:CH₂Cl₂:Et₃N (20:1, v/v, with 1% triethylamine) gives the title compound.

-61-

5'-O-Dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)-ethyl]-5-methyl uridine-3'-O-(cyanoethyl-N,N-diisopropyl)phosphoramidite

Diisopropylaminotetrazolide (0.6 g) and 2-cyanoethoxy-N,N-diisopropyl phosphoramidite (1.1 mL, 2 eq.) are added to a solution of 5'-O-dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyluridine (2.17 g, 3 mmol) dissolved in CH₂Cl₂ (20 mL) under an atmosphere of argon. The reaction mixture is stirred overnight and the solvent evaporated. The resulting residue is purified by silica gel flash column chromatography with ethyl acetate as the eluent to give the title compound.

Example 2

15 Oligonucleotide synthesis

Unsubstituted and substituted phosphodiester (P=O) oligonucleotides are synthesized on an automated DNA synthesizer (Applied Biosystems model 380B) using standard phosphoramidite chemistry with oxidation by iodine.

20 Phosphorothioates (P=S) are synthesized as for the phosphodiester oligonucleotides except the standard oxidation bottle was replaced by 0.2 M solution of 3H-1,2-benzodithiole-3-one 1,1-dioxide in acetonitrile for the stepwise thiation of the phosphite linkages. The thiation wait step was increased to 68 sec and was followed by the capping step. After cleavage from the CPG column and deblocking in concentrated ammonium hydroxide at 55°C (18 h), the oligonucleotides were purified by precipitating twice with 2.5 volumes of ethanol from a 0.5 M NaCl solution. Phosphinate oligonucleotides are prepared as 30 described in U.S. Patent 5,508,270, herein incorporated by reference.

Alkyl phosphonate oligonucleotides are prepared as described in U.S. Patent 4,469,863, herein incorporated by reference.

35 3'-Deoxy-3'-methylene phosphonate oligonucleotides are prepared as described in U.S. Patents 5,610,289 or 5,625,050, herein incorporated by reference.

Phosphoramidite oligonucleotides are prepared as described in U.S. Patent, 5,256,775 or U.S. Patent 5,366,878, herein

-62-

incorporated by reference.

Alkylphosphonothioate oligonucleotides are prepared as described in published PCT applications PCT/US94/00902 and PCT/US93/06976 (published as WO 94/17093 and WO 94/02499, 5 respectively), herein incorporated by reference.

3'-Deoxy-3'-amino phosphoramidate oligonucleotides are prepared as described in U.S. Patent 5,476,925, herein incorporated by reference.

10 Phosphotriester oligonucleotides are prepared as described in U.S. Patent 5,023,243, herein incorporated by reference.

Borano phosphate oligonucleotides are prepared as described in U.S. Patents 5,130,302 and 5,177,198, both herein incorporated by reference.

15 **Example 3**

Oligonucleoside Synthesis

Methylenemethylimino linked oligonucleosides, also identified as MMI linked oligonucleosides, methylenedimethyl-hydrazo linked oligonucleosides, also identified as MDH linked 20 oligonucleosides, and methylenecarbonylamino linked oligonucleosides, also identified as amide-3 linked oligonucleosides, and methyleneaminocarbonyl linked oligonucleosides, also identified as amide-4 linked oligonucleosides, as well as mixed backbone compounds having, for instance, 25 alternating MMI and P=O or P=S linkages are prepared as described in U.S. Patents 5,378,825, 5,386,023, 5,489,677, 5,602,240 and 5,610,289, all of which are herein incorporated by reference.

30 Formacetal and thioformacetal linked oligonucleosides are prepared as described in U.S. Patents 5,264,562 and 5,264,564, herein incorporated by reference.

Ethylene oxide linked oligonucleosides are prepared as described in U.S. Patent 5,223,618, herein incorporated by reference.

35

Example 4

PNA Synthesis

Peptide nucleic acids (PNAs) are prepared in accordance with any of the various procedures referred to in Peptide

-63-

Nucleic Acids (PNA): Synthesis, Properties and Potential Applications, *Bioorganic & Medicinal Chemistry*, 1996, 4, 5-23. They may also be prepared in accordance with U.S. Patents 5,539,082, 5,700,922, and 5,719,262, herein incorporated by reference.

Example 5

Synthesis of Chimeric Oligonucleotides

Chimeric oligonucleotides, oligonucleosides or mixed oligonucleotides/oligonucleosides of the invention can be of several different types. These include a first type wherein the "gap" segment of linked nucleosides is positioned between 5' and 3' "wing" segments of linked nucleosides and a second "open end" type wherein the "gap" segment is located at either the 3' or the 5' terminus of the oligomeric compound. Oligonucleotides of the first type are also known in the art as "gapmers" or gapped oligonucleotides. Oligonucleotides of the second type are also known in the art as "hemimers" or "wingmers".

[2'-O-Me]--[2'-deoxy]--[2'-O-Me] Chimeric Phosphorothioate Oligonucleotides

Chimeric oligonucleotides having 2'-O-alkyl phosphorothioate and 2'-deoxy phosphorothioate oligonucleotide segments are synthesized using an Applied Biosystems automated DNA synthesizer Model 380B, as above. Oligonucleotides are synthesized using the automated synthesizer and 2'-deoxy-5'-dimethoxytrityl-3'-O-phosphoramidite for the DNA portion and 5'-dimethoxytrityl-2'-O-methyl-3'-O-phosphoramidite for 5' and 3' wings. The standard synthesis cycle is modified by increasing the wait step after the delivery of tetrazole and base to 600 s repeated four times for RNA and twice for 2'-O-methyl. The fully protected oligonucleotide is cleaved from the support and the phosphate group is deprotected in 3:1 ammonia/ethanol at room temperature overnight then lyophilized to dryness. Treatment in methanolic ammonia for 24 hrs at room temperature is then done to deprotect all bases and sample was again lyophilized to dryness. The pellet is resuspended in 1M TBAF in THF for 24 hrs at room temperature to deprotect the 2' positions. The reaction is then quenched with 1M TEAA and the sample is then reduced to 1/2 volume by rotovac before being

-64-

desalted on a G25 size exclusion column. The oligo recovered is then analyzed spectrophotometrically for yield and for purity by capillary electrophoresis and by mass spectrometry.

5 [2'-O-(2-Methoxyethyl)]--[2'-deoxy]--[2'-O-(Methoxyethyl)]
Chimeric Phosphorothioate Oligonucleotides

[2'-O-(2-methoxyethyl)]--[2'-deoxy]--[-2'-O-(methoxyethyl)] chimeric phosphorothioate oligonucleotides were prepared as per the procedure above for the 2'-O-methyl chimeric 10 oligonucleotide, with the substitution of 2'-O-(methoxyethyl) amidites for the 2'-O-methyl amidites.

[2'-O-(2-Methoxyethyl) Phosphodiester]--[2'-deoxy Phosphoro-thioate]--[2'-O-(2-Methoxyethyl) Phosphodiester] Chimeric 15 Oligonucleotides

[2'-O-(2-methoxyethyl phosphodiester)]--[2'-deoxy phosphoro-thioate]--[2'-O-(methoxyethyl) phosphodiester] chimeric oligonucleotides are prepared as per the above procedure for the 2'-O-methyl chimeric oligonucleotide with the substitution of 20 2'-O-(methoxyethyl) amidites for the 2'-O-methyl amidites, oxidization with iodine to generate the phosphodiester internucleotide linkages within the wing portions of the chimeric structures and sulfurization utilizing 3, H-1,2 benzodithiole-3-one 1,1 dioxide (Beaucage Reagent) to generate 25 the phosphorothioate internucleotide linkages for the center gap.

Other chimeric oligonucleotides, chimeric oligonucleosides and mixed chimeric oligonucleotides/oligonucleosides are synthesized according to United States patent 5,623,065, herein 30 incorporated by reference.

Example 6

Oligonucleotide Isolation

After cleavage from the controlled pore glass column 35 (Applied Biosystems) and deblocking in concentrated ammonium hydroxide at 55°C for 18 hours, the oligonucleotides or oligonucleosides are purified by precipitation twice out of 0.5 M NaCl with 2.5 volumes ethanol. Synthesized oligonucleotides were analyzed by polyacrylamide gel electrophoresis on

-65-

denaturing gels and judged to be at least 85% full length material. The relative amounts of phosphorothioate and phosphodiester linkages obtained in synthesis were periodically checked by ^{31}P nuclear magnetic resonance spectroscopy, and for some studies oligonucleotides were purified by HPLC, as described by Chiang et al., *J. Biol. Chem.* 1991, 266, 18162-18171. Results obtained with HPLC-purified material were similar to those obtained with non-HPLC purified material.

10 **Example 7**

Oligonucleotide Synthesis - 96 Well Plate Format

Oligonucleotides were synthesized via solid phase P(III) phosphoramidite chemistry on an automated synthesizer capable of assembling 96 sequences simultaneously in a standard 96 well format. Phosphodiester internucleotide linkages were afforded by oxidation with aqueous iodine. Phosphorothioate internucleotide linkages were generated by sulfurization utilizing 3, H-1,2 benzodithiole-3-one 1,1 dioxide (Beaucage Reagent) in anhydrous acetonitrile. Standard base-protected beta-cyanoethyldiisopropyl phosphoramidites were purchased from commercial vendors (e.g. PE-Applied Biosystems, Foster City, CA, or Pharmacia, Piscataway, NJ). Non-standard nucleosides are synthesized as per known literature or patented methods. They are utilized as base protected beta-cyanoethyldiisopropyl phosphoramidites.

Oligonucleotides were cleaved from support and deprotected with concentrated NH_4OH at elevated temperature (55-60°C) for 12-16 hours and the released product then dried in vacuo. The dried product was then re-suspended in sterile water to afford a master plate from which all analytical and test plate samples are then diluted utilizing robotic pipettors.

Example 8

Oligonucleotide Analysis - 96 Well Plate Format

The concentration of oligonucleotide in each well was assessed by dilution of samples and UV absorption spectroscopy. The full-length integrity of the individual products was evaluated by capillary electrophoresis (CE) in either the 96 well format (Beckman P/ACE™ MDQ) or, for individually prepared

-66-

samples, on a commercial CE apparatus (e.g., Beckman P/ACE™ 5000, ABI 270). Base and backbone composition was confirmed by mass analysis of the compounds utilizing electrospray-mass spectroscopy. All assay test plates were diluted from the 5 master plate using single and multi-channel robotic pipettors. Plates were judged to be acceptable if at least 85% of the compounds on the plate were at least 85% full length.

Example 9

10 **Cell culture and oligonucleotide treatment**

The effect of antisense compounds on target nucleic acid expression can be tested in any of a variety of cell types provided that the target nucleic acid is present at measurable levels. This can be routinely determined using, for example, 15 PCR or Northern blot analysis. The following 4 cell types are provided for illustrative purposes, but other cell types can be routinely used, provided that the target is expressed in the cell type chosen. This can be readily determined by methods routine in the art, for example Northern blot analysis, 20 Ribonuclease protection assays, or RT-PCR.

T-24 cells:

The human transitional cell bladder carcinoma cell line T-24 was obtained from the American Type Culture Collection 25 (ATCC) (Manassas, VA). T-24 cells were routinely cultured in complete McCoy's 5A basal media (Gibco/Life Technologies, Gaithersburg, MD) supplemented with 10% fetal calf serum (Gibco/Life Technologies, Gaithersburg, MD), penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Gibco/Life 30 Technologies, Gaithersburg, MD). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of 7000 cells/well for use in RT-PCR analysis.

For Northern blotting or other analysis, cells may be 35 seeded onto 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide.

A549 cells:

-67-

The human lung carcinoma cell line A549 was obtained from the American Type Culture Collection (ATCC) (Manassas, VA). A549 cells were routinely cultured in DMEM basal media (Gibco/Life Technologies, Gaithersburg, MD) supplemented with 5 10% fetal calf serum (Gibco/Life Technologies, Gaithersburg, MD), penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Gibco/Life Technologies, Gaithersburg, MD). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence.

10

NHDF cells:

Human neonatal dermal fibroblast (NHDF) were obtained from the Clonetics Corporation (Walkersville MD). NHDFs were routinely maintained in Fibroblast Growth Medium (Clonetics 15 Corporation, Walkersville MD) supplemented as recommended by the supplier. Cells were maintained for up to 10 passages as recommended by the supplier.

20

HEK cells:

Human embryonic keratinocytes (HEK) were obtained from the Clonetics Corporation (Walkersville MD). HEKs were routinely maintained in Keratinocyte Growth Medium (Clonetics Corporation, Walkersville MD) formulated as recommended by the supplier. Cells were routinely maintained for up to 10 passages as 25 recommended by the supplier.

20

Treatment with antisense compounds:

When cells reached 80% confluency, they were treated with oligonucleotide. For cells grown in 96-well plates, wells were 30 washed once with 200 μ L OPTI-MEMTM-1 reduced-serum medium (Gibco BRL) and then treated with 130 μ L of OPTI-MEMTM-1 containing 3.75 μ g/mL LIPOFECTINTM (Gibco BRL) and the desired concentration of oligonucleotide. After 4-7 hours of treatment, the medium was replaced with fresh medium. Cells were harvested 16-24 hours 35 after oligonucleotide treatment.

30

The concentration of oligonucleotide used varies from cell line to cell line. To determine the optimal oligonucleotide concentration for a particular cell line, the cells are treated

-68-

with a positive control oligonucleotide at a range of concentrations. For human cells the positive control oligonucleotide is ISIS 13920, **TCCGTCATCGCTCCTCAGGG**, SEQ ID NO: 1, a 2'-O-methoxyethyl gapmer (2'-O-methoxyethyls shown in bold) with a phosphorothioate backbone which is targeted to human H-ras. For mouse or rat cells the positive control oligonucleotide is ISIS 15770, **ATGCATTCTGCCGCCAAGGA**, SEQ ID NO: 2, a 2'-O-methoxyethyl gapmer (2'-O-methoxyethyls shown in bold) with a phosphorothioate backbone which is targeted to both mouse and rat c-raf. The concentration of positive control oligonucleotide that results in 80% inhibition of c-Ha-ras (for ISIS 13920) or c-raf (for ISIS 15770) mRNA is then utilized as the screening concentration for new oligonucleotides in subsequent experiments for that cell line. If 80% inhibition is not achieved, the lowest concentration of positive control oligonucleotide that results in 60% inhibition of H-ras or c-raf mRNA is then utilized as the oligonucleotide screening concentration in subsequent experiments for that cell line. If 60% inhibition is not achieved, that particular cell line is deemed as unsuitable for oligonucleotide transfection experiments.

Example 10

Analysis of oligonucleotide inhibition of Protein Kinase R expression

Antisense modulation of Protein Kinase R expression can be assayed in a variety of ways known in the art. For example, Protein Kinase R mRNA levels can be quantitated by, e.g., Northern blot analysis, competitive polymerase chain reaction (PCR), or real-time PCR (RT-PCR). Real-time quantitative PCR is presently preferred. RNA analysis can be performed on total cellular RNA or poly(A)+ mRNA. Methods of RNA isolation are taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.1.1-4.2.9 and 4.5.1-4.5.3, 30 John Wiley & Sons, Inc., 1993. Northern blot analysis is routine in the art and is taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.2.1-4.2.9, John Wiley & Sons, Inc., 1996. Real-time quantitative (PCR) can be conveniently accomplished using the

-69-

commercially available ABI PRISM™ 7700 Sequence Detection System, available from PE-Applied Biosystems, Foster City, CA and used according to manufacturer's instructions.

Protein levels of Protein Kinase R can be quantitated in a variety of ways well known in the art, such as immunoprecipitation, Western blot analysis (immunoblotting), ELISA or fluorescence-activated cell sorting (FACS). Antibodies directed to Protein Kinase R can be identified and obtained from a variety of sources, such as the MSRS catalog of antibodies (Aerie Corporation, Birmingham, MI), or can be prepared via conventional antibody generation methods. Methods for preparation of polyclonal antisera are taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 11.12.1-11.12.9, John Wiley & Sons, Inc., 1997. Preparation of monoclonal antibodies is taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 11.4.1-11.11.5, John Wiley & Sons, Inc., 1997.

Immunoprecipitation methods are standard in the art and can be found at, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 10.16.1-10.16.11, John Wiley & Sons, Inc., 1998. Western blot (immunoblot) analysis is standard in the art and can be found at, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 10.8.1-10.8.21, John Wiley & Sons, Inc., 1997. Enzyme-linked immunosorbent assays (ELISA) are standard in the art and can be found at, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 11.2.1-11.2.22, John Wiley & Sons, Inc., 1991.

30 **Example 11**

Poly(A)+ mRNA isolation

Poly(A)+ mRNA was isolated according to Miura et al., *Clin. Chem.*, 1996, 42, 1758-1764. Other methods for poly(A)+ mRNA isolation are taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.5.1-4.5.3, John Wiley & Sons, Inc., 1993. Briefly, for cells grown on 96-well plates, growth medium was removed from the cells and each well was washed with 200 µL cold PBS. 60 µL lysis buffer (10

-70-

5 mM Tris-HCl, pH 7.6, 1 mM EDTA, 0.5 M NaCl, 0.5% NP-40, 20 mM vanadyl-ribonucleoside complex) was added to each well, the plate was gently agitated and then incubated at room temperature for five minutes. 55 μ L of lysate was transferred to Oligo d(T) 5 coated 96-well plates (AGCT Inc., Irvine CA). Plates were incubated for 60 minutes at room temperature, washed 3 times with 200 μ L of wash buffer (10 mM Tris-HCl pH 7.6, 1 mM EDTA, 0.3 M NaCl). After the final wash, the plate was blotted on paper towels to remove excess wash buffer and then air-dried for 5 10 minutes. 60 μ L of elution buffer (5 mM Tris-HCl pH 7.6), preheated to 70°C was added to each well, the plate was incubated on a 90°C hot plate for 5 minutes, and the eluate was then transferred to a fresh 96-well plate.

15 Cells grown on 100 mm or other standard plates may be treated similarly, using appropriate volumes of all solutions.

Example 12

Total RNA Isolation

20 Total RNA was isolated using an RNEASY 96™ kit and buffers purchased from Qiagen Inc. (Valencia CA) following the manufacturer's recommended procedures. Briefly, for cells grown on 96-well plates, growth medium was removed from the cells and each well was washed with 200 μ L cold PBS. 100 μ L Buffer RLT was added to each well and the plate vigorously agitated for 20 25 seconds. 100 μ L of 70% ethanol was then added to each well and the contents mixed by pipetting three times up and down. The samples were then transferred to the RNEASY 96™ well plate attached to a QIAVAC™ manifold fitted with a waste collection tray and attached to a vacuum source. Vacuum was applied for 15 30 seconds. 1 mL of Buffer RW1 was added to each well of the RNEASY 96™ plate and the vacuum again applied for 15 seconds. 1 mL of Buffer RPE was then added to each well of the RNEASY 96™ plate and the vacuum applied for a period of 15 seconds. The Buffer RPE wash was then repeated and the vacuum was applied for 35 an additional 10 minutes. The plate was then removed from the QIAVAC™ manifold and blotted dry on paper towels. The plate was

-71-

then re-attached to the QIAVAC™ manifold fitted with a collection tube rack containing 1.2 mL collection tubes. RNA was then eluted by pipetting 60 μ L water into each well, incubating 1 minute, and then applying the vacuum for 30 5 seconds. The elution step was repeated with an additional 60 μ L water.

The repetitive pipetting and elution steps may be automated using a QIAGEN Bio-Robot 9604 (Qiagen, Inc., Valencia CA). Essentially, after lysing of the cells on the culture plate, the 10 plate is transferred to the robot deck where the pipetting, DNase treatment and elution steps are carried out.

Example 13

Real-time Quantitative PCR Analysis of Protein Kinase R mRNA

15 Levels

Quantitation of Protein Kinase R mRNA levels was determined by real-time quantitative PCR using the ABI PRISM™ 7700 Sequence Detection System (PE-Applied Biosystems, Foster City, CA) according to manufacturer's instructions. This is a closed- 20 tube, non-gel-based, fluorescence detection system which allows high-throughput quantitation of polymerase chain reaction (PCR) products in real-time. As opposed to standard PCR, in which amplification products are quantitated after the PCR is completed, products in real-time quantitative PCR are 25 quantitated as they accumulate. This is accomplished by including in the PCR reaction an oligonucleotide probe that anneals specifically between the forward and reverse PCR primers, and contains two fluorescent dyes. A reporter dye (e.g., JOE, FAM, or VIC, obtained from either Operon 30 Technologies Inc., Alameda, CA or PE-Applied Biosystems, Foster City, CA) is attached to the 5' end of the probe and a quencher dye (e.g., TAMRA, obtained from either Operon Technologies Inc., Alameda, CA or PE-Applied Biosystems, Foster City, CA) is attached to the 3' end of the probe. When the probe and dyes 35 are intact, reporter dye emission is quenched by the proximity of the 3' quencher dye. During amplification, annealing of the probe to the target sequence creates a substrate that can be cleaved by the 5'-exonuclease activity of Taq polymerase.

-72-

During the extension phase of the PCR amplification cycle, cleavage of the probe by Taq polymerase releases the reporter dye from the remainder of the probe (and hence from the quencher moiety) and a sequence-specific fluorescent signal is generated.

5 With each cycle, additional reporter dye molecules are cleaved from their respective probes, and the fluorescence intensity is monitored at regular intervals by laser optics built into the ABI PRISM™ 7700 Sequence Detection System. In each assay, a series of parallel reactions containing serial dilutions of mRNA
10 from untreated control samples generates a standard curve that is used to quantitate the percent inhibition after antisense oligonucleotide treatment of test samples.

Prior to quantitative PCR analysis, primer-probe sets specific to the target gene being measured are evaluated for
15 their ability to be "multiplexed" with a GAPDH amplification reaction. In multiplexing, both the target gene and the internal standard gene GAPDH are amplified concurrently in a single sample. In this analysis, mRNA isolated from untreated cells is serially diluted. Each dilution is amplified in the
20 presence of primer-probe sets specific for GAPDH only, target gene only ("single-plexing"), or both (multiplexing). Following PCR amplification, standard curves of GAPDH and target mRNA signal as a function of dilution are generated from both the single-plexed and multiplexed samples. If both the slope and
25 correlation coefficient of the GAPDH and target signals generated from the multiplexed samples fall within 10% of their corresponding values generated from the single-plexed samples, the primer-probe set specific for that target is deemed multiplexable. Other methods of PCR are also known in the art.

30 PCR reagents were obtained from PE-Applied Biosystems, Foster City, CA. RT-PCR reactions were carried out by adding 25 µL PCR cocktail (1x TAQMANTM buffer A, 5.5 mM MgCl₂, 300 µM each of dATP, dCTP and dGTP, 600 µM of dUTP, 100 nM each of forward primer, reverse primer, and probe, 20 Units RNase inhibitor,
35 1.25 Units AMPLITAQ GOLD™, and 12.5 Units MuLV reverse transcriptase) to 96 well plates containing 25 µL total RNA solution. The RT reaction was carried out by incubation for 30

-73-

minutes at 48°C. Following a 10 minute incubation at 95°C to activate the AMPLITAQ GOLD™, 40 cycles of a two-step PCR protocol were carried out: 95°C for 15 seconds (denaturation) followed by 60°C for 1.5 minutes (annealing/extension).

5 Gene target quantities obtained by real time RT-PCR are normalized using either the expression level of GAPDH, a gene whose expression is constant, or by quantifying total RNA using RiboGreen™ (Molecular Probes, Inc. Eugene, OR). GAPDH expression is quantified by real time RT-PCR, by being run simultaneously
10 with the target, multiplexing, or separately. Total RNA is quantified using RiboGreen™ RNA quantification reagent from Molecular Probes. Methods of RNA quantification by RiboGreen™ are taught in Jones, L.J., et al, *Analytical Biochemistry*, 1998, 265, 368-374.

15 In this assay, 175 µL of RiboGreen™ working reagent (RiboGreen™ reagent diluted 1:2865 in 10mM Tris-HCl, 1 mM EDTA, pH 7.5) is pipetted into a 96-well plate containing 25uL purified, cellular RNA. The plate is read in a CytoFluor 4000 (PE Applied Biosystems) with excitation at 480nm and emission at
20 520nm.

25 Probes and primers to human Protein Kinase R were designed to hybridize to a human Protein Kinase R sequence, using published sequence information (GenBank accession number NM_002759, incorporated herein as SEQ ID NO:3). For human Protein Kinase R the PCR primers were:

forward primer: CAGAATTGACGGAAAGACTTACGTTA (SEQ ID NO: 4)
reverse primer: CATGATCAAAGTTTGCCAATGC (SEQ ID NO: 5) and the PCR probe was: FAM-CGCTCCGCCTCTCGTTATTATTTAACACG-TAMRA (SEQ ID NO: 6) where FAM (PE-Applied Biosystems, Foster City, CA) is the fluorescent reporter dye and TAMRA (PE-Applied Biosystems, Foster City, CA) is the quencher dye. For human GAPDH the PCR primers were:

forward primer: GAAGGTGAAGGTCGGAGTC (SEQ ID NO: 7)
reverse primer: GAAGATGGTGATGGGATTTC (SEQ ID NO: 8) and the PCR probe was: 5' JOE-CAAGCTTCCGTTCTCAGCC- TAMRA 3' (SEQ ID NO: 9) where JOE (PE-Applied Biosystems, Foster City, CA) is the fluorescent reporter dye and TAMRA (PE-Applied Biosystems, Foster City, CA) is the quencher dye.

Example 14**Northern blot analysis of Protein Kinase R mRNA levels**

5 Eighteen hours after antisense treatment, cell monolayers
were washed twice with cold PBS and lysed in 1 mL RNAZOL™ (TEL-
TEST "B" Inc., Friendswood, TX). Total RNA was prepared
following manufacturer's recommended protocols. Twenty
micrograms of total RNA was fractionated by electrophoresis
10 through 1.2% agarose gels containing 1.1% formaldehyde using a
MOPS buffer system (AMRESCO, Inc. Solon, OH). RNA was
transferred from the gel to HYBOND™-N+ nylon membranes (Amersham
Pharmacia Biotech, Piscataway, NJ) by overnight capillary
transfer using a Northern/Southern Transfer buffer system (TEL-
15 TEST "B" Inc., Friendswood, TX). RNA transfer was confirmed by
UV visualization. Membranes were fixed by UV cross-linking
using a STRATALINKER™ UV Crosslinker 2400 (Stratagene, Inc, La
Jolla, CA) and then probed using QUICKHYB™ hybridization
solution (Stratagene, La Jolla, CA) using manufacturer's
20 recommendations for stringent conditions.

 To detect human Protein Kinase R, a human Protein Kinase R
specific probe was prepared by PCR using the forward primer
CAGAATTGACGGAAAGACTTACGTTA (SEQ ID NO: 4) and the reverse primer
CATGATCAAGTTTGCCAATGC (SEQ ID NO: 5). To normalize for
25 variations in loading and transfer efficiency membranes were
stripped and probed for human glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) RNA (Clontech, Palo Alto, CA).

 Hybridized membranes were visualized and quantitated using
a PHOSPHORIMAGER™ and IMAGEQUANT™ Software V3.3 (Molecular
30 Dynamics, Sunnyvale, CA). Data was normalized to GAPDH levels
in untreated controls.

Example 15

 Antisense inhibition of human Protein Kinase R expression by
35 chimeric phosphorothioate oligonucleotides having 2'-MOE wings
and a deoxy gap

 In accordance with the present invention, a series of
oligonucleotides were designed to target different regions of

-75-

the human Protein Kinase R RNA, using published sequences (GenBank accession number NM_002759, incorporated herein as SEQ ID NO: 3, residues 33001-86000 from GenBank accession number AC007899, incorporated herein as SEQ ID NO: 10, GenBank accession number AW468555, representing an EST suggesting an mRNA variant that extends from the 3' end of exon 3 into intron 3, the complement of which is incorporated herein as SEQ ID NO: 11, GenBank accession number AI417032, an EST suggesting an mRNA variant that extends from the 3' end of exon 2 into intron 2, incorporated herein as SEQ ID NO: 12, and GenBank accession number AW149070, representing an extension 3' from the end of SEQ ID NO: 3, the complement of which is incorporated herein as SEQ ID NO: 13). The oligonucleotides are shown in Table 1. "Target site" indicates the first (5'-most) nucleotide number on the particular target sequence to which the oligonucleotide binds. All compounds in Table 1 are chimeric oligonucleotides ("gapmers") 20 nucleotides in length, composed of a central "gap" region consisting of ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by five-nucleotide "wings". The wings are composed of 2'-methoxyethyl (2'-MOE) nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines. The compounds were analyzed for their effect on human Protein Kinase R mRNA levels by quantitative real-time PCR as described in other examples herein. Data are averages from two experiments. If present, "N.D." indicates "no data".

Table 1

30 Inhibition of human Protein Kinase R mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap

ISIS #	REGION	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	%INHIB	SEQ ID NO
139382	5'UTR	3	51	caagtgtggagctgaatgcc	40	14
139383	5'UTR	3	63	ctgtggttctaccaagtgt	59	15
139384	5'UTR	3	68	cgtgcctgtggttcaccaa	32	16
139385	5'UTR	3	79	tctatgcttgcgtgcctgt	65	17
139386	5'UTR	3	115	gacctcgatgcctcgatgaa	42	18
139387	5'UTR	3	151	tatgatagccagggtctcct	22	19
139388	5'UTR	3	169	ccagcgaagactaaggctca	50	20
139389	5'UTR	3	172	ataccagcgaagactaaggt	70	21

139390	5'UTR	3	243	gctccagaaaactggtaaaag	0	22
139391	5'UTR	3	269	caaatccaggaaggcaaact	12	23
139392	5'UTR	3	330	cagagaagcaaacctgagtc	62	24
139393	5'UTR	3	380	aaatgcacgcagataatcac	0	25
139394	5'UTR	3	384	tccaaaatgcacgcagataa	15	26
139395	5'UTR	3	410	ttcccgatctctggttggaa	55	27
139396	Start Codon	3	428	atcaccagccatTTCTTCTT	10	28
139397	Coding	3	507	gcagttcttgatatttaagt	12	29
139398	Coding	3	521	aggccctgaatttaggcagtt	7	30
139399	Coding	3	553	ataacttgaatgtaaacct	17	31
139400	Coding	3	559	tctattataacttggaaatgt	22	32
139401	Coding	3	586	ccttcaccttctggaaattc	50	33
139402	Coding	3	593	tgatctacccacccaccc	43	34
139403	Coding	3	629	agctaatttgcgtgcggcat	52	35
139404	Coding	3	634	tcaacagctaatttgcgtgc	0	36
139405	Coding	3	691	gaattcgttgggtcaataa	37	37
139406	Coding	3	706	gataatccttcttgcggatt	47	38
139407	Coding	3	779	acactgttccataatttacag	48	39
139408	Coding	3	815	ataatggaaatccttctggcc	62	40
139409	Coding	3	856	cctgtaccaataactatattc	49	41
139410	Coding	3	864	tagtagaacctgtaccaata	45	42
139411	Coding	3	870	cctgttttagtagaacctgt	0	43
139412	Coding	3	875	tgcttcctgtttagtagaac	42	44
139413	Coding	3	995	taaagagttgtttggact	35	45
139414	Coding	3	1019	ttcagaagcgagtggtgtgg	74	46
139415	Coding	3	1033	ccttcagatgtatttcaga	42	47
139416	Coding	3	1076	gtcactgttagaatttatct	72	48
139417	Coding	3	1090	gaactgtttaactgtcact	66	49
139418	Coding	3	1148	tgccaaagatctttgcct	23	50
139419	Coding	3	1177	tcttcatgtcaggaaaggc	67	51
139420	Coding	3	1261	aaaacttggccaaatccacc	1	52
139421	Coding	3	1269	ttgccttgcggaaacttggcc	79	53
139422	Coding	3	1276	ctgtgtttgtttgcggaaac	29	54
139423	Coding	3	1305	gtttaataacgttaagtcttt	69	55
139424	Coding	3	1334	ctccgccttcgttattat	33	56
139425	Coding	3	1529	tttatcacagaattccattt	24	57
139426	Coding	3	1543	tgttccaagggtcccttattc	11	58
139427	Coding	3	1660	agatctctatgttagattt	29	59
139428	Coding	3	1674	tattacttggcttaagatct	56	60
139429	Coding	3	1685	tactaagaatattacttg	20	61
139430	Coding	3	1803	gcgaagaaatctgttctgg	8	62
139431	Coding	3	1822	acttccttcatgtcttg	45	63
139432	Coding	3	1847	aattagccccaaagcgtaga	36	64
139433	Coding	3	1891	gatgtttcaaaaggcgtgtc	0	65
139434	Coding	3	1897	aactttgtatgtttcaaaagc	11	66
139435	Coding	3	1905	ctgtaaaaactttgtatgtt	48	67
139436	Coding	3	1973	gagtaatttctgttagaagag	34	68
139437	Coding	3	1976	tgagagtaatttctgttagaa	25	69
139438	Coding	3	2042	gctttcttcacacagtca	23	70
139439	Stop Codon	3	2080	gaagggctctaacatgtgt	68	71
139440	3'UTR	3	2092	gatacttttcagaaggcgt	78	72
139441	3'UTR	3	2162	aaggtaaatatctattgata	39	73
139442	3'UTR	3	2220	ctgtttctgcagaaaggatta	21	74
139443	3'UTR	3	2251	atgttttgcaggaaaaaga	0	75
139444	3'UTR	3	2651	ttgattcattaatgtataa	0	76
139445	3'UTR	3	2684	gcggtagaaatttataaaat	9	77
139446	3'UTR	3	2743	ccagctggcttgcgttat	46	78
139447	3'UTR	3	2764	tttaatgagtaccatattc	60	79

-77-

139448	Intron2	10	8938	tatgagcaaactgaaatgta	50	80
139449	Intron 3	10	9384	attgacttagatgatgccac	34	81
139450	Intron 10	10	22626	gttgaatgtaaaactcaaat	2	82
139451	Intron 11	10	23227	cttggattgggagcaggcag	0	83
139452	Intron 11	10	27862	aactcctgacccctcaggtgat	14	84
139453	Intron 11	10	28126	ctcaagtccatcatctccca	12	85
139454	mRNA variant	11	233	ttgtccttgcgatagttgc	57	86
139455	mRNA variant	11	304	ccttcctgtgtccatgtgtt	30	87
139456	mRNA variant	11	402	tgcacccattaactcgcat	17	88
139457	mRNA variant	12	333	tctggaaacaataacaatttg	1	89
139458	mRNA variant	12	443	caaatgagtgccataaaacc	0	90
139459	3'UTR	13	410	aatgccaaattgtttccga	43	91

As shown in Table 1, SEQ ID NOS 14, 15, 16, 17, 18, 20, 21, 24, 27, 33, 34, 35, 37, 38, 39, 40, 41, 42, 44, 45, 46, 47, 48, 5 49, 51, 53, 55, 56, 60, 63, 64, 67, 68, 71, 72, 73, 78, 79, 80, 81, 86, 87 and 91 demonstrated at least 30% inhibition of human Protein Kinase R expression in this assay and are therefore preferred. The target sites to which these preferred sequences are complementary are herein referred to as "active sites" and 10 are therefore preferred sites for targeting by compounds of the present invention.

Example 16

15 Western blot analysis of Protein Kinase R protein levels

Western blot analysis (immunoblot analysis) is carried out using standard methods. Cells are harvested 16-20 h after oligonucleotide treatment, washed once with PBS, suspended in Laemmli buffer (100 ul/well), boiled for 5 minutes and loaded on 20 a 16% SDS-PAGE gel. Gels are run for 1.5 hours at 150 V, and transferred to membrane for western blotting. Appropriate primary antibody directed to Protein Kinase R is used, with a radiolabelled or fluorescently labeled secondary antibody directed against the primary antibody species. Bands are 25 visualized using a PHOSPHORIMAGER™ (Molecular Dynamics,

-78-

Sunnyvale CA).

What is claimed is:

5 1. A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding Protein Kinase R, wherein said compound specifically hybridizes with said nucleic acid molecule encoding Protein Kinase R and inhibits the expression of Protein Kinase R.

10 2. The compound of claim 1 which is an antisense oligonucleotide.

15 3. The compound of claim 2 wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO: 14, 15, 16, 17, 18, 20, 21, 24, 27, 33, 34, 35, 37, 38, 39, 40, 41, 42, 44, 45, 46, 47, 48, 49, 51, 53, 55, 56, 60, 63, 64, 67, 68, 71, 72, 73, 78, 79, 80, 81, 86, 87 or 91.

20 4. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

25 5. The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.

6. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

7. The compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

8. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

9. The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.

30 10. The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

35 11. A compound 8 to 50 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of an active site on a nucleic acid molecule encoding Protein Kinase R.

12. A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

13. The composition of claim 12 further comprising a colloidal dispersion system.

-80-

14. The composition of claim 12 wherein the compound is an antisense oligonucleotide.

15. A method of inhibiting the expression of Protein Kinase R in cells or tissues comprising contacting said cells or 5 tissues with the compound of claim 1 so that expression of Protein Kinase R is inhibited.

16. A method of treating an animal having a disease or condition associated with Protein Kinase R comprising administering to said animal a therapeutically or 10 prophylactically effective amount of the compound of claim 1 so that expression of Protein Kinase R is inhibited.

17. The method of claim 16 wherein the disease or condition results from an infection.

18. The method of claim 17 wherein the disease or 15 condition is associated with apoptosis.

19. The method of claim 16 wherein the disease or condition is an autoimmune disorder.

20. A method of modulating the process of RNA-mediated interference (RNAi) in a cell or animal comprising administering to said cell or animal a therapeutically or prophylactically effective amount of the compound of claim 1 so that expression of Protein Kinase R is inhibited.

-1-

SEQUENCE LISTING

<110> Isis Pharmaceuticals, Inc.
Donna T. Ward
Andrew T. Watt

<120> ANTISENSE MODULATION OF PROTEIN KINASE R EXPRESSION

<130> RTSP-0412

<150> 09/953,611
<151> 2001-09-13

<160> 91

<210> 1
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 1
tccgtcatcg ctcctcaggg

20

<210> 2
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 2
atgcattctg cccccaagga

20

<210> 3
<211> 2808
<212> DNA
<213> Homo sapiens

<220>
<221> CDS
<222> (436) . . . (2091)

<400> 3
gcggcggcgg cggcgagtt tgctcatact ttgtgacttg cggtcacagt ggcattcagc 60

tccacacttg gtagaaccac aggcacgaca agcatagaaa catcctaaac aatcttcatc 120

gaggcatcga ggtccatccc aataaaaatc aggagaccct ggctatcata gaccttagtc 180

ttcgctggta tactcgctgt ctgtcaacca gcgggttgcact ttttttaagc cttcttttt 240

-2-

ctcttttacc agtttctgga gcaaattcag tttgccttcc tggatttgta aattgtatg 300
 acctcaaaac tttagcagtt cttccatctg actcaggttt gcttctctgg cggctttcag 360
 aatcaacatc cacacttccg tgattatctg cgtgcatttt ggacaaagct tccaaaccagg 420
 atacgggaag aagaa atg gct ggt gat ctt tca gca ggt ttc ttc atg gag 471
 Met Ala Gly Asp Leu Ser Ala Gly Phe Phe Met Glu
 1 5 10
 gaa ctt aat aca tac cgt cag aag cag gga gta gta ctt aaa tat caa 519
 Glu Leu Asn Thr Tyr Arg Gln Lys Gln Gly Val Val Leu Lys Tyr Gln
 15 20 25
 gaa ctg cct aat tca gga cct cca cat gat agg agg ttt aca ttt caa 567
 Glu Leu Pro Asn Ser Gly Pro Pro His Asp Arg Arg Phe Thr Phe Gln
 30 35 40
 gtt ata ata gat gga aga gaa ttt cca gaa ggt gaa ggt aga tca aag 615
 Val Ile Ile Asp Gly Arg Glu Phe Pro Glu Gly Glu Gly Arg Ser Lys
 45 50 55 60
 aag gaa gca aaa aat gcc gca gcc aaa tta gct gtt gag ata ctt aat 663
 Lys Glu Ala Lys Asn Ala Ala Lys Leu Ala Val Glu Ile Leu Asn
 65 70 75
 aag gaa aag gca gtt agt cct tta tta ttg aca aca acg aat tct 711
 Lys Glu Lys Ala Val Ser Pro Leu Leu Leu Thr Thr Asn Ser
 80 85 90
 tca gaa gga tta tcc atg ggg aat tac ata ggc ctt atc aat aga att 759
 Ser Glu Gly Leu Ser Met Gly Asn Tyr Ile Gly Leu Ile Asn Arg Ile
 95 100 105
 gcc cag aag aaa aga cta act gta aat tat gaa cag tgt gca tcg ggg 807
 Ala Gln Lys Lys Arg Leu Thr Val Asn Tyr Glu Gln Cys Ala Ser Gly
 110 115 120
 gtg cat ggg cca gaa gga ttt cat tat aaa tgc aaa atg gga cag aaa 855
 Val His Gly Pro Glu Gly Phe His Tyr Lys Cys Lys Met Gly Gln Lys
 125 130 135 140
 gaa tat agt att ggt aca ggt tct act aaa cag gaa gca aaa caa ttg 903
 Glu Tyr Ser Ile Gly Thr Gly Ser Thr Lys Gln Glu Ala Lys Gln Leu
 145 150 155
 gcc gct aaa ctt gca tat ctt cag ata tta tca gaa gaa acc tca gtg 951
 Ala Ala Lys Leu Ala Tyr Leu Gln Ile Leu Ser Glu Glu Thr Ser Val
 160 165 170
 aaa tct gac tac ctg tcc tct ggt tct ttt gct act acg tgt gag tcc 999
 Lys Ser Asp Tyr Leu Ser Ser Gly Ser Phe Ala Thr Thr Cys Glu Ser
 175 180 185
 caa agc aac tct tta gtg acc agc aca ctc gct tct gaa tca tca tct 1047
 Gln Ser Asn Ser Leu Val Thr Ser Thr Leu Ala Ser Glu Ser Ser Ser
 190 195 200
 gaa ggt gac ttc tca gca gat aca tca gag ata aat tct aac agt gac 1095

-3-

Glu	Gly	Asp	Phe	Ser	Ala	Asp	Thr	Ser	Glu	Ile	Asn	Ser	Asn	Ser	Asp	205	210	215	220	
agt	tta	aac	agt	tct	tcg	ttg	ctt	atg	aat	ggt	ctc	aga	aat	aat	caa					1143
Ser	Leu	Asn	Ser	Ser	Ser	Leu	Leu	Met	Asn	Gly	Leu	Arg	Asn	Asn	Gln					
																225	230	235		
agg	aag	gca	aaa	aga	tct	ttg	gca	ccc	aga	ttt	gac	ctt	cct	gac	atg					1191
Arg	Lys	Ala	Lys	Arg	Ser	Leu	Ala	Pro	Arg	Phe	Asp	Leu	Pro	Asp	Met					
																240	245	250		
aaa	gaa	aca	aag	tat	act	gtg	gac	aag	agg	ttt	ggc	atg	gat	ttt	aaa					1239
Lys	Glu	Thr	Lys	Tyr	Thr	Val	Asp	Lys	Arg	Phe	Gly	Met	Asp	Phe	Lys					
																255	260	265		
gaa	ata	gaa	tta	att	ggc	tca	ggt	gga	ttt	ggc	caa	gtt	ttc	aaa	gca					1287
Glu	Ile	Glu	Leu	Ile	Gly	Ser	Gly	Gly	Phe	Gly	Gln	Val	Phe	Lys	Ala					
																270	275	280		
aaa	cac	aga	att	gac	gga	aag	act	tac	gtt	att	aaa	cgt	gtt	aaa	tat					1335
Lys	His	Arg	Ile	Asp	Gly	Lys	Thr	Tyr	Val	Ile	Lys	Arg	Val	Lys	Tyr					
																285	290	295	300	
aat	aac	gag	aag	gcg	gag	cgt	gaa	gta	aaa	gca	ttg	gca	aaa	ctt	gat					1383
Asn	Asn	Glu	Lys	Ala	Glu	Arg	Glu	Val	Lys	Ala	Leu	Ala	Lys	Leu	Asp					
																305	310	315		
cat	gtt	aat	att	gtt	cac	tac	aat	ggc	tgt	ttg	gat	gga	ttt	gat	tat					1431
His	Val	Asn	Ile	Val	His	Tyr	Asn	Gly	Cys	Trp	Asp	Gly	Phe	Asp	Tyr					
																320	325	330		
gat	cct	gag	acc	agt	gat	tct	ctt	gag	agc	agt	gat	tat	gat	cct					1479	
Asp	Pro	Glu	Thr	Ser	Asp	Asp	Ser	Leu	Glu	Ser	Ser	Asp	Tyr	Asp	Pro					
																335	340	345		
gag	aac	agc	aaa	aat	agt	tca	agg	tca	aag	act	aag	tgc	ctt	ttc	atc					1527
Glu	Asn	Ser	Lys	Asn	Ser	Ser	Arg	Ser	Lys	Thr	Lys	Cys	Leu	Phe	Ile					
																350	355	360		
caa	atg	gaa	ttc	tgt	gat	aaa	ggg	acc	ttg	gaa	caa	tgg	att	gaa	aaa					1575
Gln	Met	Glu	Phe	Cys	Asp	Lys	Gly	Thr	Leu	Glu	Gln	Trp	Ile	Glu	Lys					
																365	370	375	380	
aga	aga	ggc	gag	aaa	cta	gac	aaa	gtt	ttg	gct	ttg	gaa	ctc	ttt	gaa					1623
Arg	Arg	Gly	Glu	Lys	Leu	Asp	Lys	Val	Leu	Ala	Leu	Glu	Leu	Phe	Glu					
																385	390	395		
caa	ata	aca	aaa	ggg	gtg	gat	tat	ata	cat	tca	aaa	aaa	tta	att	cat					1671
Gln	Ile	Thr	Lys	Gly	Val	Asp	Tyr	Ile	His	Ser	Lys	Lys	Leu	Ile	His					
																400	405	410		
aga	gat	ctt	aag	cca	agt	aat	ata	ttc	tta	gta	gat	aca	aaa	caa	gta					1719
Arg	Asp	Leu	Lys	Pro	Ser	Asn	Ile	Phe	Leu	Val	Asp	Thr	Lys	Gln	Val					
																415	420	425		
aag	att	gga	gac	ttt	gga	ctt	gta	aca	tct	ctg	aaa	aat	gat	gga	aag					1767
Lys	Ile	Gly	Asp	Phe	Gly	Leu	Val	Thr	Ser	Leu	Lys	Asn	Asp	Gly	Lys					
																430	435	440		

-4-

cga aca agg agt aag gga act ttg cga tac atg agc cca gaa cag att	1815
Arg Thr Arg Ser Lys Gly Thr Leu Arg Tyr Met Ser Pro Glu Gln Ile	
445 450 455 460	
tct tcg caa gac tat gga aag gaa gtg gac ctc tac gct ttg ggg cta	1863
Ser Ser Gln Asp Tyr Gly Lys Glu Val Asp Leu Tyr Ala Leu Gly Leu	
465 470 475	
att ctt gct gaa ctt ctt cat gta tgt gac act gct ttt gaa aca tca	1911
Ile Leu Ala Glu Leu Leu His Val Cys Asp Thr Ala Phe Glu Thr Ser	
480 485 490	
aag ttt ttc aca gac cta cgg gat ggc atc atc tca gat ata ttt gat	1959
Lys Phe Phe Thr Asp Leu Arg Asp Gly Ile Ile Ser Asp Ile Phe Asp	
495 500 505	
aaa aaa gaa aaa act ctt cta cag aaa tta ctc tca aag aaa cct gag	2007
Lys Lys Glu Lys Thr Leu Leu Gln Lys Leu Leu Ser Lys Lys Pro Glu	
510 515 520	
gat cga cct aac aca tct gaa ata cta agg acc ttg act gtg tgg aag	2055
Asp Arg Pro Asn Thr Ser Glu Ile Leu Arg Thr Leu Thr Val Trp Lys	
525 530 535 540	
aaa agc cca gag aaa aat gaa cga cac aca tgt tag agcccttctg	2101
Lys Ser Pro Glu Lys Asn Glu Arg His Thr Cys	
545 550	
aaaaagtatc ctgcttctga tatgcagttt tccttaaatt atctaaaatc tgctaggaa	2161
tatcaataga tatttacctt ttatTTtaat gtttccttta atTTTTact atTTTTacta	2221
atctttctgc agaaacagaa aggtttctt cttttgctt caaaaacatt cttacatTTT	2281
actttttcct ggctcatctc tttattctt ttttttttt taaagacaga gtctcgctct	2341
gttgcCcagg ctggagtgca atgacacagt cttggctcac tgcaacttct gcctcttggg	2401
ttcaagtatc tctcctgcct cagcctcctg agtagctgga ttacaggcat gtgccaccca	2461
cccaactaat ttttgtgttt ttaataaaga cagggtttca ccatgttggc caggctggc	2521
tcaaactct gacctcaagt aatccacctg cctcggcctc ccaaagtgtct gggattacag	2581
ggatgagcca ccgcggccag cctcatctct ttgttctaaa gatggaaaaaa ccaccccaa	2641
atTTTCTTT tatactatta atgaatcaat caattcatat ctatTTtatta aatttctacc	2701
gcttttaggc caaaaaaatg taagatcgTT ctctgcctca catagcttac aagccagctg	2761
gagaaatatg gtactcatta aaaaaaaaaaaa aaaagtgtatg tacaacc	2808

<210> 4

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 4

cagaattgac ggaaagactt acgtta

26

<210> 5

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 5

catgatcaag ttttgccaaat gc

22

<210> 6

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Probe

<400> 6

cgctccgcct tctcgttatt atatttaaca cg

32

<210> 7

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 7

gaagggtgaag gtcggagtc

19

<210> 8

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 8

gaagatggtg atgggatttc

20

-6-

<210> 9
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> PCR Probe

<400> 9
caagcttccc gttctcagcc

20

<210> 10
<211> 53000
<212> DNA
<213> Homo sapiens

<220>
<221> intron
<222> (1)...(1217)
<223> Intron 1

<221> intron
<222> (1298)...(8947)
<223> Intron 2

<221> intron
<222> (9349)...(10382)
<223> Intron 3

<221> intron
<222> (10518)...(11231)
<223> Intron 4

<221> intron
<222> (11353)...(16503)
<223> Intron 5

<221> intron
<222> (16653)...(18447)
<223> Intron 6

<221> intron
<222> (18575)...(19619)
<223> Intron 7

<221> intron
<222> (19697)...(19841)
<223> Intron 8

<221> intron
<222> (19936)...(21187)
<223> Intron 9

<221> intron
<222> (21223)...(22658)
<223> Intron 10

<221> intron
<222> (22722) ... (31793)
<223> Intron 11

<221> intron
<222> (31917) ... (35540)
<223> Intron 12

<221> intron
<222> (35700) ... (38065)
<223> Intron 13

<221> intron
<222> (38247) ... (43348)
<223> Intron 14

<221> intron
<222> (43475) ... (48909)
<223> Intron 15

<221> intron
<222> (49012) ... (50677)
<223> Intron 16

<221> intron
<222> (50732) ... (53000)
<223> Intron 17

<400> 10
ttttttttt tgaattggag tcccaactctg tcacccaggc tggagtgtag tggcatgatc 60
tcagctcaact acaatctctg cctcccaagg tcaagcaatt ctccctgcct cagcctctgg 120
agtagctggg attacaggtg cctgccacca cgcccagcta atttttgtgt ttttttagtag 180
agacggggtt ttgccatgtt ggcaggctg gtcctgaact cctgacacta ggtgatccgc 240
ccgtctcagc ctcccaaatt tctgggatta caggcatgag ccaccgcgccc ggcctaggca 300
taatatttaa tgtatatttg aggtctgtct ttggaccacc ttccctctttt atcccaagcta 360
agatactgag agtacaaaact cctggttata attctaactc cgctgcttac tacctgtgtt 420
aatccaaattt ctctgtgcct caatactcat tagtcaactgt gccaatgaac tctggaactc 480
tgtgtactc tgggagtggtc tcgcagtcctca tcaggtgagt agaatttcta taaatcgagg 540
actactgggtt ttggactatgt gtaggaagct ccctggggta ctgttaggaag caggtgtctc 600
tatttagcag caggactggc ccacagggtc ttttacagcg gctggcaagt gtctgctcat 660
gaatgaatgg atgggtggga gcgagtgaa ggagattacg ccccccaggcc tctgatcccc 720
aggcttgtaa aggtgagggg gccgcgggtt ggcaagaggg aaagagtgct ttgggtttta 780
caggccccga cttgaactga atccctggctt tgccacttac gagcggcagg accccctgggt 840
gagttcattt actcagttt ctctattgtt gaatggagct ggttaagatcc atcttccaa 900
ccccacccca aatatttgtt ttgagagtaa gtggaaacctt tgattcgaga accttagtgcg 960
gccagcggac taggccagcg gagaacccta ggagccccgg gggcgggggg tgggggtgca 1020
gggtcctggc cgtcagggg cagcacgtgg gtgccaagcc cgcctggccg tgccaagccc 1080
gccccccggc gccaagcccg cccgcccagg tctctcgccgc gcactctggc tccagcgcc 1140
atttacccca atccctgtac agacgaggcc ttgtgcgaga gggggccggg cggctgcagg 1200
gaaggcggag tccaaaggggaa aaacgaaaact gagaaccagc tctcccgaaag cccgcgggtct 1260
ccggccggcg gccccggccgg cggccggccggc ggcgcagggtc agcagggcag gggcagccg 1320
agggagcgcg gggagcgggg gccccggggc cacgtacgag gggctgcagg cccagccggg 1380
gcgggactcg ccaatctgc gtcccccagct caggacgcgg acgctgatcc gaagccctg 1440
gccccggctg ggtcagcact gggagagcag gcccagggtcc gcagccccggg tggggggccc 1500
tccccaaatc cagggaaagg atcgtggagc ggggtgggaa ctgaaaagccaa tttccttccc 1560
gtgaagaatt ttatcagtg caagtaacaa atatttccaa ggcagcagtt gtggggcggg 1620
gtcttagtggaa agacgaatag gccttagtggc ttgacacatg gaaaatacgg aggcctgaaa 1680
tactcataga ctggctgaac aatcttggc taaaaatctc ttccgtggag agttgcagta 1740
gtttcccaat tgcctggccg cagttcctgt tcccactccg tatectcacc cctgaaccc 1800

cacccctac ctcttctcca cacctcagca tctggatgt tccttaagt aagaaccaga 1860
ctctccctg ctccgacctt ccccgtagct ttccctgtctc atcagaatcc tataaacatt 1920
tattaaggct cacaggcaag gcccctcgca ccccctactc cggccacgct ggcttccttg 1980
ctgttctgg tgacacagcca agcatctcc agcctctagg ccttgcact gcttggctt 2040
tctttctgga aagcttcttc cccagataac tgcatgggaa aatccctccc ttatcctgca 2100
ctgcttcca tgccagctt tcagagcagc cttctcaaa caacctgcct atacaagaaa 2160
ccccgcctg ccctgtctgt tcccccttcc actacttcgg ttgtcaacat agtagttatc 2220
acctggtgac attttcttcc ttttcttcc tttttttt ttttgagac agattctcac 2280
tctgtcgcca ggctggaaatg cagtggcacg atctgggctc actgcaacct ctgcctctca 2340
ggttcaagcg attttcttcc ctcagcctcc caggtagctg ggactacagg tgccgcagg 2400
cacagccaac taattttttt attttttagta gagacagggt ttcaccgtgt tgccaggt 2460
gtatgtagtc tgctggaaag gaagtggagg catagccaaa ataatttctg ggcattagta 2520
agatggacaa atattttttt ttagtgatta tgatggaggt ttcttccaga tgagtgaata 2580
agatgtagaa tctgctcccc aaagagctca ctaatttagtt taaaaagcag tcagggctgt 2640
gttgaagggtt gggcaagggt gagtggcaag cccatactag ctgaccctcc agcatcaaag 2700
aaggctgtgt tgatcctgtat agatgagtgg atattgggtt gtacagagag aatgcagata 2760
ttgcactata aatgttagaga aaagcagggt acaagtccctg gatgggtat ctggagatata 2820
tttggtaactc actcattcat tattgagcct gtccttac ctgttagtaat tcatgctcta 2880
ttttggaaaa tagttaaata agcaatttta ataaaggaaa tgagactgt ggaagagcct 2940
gtgaaggagt gtctgggatt ttgagctgaa atctgttaga agtagaaatt gaccaggcca 3000
agacagcaga aggaatagag tcaagggcat tttaggaggg acaggttgg acagaggcag 3060
tttggagttc aggagagagt ccatgggtt agcgtgttt tgagaaccat cattgtgtcc 3120
gttgaattta aagccacaaa cctggaggtg atcaccagg gagtggatcc aagttagaaaa 3180
gagcaagtct aaggaccggg cccagtgtg cttagaatatc tagaaaagag gaagtttagaa 3240
ccatagaaaaa gttaaaaaaa aaaaaatag aagaaaagaa gttgaagatg aaccaggaaaa 3300
ggagacagaa aaggagtagc ttgtcagaac aagaagaaaac cagggccagg tgccatggct 3360
catgcctgta atcgcagcac tttggaggg caaggtgggt ggatcacctg aggtcagggag 3420
ttttagacca gcctggccaa catggggaaa cccctctt actaaaaata taaaaaattta 3480
gccgggctg gtgggtggcg cctgtatcc cagctactcg gaatgctgag gcaggagaat 3540
cgcttgaacc cgggaggcag aggttgcagc gagccgagat gcccacatca cactccagcc 3600
tggcaacaa gagcggaaact ctgtctcaaa agaagaaaac taggagagt ggtgtcttaa 3660
aagtccaaagc taagacaggg agaggaggc gaagaggatg cgcaacccca tcaaattgtcg 3720
gttgttaagtc aagttagagaa ggactaagaa ctgactactg gatttagtga tagggaagcc 3780
attggtaacc tcgacaaaaaa caatttcaatggcttgc gactgcatga ttgaatttgat 3840
gttttttgtt ttgtttgtt ttgtttgtt ttgttttttg agacggagtt tgcctctgt 3900
tgcctcaggct ggagtgcattt ggcacatct cagctcaccc caacctccac ctcctgggtt 3960
caagcgattt tccttcctca gcatcccgg tagctggat tacaggcatg tgccaccacc 4020
ccggctaatt ttgttattttt agtagagatg gggtttctcc atgttggatca ggctggcttt 4080
gaagtcccga ctcaggtga tctgcccggcc ttggcctccc aaagtgcgtgg gattacaggt 4140
gtgagccacc ggcctggcc actgaattga ttgtttttaaa agatcatgtat gtggctgtat 4200
aaaaaaagaa aacagataat aacaagtgtat ggtgaggatg tggagaaatt agaaccctcg 4260
tgcattgtcg gtggaaatgt aacatgggtg taaccactgt ggaaaacaat ttgggtatttc 4320
atcacaaagt taaacagaat tatcatgtga ttcaattccca cttatataacc acaaataatttc 4380
agaagttaggg acttaaacaag atataatgtat accagtgttc acagcagcat gattcaagat 4440
ggccaaaaagg ttgaaataaac cagtgtccat tcataaaatga atgcattgaac aaaatatgg 4500
atataatacac aacggaaatat tattcagcct taaaaaggaa aggaattctg acatatgtcta 4560
caacatagat gaaccttggaa gacatttgc taagtgaat aaccagacac aaaaggacaa 4620
atactgtttt attcactta tatgaggtac cttagaacagg caaatttaca gagacagaag 4680
agagattaga aaatataaaa aattaaccag gcatggccac gcctatggtc ccagctactc 4740
gggaggctga ggtggggagga tcgcttgagc ccaggttca aggctgcagt aagctgtgat 4800
cacaccactg cactccagcc tggcaacag agcgagaccc tgtctcaaaa aaaaaaaaaa 4860
aaaaaaagat tagcagagac tggaaaggact gggaaatggg gagttactgt ttaatgggtt 4920
cacactttct gtttggaaag attaagagtt gtggatgtgg atgtgggtggc ggctacacaa 4980
cattgtgaat gtacttaaaag gcagggaaatt aatacattga aaaatagtac atttcatgtt 5040
atgtgtatattt tatcacaatt taaaacata aaaaaaaaaa tcacaatggt tgcagggttag 5100
agaaggaatt gaagtagctg tcggaactgg ttctgagatt ctcacagcaa tccaggaatg 5160
aggtgggtt ggcttgaact agatggtaa gtgtagacat ctggagaag tagaaagatt 5220
ttggtgacag gacttagtta tagatttagaa ggcagggaga gggaaatgtca aggatgcctc 5280
ccagattgtat qqcttcaqa ctqqataqa tqgtqqactc atttcctgtg aaaggaaact 5340

tc当地accagc ttgggagaag atcatacatg cagtacagga tattttgagt taaaagttcg 5400
ttcaagatgt tcaagtggag aatttggata gagagatctg aaactcagag cggttcataa 5460
ggaatatgt aacttttagag gtaatggcgt atagatgatc actgaaatca tggacgtgaa 5520
agaaaatcacc ttaaggagaa agtataagatc gaagagaaga ggattgttgg gccatgccag 5580
catttagagc tacaaagatt aaggtgttt aaaaagagtg gcccggccag gcgtggtggc 5640
ccacacctgt aatcccagca ctttgggagg ctgaggctgg tggatcactg gagttcagga 5700
gttggagacc agcctggcca acaccggaa acctcaaaaa tacaaaaatt agctggcgt 5760
ggtgggtggc acctgttagtc ccatagtccc agctacttga gaggctgtgg caggaaaatt 5820
gcttgaacct gggaggcaga tgctgcagtg agctgagatc atgttactgc actccagcct 5880
gggcaacaga gtgaggccct gtctcaaaaa caaaaaacag aaagagtggc cctggaagaa 5940
agaagatcaa aagagcttc caagaagaat taagagggtt acaggatctg atttctgcct 6000
ttatggattt accgattctg gaagttcat ataaaatggga atcatacaat atgtgtgaaa 6060
ttttatgtct ggattttca ttttcataa tggtttttag gtttatccat gtttttgg 6120
ttgtgggtgt tggtttttag gatggagtct tcgtctgtc ggcaggctg gagtgcatg 6180
gcgcgatctc agctcactgc aagctccgcc tgccgggttc acggcattct cctgcctcag 6240
cctcgcgagt agctgggact acaggcgcgc gccaccgcgc ccgcttaatt ttttgttatt 6300
tttagtggaga cggagtttca cgggtgtctc gatctcctga cctcgtgatc cgcccgccctc 6360
ggcctcccag agtggggta gtacaggcat gagccacggc gcctggccta tccatgttgc 6420
agcatgtatc agtacttcat tttttttagt actgaataat attccgctgt gtagatataat 6480
ttcacatttt gttcaccatt tatccgttga tggacactt gttgtttcc acctttggc 6540
tattgttaac agtgctgcta tgtacattcc tgtctaaatc tttgtttgg aacctgtttt 6600
ccaattctt gaaatatcta ggaatggaaat tgctgagttt tatgataatt caaagttac 6660
cttctagagg aaccccagca accgtattgt tttacattct tattcagcagt gtttgagggg 6720
tccagttct ccatgtcctc accaacaactt attttttattt atttcctgtat tattattatt 6780
attgccatac tagtgggtgt gaaattgtat ttagttgtgg tttgaattc catttctta 6840
atgactcatg atggtggata tcttttcatg tgcttatgg cgatttacat attttctttg 6900
gagagatgtc tggtcaagcc cctttgccta ttttttaat tgggtgggtt gtcttttgc 6960
tggttagctg taagaattct ttatatatct ggttactaga ccctcatcag atatatgatt 7020
tgtaaatattt ctattctgtt gattgtcatt ttatattttt catagtgtcc tttgatacac 7080
aaacgttttta aattttgtat aagcccaattt tatctctgtt ttcttttgc 7140
ttgctgtcat agctaaaattt ttatcacca atccaaagtc atgaagatct ccccccattt 7200
ttcttcttaag agttttagt tttcgctt gatattata ttttatatcc tctaaattttt 7260
gtttataattt taaatcattt ctatagactt ggtccagtgta gacctataaaa cagaggctt 7320
aatttactca gtggtaaat tgcctaaaaa ttgatttctg caaaaattcag agggggagatt 7380
tttgggattt catagagaaa tctatatcca tacagttaaa tccttcatga tttcatacac 7440
ttcacttttt taaagtatta aaactttttt atttgaagaa tacgtggggaa gaagagaaat 7500
atatttcagc acttagatattt gtagattttt tccaaaatag tttaccactc aactagtac 7560
ttctgtgtaa atcagtttc cctgaagcaa gcattgtgtt gttccggct acaagcggtc 7620
ctcattttgc atggtaactgt gggaccataa aaatggccat gcaaagcaat cttataatc 7680
aatggggaaa atgatgattt ttcatgacc tttaaaaattt tgctaaaata ttaaaactct 7740
taaggtcagt tataaatgtt gaaaaaaatg caaaaaaaaaat ttaaaaatattt ttagtacact 7800
gtaattttaa acattaaaaa tagaattttt gtttttttattt tcattgtgaa aactaagtatg 7860
tttgaatagg gattgccttt ttttctgtt aagtgactt aactgttgc taagcatctt 7920
ttcttattcat ggccaaactgt catactcctt ttaagttgg gtgagcttco agcctttat 7980
tgctgtgtct ttcaatgtt tgaagtattt ctgtattcac attaaatgtt cttagtgc 8040
aagtttgc 8100
aatcactttt ctatattgtt ttgataagtt tgccttact aagtccttat gaatgcacag 8160
caggaagaac atccccatgtt tcagtgcattt cttctacaaa tccattttatg tttgatttca 8220
atttcacttc cagtgttattt attttcgtt gttttgttgg actttcatct ttgttggcca 8280
gttcttcga ttgttcaactt ctataaaaatg tcaggtggag gacaaagaga cagtgtact 8340
acgtgtctg ctgtgagtgta actgatcattt agatgcacag ggaccaacca ctggaagaat 8400
ttgaaaacaag taacacgact ggtcactgtat catgaagcat atctgttattt tacatgtga 8460
ttttagact gaagaacttag cagagaagtt ttttttttctt gtaattactc agagttatac 8520
tgtgttaccc taaaattttaa ccttaggtttt aacaacacca gtttccttac cagtttcctt 8580
tccttcctgg taagggaaactt ggttattttttttaa cttaaatcttgc gtcactgtttt tttgtgccat 8640
gggaaccgtg cacattgggg acctgcctac accctacatg ttttatattgg tccaggcagg 8700
cttaatgttgc actactgaga aataggctat ctgaattttt atcaaaatgtt gaatctttaaa 8760
gcacccaaaga tggaaaatttgc acgtgtttt aaaaatcttgc tcatatttttgc 8820
atcaagctttaaaatgtatctt tagactaacc gaattttttaga aataaagacc tttaaaggcc 8880

ccatagttt ataccacaga ttatccagca tgtttataat gaattatttc tcctccctca 8940
 atttcagttt gtcatactt tgtgacttgc ggtcacagtgc gcattcagct ccacacattgg 9000
 tagaaccaca ggcacgacaa gcatagaaac atccctaaaca atcttcatcg aggcatcgag 9060
 gtccatccca ataaaaatca ggagaccctg gctatcatag accttagtct tcgctggat 9120
 cactcgctg tctgaaccag cggttgcatt ttttaagcc ttctttttc tcttttacca 9180
 gtttctggag caaattcaat ttgccttct ggatttgtaa attgtatga cctcaaaaact 9240
 ttagcagttc ttccatctga ctcaggtttg cttctctggc ggtcttcaga atcaacatcc 9300
 acactccgt gattatctgc gtgcattttg gacaaagctt ccaaccaggat acaagcggtc 9360
 ttccgaattt tgcactcaga aaagtggcat catctaagtc aattacatgc aaattctggg 9420
 gggctagttt tttgtgtatg taaaatgggt cacaacacga ctctgtaaa tcctcaaatc 9480
 tgtcaatata aattttatg tgatgaaagc aaattgtatt gttcttagaa agtgtcccttc 9540
 cagttctaag ttgaagtaaa agcatgtcat ttgatgacaa ttcttgcac acatctaaaac 9600
 ctgtgtgaca agtatagttag gttttatggc actcattttg agtacgaagc tggactgcaa 9660
 ctatcgatcc atcattgtt attctagcat attttcctt ttttattttg tctagagatc 9720
 taggtcacgg gtcgtatcacc cttagcttga gtcctccccc gcctggcttc cggcaggatc 9780
 cacgtccaca caggcacact tgcctgccc ttcattttcc agcctgtccc catgttacca 9840
 ctcccaacttca cttattataat atactctaaa tctttttctt ctcaacataa aacattctac 9900
 aatcctgcag ctttttact ttttaagca ggttaggcaaa catgttagttg atactcagtg 9960
 gaagcacaga gcagagttaa agagaaggac cccctttcac tgaccagttg agttttttt 10020
 ctttccttta ttttttaaaa caatttcaaa attgagatgg ggttgcacca tggactccag 10080
 gctggctcg aactcctgag ctcaggtgtat cggcccacct tggctggat tataaggcgtg 10140
 agccaccaca cctggccaag ttgagtttt aaagtagaaa attttggaga atttaacttt 10200
 attgtcagt gaatgagaaa gaaagaacgg ttttgaagaa aagtctctgc atttatgtga 10260
 gactgagatg agtcctataa agggagatct ccccaacccc tctgtctctt aaactgcatt 10320
 gggaaactca gattaaataat gttctgttagt catcactcat tcaaattgtct cttccattgt 10380
 aggatacggg aagaagaaat ggctgggtat ctttcagcag gttcttcat ggaggaactt 10440
 aatacatacc gtcagaagca gggagtagta cttaaatatc aagaactgccc taattcagga 10500
 cctccacatg ataggaggtt ggttgcataaaaatgata tggcagccat aaaaaatgtat 10560
 gagttcatgt cttttgttagg gacatggatg aagctggaaa ccattattct cagcaaacta 10620
 tcgcaaggac aaaaaaaccat aacaccgcatttgcactc ataggtgaga actgagcaat 10680
 gagaacacat ggacacagga agggaaacat cacacacccat ggactgtgtt ggggtgggg 10740
 gagggggggag ggtatgcatttggatgatata cctaattgtca aatgacgagt taatgggtgc 10800
 agcacaccaa catggcacat gtatacatat gtaacctgca cgttgcac atgtacccata 10860
 aaacttaaag tataataata ataaaaattaa aaaaaaaaaaaga aaaaagatata gaccttataa 10920
 atgttaagctg ggggaatggc aactctggca caacttttagt gtcacacatt tagtttgtg 10980
 agagtgcctt tggcataaaatgatgatata ggtggagccat cagttgactc cagagagaaa 11040
 agagggtaga aaccttcca tgcttcaaca agacatgtc ctttactgtt tgaggtgact 11100
 gcttaaatgc tatattgaat gtaggttcaa accctcaaaatgc gtagtcatag gaggtgtga 11160
 tgacttagatg acttggatttt agatagtgc tgagttgtat aatattttat gaatattctc 11220
 tttgtatca ggtttacatt tcaagttata atagatgaa gagaatttcc agaaggtaa 11280
 ggttagatcaa agaaggaagc aaaaaatgcc gcagccaaat tagctgtga gataactaat 11340
 aaggaaaaaga aggtgatgttgc ttgcctttt tcctaataaa tggaaacttgc caaatacatt 11400
 ttctgtttct ctctgtgaga aaatacttc atacagatgtt aagccattca cacgttccct 11460
 tacattcaag agtttggatg agtcttgcattc cctatctca ttcttatgaa accctgagtg 11520
 agagccacac ctggacacc atggccaaatgc ctggataata gttattttaga gtgtcagcag 11580
 cagttaaata ctctaaatgtt gacaaatataat gggaaaggatgttgc gaagtgttca gtgggaaatg 11640
 agctgacagg ttctggggagg agtcccctcc acctaaatgtt ggaagtacag taaaaaagga 11700
 aaaagagatg aaagtgtatggatg tagggagaat aatgtacatgtt ggtcactcactc tctctgtggg 11760
 gaattggatc caggactccc tggatgtcc gaaatggatc tttttttatgc tcccttataat 11820
 aaaatggcat agtatttaca tataaccttgc ttacatcttc ccatatacag ttatgcatttgc 11880
 cttacaacagg agaatacatt gtgagaaatgc caccctttggg caatttccctc attgggcaaa 11940
 catcatagag gtacttacac aatcctgaat ggtacaacca gtacacacccat aggctgtgt 12000
 gtatagctt ttgccttagt actacgttgc tatacagcat attattgtac tgaataactgt 12060
 agccaaattgtt aacacaatgtt ttagtattca tttatctaaatcatatctaaatc cacagaaaaaa 12120
 gtacggatggaaatgttgc gggccgggtgg aggctgggtt ggtggctca cacctgtat 12180
 cctagcactt tggaaagctg agggccgggtgg atcacctgtt gtcaggatgtt gaaaaccaggc 12240
 ctggccaaaca tggtaatccca ctgtctctac taaaatataca aaaaatttagc tggggcgtgtt 12300
 ggtggacgccc tggtaatccca gctacttggg aggctgaggtt aggagaatttgc tttgaaccccg 12360
 ggagaaggag gttgcagtga gctgaggttgc tgccactgca ctccagcctg gggatccat 12420

ctcaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa aagacaagca aaagtacacc 12480
 catataaggc acataccatg cataaataga gcttgcagga ctgaaagttt ccctgagttt 12540
 gtcagcaagt ggggtgtgaa tgaatgtgaa ggccttaggc attattgttt accactgttag 12600
 actttataaa cactgtatac ataagcaaca ttcatttt ttaaattttt tttcttcaat 12660
 aataaattaa ccttagctt ctataactct ttactttt aaacttctt ttttaacat 12720
 tttcactctt tccaaataac acttagccta aaacacaaac gcggccaggc gcggtggtc 12780
 atgcctgtaa tcctggact ttgggaggcc aaggcaggca gatcacctga ggtcaggagt 12840
 ttaagatcg cctggccaaac acggtaaac cctgtctctt ctgaaaatac aaaaattagc 12900
 cgggcatggt ggtgggcacc tataattccg gctacttggg aggctgaggc aggagaattg 12960
 cttgaactca ggaagcggag gttcagtgaa gccgagatcg tgccactaca ttccagcc 13020
 ggcgacaagg caagactctg tctaaaaaaaaaaaaaa aaacccacaa aaccacaaac 13080
 aaacacatag tatggctgtt caaaaatatt ttgtttctt acatgtttt tctataagct 13140
 ttttctatt tttaaaattt taaactttt ttttaactt ttaaactttt ttgtaaaaaa 13200
 ttaaatcatg gttgggcata gcgggtcatg cctggatgt cgaggagcca tgattgtgcc 13260
 actgtactcc agcctgggtg acagagttag accctgtctc aaaacaaaac aaaacaaaac 13320
 aaaggctggg tttgggtgtt catgcctgtt gtcccagcac tttggtaggt caaggttagt 13380
 ggatcacttgc aatttgggatg tttgagatggc gcctaggca catggtaaa ccctgtctgt 13440
 actaaaaacaa caaaacattt gcccggctt gttgcatgtg cctgtgttc cagctactca 13500
 ggaggctagg cgggaggatc acgtgcctgtt gaggctaggc ctgcagtgag ctgtgtatctt 13560
 ctgactgcac tccagcctgg gcaacagagc aagaccctgt ctaaaaaaaaaaa aaaaagaaag 13620
 aaaaaaaaaattt acaacacaaaa cacacacatc agcctaggcc tacacagcgt caggatcatc 13680
 tacatcacca tcttccaccc ccagattttt tccctcttggaa aagtgttcag gagcaataac 13740
 atacatggag gtgtcatctc ctattgttagc aattccttctt tttggattac ctaccgaagg 13800
 acctgcctgtt ggctgtttt cagtttactt tttttttt aagtagaagg agtaacttct 13860
 aaaataatgt taaaaaaaaatgt atagtaataa tataaaccag taagttactt atcattatcc 13920
 agtattatgt actatacata attgtgtgtt cttagactttt ttataagact gttagaacagt 13980
 agatttggttt acagtagtgtt caccacaaat gtgtgagtaa tgcattgtgc tgtaaccag 14040
 gagttaaaaa ttatccttggg caatatggcg aaatgctgtc tttactaaaa atatgaaatt 14100
 tagcattttt acgtggctatg accttattttt atgacagttt ttttttagct ccattataat 14160
 cttatggac cactgtcata tatgcgttcc attgttgacc aaaatgttatgat tatgttagtac 14220
 atgattatcc ttttagatcat ctctagatggc ttatataatcttataataca atgtaaatgc 14280
 tatgtaaata gttttttttt tttttttttt gtcgtttttt gagacagggt cgtactctgt 14340
 caccaggct ggagtgcgtt ggcattgtca agggtcactg cagcctcaat ctccccaggc 14400
 tcaggtgatc ctccccaccc agcatccaa ctggctggga ctacaggcac gagccaccac 14460
 acctggccaa tttttgcatt ttttttagcg atggagtttc actatgttgc ccaggctgg 14520
 cttgaactcc tggactcaag caatctgccc acctcagcct cccaaagtgc taggattgca 14580
 ggcattgtggcc accacaccca gctataagta gttgttatgc tttttttt aggaaataat 14640
 acaagaaaaaa aaatctgtcat atattttgtt cagatgtcaac catcattttt tttccaaata 14700
 tttttgtatcc atgattgtttt gaatccagggtt atttggaaacc cttttttt cttttttt 14760
 tgtttacaga gagcaggtaa tggagaacca atatacatgt gactgttgc cccggaaaata 14820
 agaacagagt aaatagtgcgaa gaaatggatc atctgaagag atttcagcag acaatgttta 14880
 tgaaataaaag aaagacttgcgaa cttttttttt tttttttt ttgagacaga gtctcgctct 15000
 aaccaccccg accaaccatggc attttttttt tttttttt tttttttt tttttttt 15060
 gttgtccagg ctggagggtt gttttttttt tttttttt tttttttt tttttttt tttttttt 15120
 gcaattctct gcctcaggct ccttgggtttt tttttttt tttttttt tttttttt tttttttt 15180
 gcttaattttt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt 15240
 taactcctgtt cttttttttt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt 15300
 gagccaccgc gcccccccccc aacattttttt tttttttt tttttttt tttttttt tttttttt 15360
 gaaagaattt tataaggatc tagagagaag aacccaggatc atagttgttgc aatgtttttt 15420
 aaaatttcat gctgtgcaca gcaacattttt tttttttt tttttttt tttttttt tttttttt 15480
 aaatgaaaca tgaaggatc tacattttttt tttttttt tttttttt tttttttt tttttttt 15540
 atgttggaa aattttttttt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt 15600
 ctaaccaatt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt 15660
 aattttttttt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt 15720
 gaaagaaaaat aacaatgggtt gaaattttttt tttttttt tttttttt tttttttt tttttttt 15780
 caataaaaacc aaaagctttttt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt 15840
 gtggtggtc acacccctttt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt 15900
 gctttaggtt tcgagaacag cctttttttt tttttttt tttttttt tttttttt tttttttt tttttttt 15960

acaggaagat gggttgaacc caggaggtca aggctgcagt gagctgaggt tgcaccact 16020
cactctagcc tgggtgacaa agtgacaccc tgtctgaaaa aaattaaaaaa aatatcaaaa 16080
cttggacaa gattttgtc ggactaagaa aaaaaggtag agataataat agtagaaatg 16140
atgctattat attcatctt ttcattaaagt tatgatccag tatacagctt tactgtataa 16200
tctcttgct tggggggtaa gattagaaag ggtataacaa gctagaaagt gttatagttac 16260
tttccaagga caaacaagaa aaagtgactt ctttccatt gttaaaatct atttcgctg 16320
attttttct ggttagaggg aatacgtagt cacactttt ctcaggtaa tataatagga 16380
aaatatataa catccaagtt gtcttcaaa ttgctcatt agtaattta tttagaagaat 16440
gatttttaaa aggttaaatc tttgttgc tttatattaa acaggaattt ttttctt 16500
taggcagttt gtccttattt attgacaaca acgaattctt cagaaggattt atccatgggg 16560
aattacatag gccttatcaa tagaattgccc cagaagaaaa gactaactgt aaattatgaa 16620
cagtgtgcat cgggggtgca tggccagaa gggtaagaca taatttgct tttcttctg 16680
tttcattgtt ttaagcaat aaagttgggt tatttcgtg tctaattttc cagaaatatg 16740
tgcctttt agcattctgt atgcaaggtt ttacatgatt gataagtaat tggatttata 16800
atttgttaattt aaaaatgctt attgctgaag ccatggaaacc catttaccat aattgtatcaa 16860
attaggtaa tccttattt cagagaagta gctggatggg ttagtctgtt gAACACCCAA 16920
gagagtacag ggtgccactg ctcgaagaat acagaaatct tttcatcattt gaggacatga 16980
tgggtgtaac tggctgaaaaa cctctctgccc acatgtatag aatcactctt cacccttgct 17040
agatcaggga gctcttgc caggtatttgc tccttcaat ttgattaaat gaacaaatc 17100
catgtatcag aaggaatgag cttagccctt agactatgag gagaccgggat tttgagggt 17160
ctgatgagac agatgaacta gagtttcaaa gttactgaga acatcaccag tgagctaaga 17220
tgggtgaaaa taggataaaat aatggattgg aactgaaaaaa agcagaaatc aaatgagtt 17280
gaggcaattt ttttcaact acaaccaacc agttaaagag aaagaagaaaa aaaaatatct 17340
acatggcaaa tagtttaat catcaatttta ggatacactt ctatgaattt actcagctat 17400
ttacagtcattt ggcctttag cccaaaccag gaagagaaaaa atgatataatc attcatttgg 17460
atgaaatagt caaaatgtt cttgtgatc aatctcaata attaagagat gattttattt 17520
tctgtagctc actttttgg tttctttaaa ttatgctaac attagatacc taaaagaaag 17580
aagaaatctg ttgcgggggg gggcagttt ctgaaaaaaa taggagctat agaaatgatc 17640
cagtcactca acccagctat ttaattcagg gtctagcggg gaagactcac cctgttttgg 17700
tgggttctc tcgatggctt ccaacagaaaa cataaagcaa aaggagttca aatactggaa 17760
tcattttca gtaatagata gtaaccctgtt gatataaattt gccatgttcca ttgttttac 17820
ccttaaaaat agttattata taattgttcca agtattcctt cctaaccaca aatgtcctt 17880
catctaatacg gaggagatgt tggacttttgc tataaggaaat ctgcactgtg gggattttct 17940
caaatttttgc tgacatgag cagatggcag acaatggta agttagagca gaatccatgc 18000
tttgctttc ccctacacta taacctcata gtttctctt gggacttcca ctttctctgc 18060
tggcttttcc cttccattt gggacttctt gaaaaattt actggatctc tttctttttt 18120
ttctacccctt gttatcttttgc acctttgggg aattaaaaaa aaaaatcac cacttagtgc 18180
ctttgtgcca gatcttcag caaagcaaca aaaaatttgc aattgcctgg aaaaatgcaag 18240
ctcagatgtc agtgcattt gggatttcag agaaatttgc caggcatgtt actgagggtt 18300
taaattatgc aagatatgaa ctataaatctt atctaataaaa ttgggtttat cttaaatgtct 18360
ctgttaatattt gttatcttttgc tttttttttt gttatcttttgc tttttttttt 18420
ataagtacat tctatgattt ctccttagatt tcattataaa tgcaaaatgg gacagaaaga 18480
atatagtattt ggtacaggtt ctactaaaca ggaagcaaaa caattggccg ctaaacttgc 18540
atatacttcag atattatgc aagaaacccctt agtggatctt attgccttttgc gattaaattt 18600
ttatgtttta aaattccctt tgaagttgac ttgagggttag actgtgtttaa cattatgcca 18660
agacagccag tgatgttgc aaatgattcc tccattctgt gtcgtaccga tgagccatgc 18720
accatggggc catgaggcctt cagaggata aatttctgg tggcaactca gggtagttt 18780
taaactccag gctggctgg gttgtggc tcacacctgtt aatcccagca ctttgggagg 18840
ccaaggccagg tggatcttgc gagttcagga gttttttttt tttttttttt gagatggaaat 18900
ctcgctctgt tgcccaggctt agatgtcagg ggcacgtt cggctcactg caacccctccgc 18960
ctccccatgtt caagcaattt tcctgcctca gcctactgag tagctggac tacaagcgcc 19020
tgctaccgtt cccggctaat tttttttttt tagtagagat ggggtttcactt tttttttttt 19080
aggctggctt tgaactctgtt acctcatgtt ccacccacccctt cagccttcaat aagtgttggg 19140
gtttacaggc ttgagccactt gcaaccccttgc gaaactcaggaa gttttagacc accctggccgg 19200
ggcaacacacag caaaaccatg tggctacaaa aaaaaaaaaa aatttagacgg gttgtggc 19260
atgttacccgtt agtccttagt actcaggagg ctgaggcggg aggattgcctt gaggcctggg 19320
gatggaggtt gcaatgttgc aagattgtgc cactgcactt caacccatgtt aacagagcc 19380
gatccctgtt gaaaagaaag aaacaaacaa aatatgttcca ctgttacaaa gaaaatgtttttt 19440
ataaaaaaaataa aaataaaaatc cagaccaac atccaaaaaaa tttttttttt tttttttttt 19500

tgagtgttgg tcagggtcca aaatcagtgt tgaagataaa agagtagcag gattaggagt 26640
gagcatctgt gaagagagat ggagggttga atgttagggct tgcatactgaggat 26700
ggaggtgagc gccttatggc tgagcatatc ttatagactg tgagaagaaa acacctaag 26760
aggttcatacg aatgtgagtt tgtgcctcg ggataattaa agaggctgtg gacaaaattt 26820
ttaagcaaag gggccaggtt ttgtaaatgg ggtctagttg tttgaagaa tatgccactg 26880
gttggaggga atctccatg gattggcta atagtccaaag ggctgttta tgagaactgt 26940
gtaaatatag ataaaaggt cttaggggtt ttggaaggcc taaagtgggg gcctgtata 27000
aggcacattt taggtgacag aaagcatgtt aaaggtctgg ggttaggatg agtgggtat 27060
caagattcc tcttgtgtt tcataaaagag gtttagtcatg agtggcaaaa tttgtatct 27120
ataatcagaa atatccact aatttggaa aagaaaataa gtcctttt gtcttagaa 27180
atggacttg ttaaatgcct tgctttcatg ctagtggaaat ttccctggta tttggagtt 27240
tgattaatcc tagctatgaa acgtttggag aggttaaattt gggcttcct tttggatatc 27300
tggtacccac attcagccaa aaaattttaaa agcctggctg tttgttgaat acagtgttct 27360
agagaggggc tgcaaaagaag taaattgtcc acatattgaa gaaaaacact ggggtgtaga 27420
ggttagttggg aaaggtccaa tcaaagtgcc tgaccgaaat agtggggct gtcctaaac 27480
ccctggggga agacagtcca ggttagttgt tggagtagc ctgtgtcagc gtcagtc当地 27540
gtaaaagcaa aaagggtttt agaggaggaa gatagaggaa taatataaaa ggcattttg 27600
aggctcaatg cagagaaata gcttagtattg ggaagaattt gcaatatgag gatataagggg 27660
tttgggacaa caggacaaac agaacatgtt tggagttatt tttgtcaat cctgaaccag 27720
tctataggag ccatctgtt ttgtaaattgg gagaataatgaa gtattgtggg gagaatgggt 27780
ggggatttaaa atattggcag ccaggccagg tcggtgccct acgcctgtaa tccgagcact 27840
tttgggaggcc aaggcgggtt gatcacctga caaaaattt tagtggcatgg tggcacacac 27960
catggggaaa ccccatctt actaaaaata ctatagtc当地 agctactcaa gaggctgagg caggagaattt acttgaatct gggaggcagg 28020
agttgcagtg agccaagattt gcccattgtt gctccagcct ggggtgacaag agcaagactc 28080
catctcaaaa aaataaaaata aaataaaaata ttggcagcca aaagttgggaa gatgtggac 28140
tttagtcccc atagtccattt agggatattt gtagacttgc cccagttatcc aaaagaaagg 28620
tcattgaaat ttgaatttgg gaaatggggg tagtaacat gggggagtc gtttcata 28260
ctatgggatt tacagggttgg aggaatttgg gatttaatgtc tttgtatgat ggaatgtctg 28320
aggaagggtt ctgttctgtt gatgataata aatagggtt gctttgggtt aggggttata 28380
aatgaatgtt tcgtccccgt ttgtgttagg tttcccttcc tagtaaagga gttggggaaat 28440
gaggaatgtt caagaaagag tgagttaggg tgactccctg aaatgagcaa tatagaggca 28500
gtgtttgtt tgggtttct tttatgtccct tcattccatc aacagaaaca aatgaacatt 28560
ctaattggcc ttgttatca gttaatgcca gtagacttgc cccagttatcc aaaagaaagg 28680
aaataatctt accagatacc gtc当地 ccttccattt acctgggtt tttgttactca ctagatgtgg 28740
ggcgaagga tgccgggttcc cctcattttt ccgttgc当地 caccacaaatgaaatgat 28800
cctcctgtta ttgtttgggg gcttcattat gatgttacc cgaatggggaa aggtgtccct 28860
gttggaggca ttccatcgcc cagtttttttccca aagactgca agttggcat gttttgttgg 28920
gaggccaggaa gataggacaa gctttttccca agtgc当地 cagg gttccctttagt tgaaaacaga 28980
ctctggaga ggtgggggat ttcccttttgg gtttatttgg aggttttc当地 ataaactgtact 29040
tttggacaggc agaggcaagc atctggattt ttaaatgggat tttttgttcc tttgttactt 29100
tttggccttc atctctgtt ttaaagacat ggaagggttgcg atttaggagc tcccaccaag 29160
atgtctgggg gcccctctt aattttgtt aattttccg aatatctggg gttggatggg 29220
aaataaattt gaggttagaga aaagtttgc当地 cttctctttagt ttctgggtcc aatttggtat 29280
atttttagcat agtttc当地 aggtgttgc当地 agaaaaggc aggttttac tgggtctt 29340
gtgttatttcc tcttgc当地 ttccatatttgc当地 ggcatttttgc当地 tccatgccc当地 29400
tgaggagaca ggttataatc当地 tttgttcttcc acctgtatgc当地 attgttctcc tttgttgc当地 29460
tccatctgg gcctctatgg gggactgc当地 cattggccac tggattttgtt atagggttcc 29520
tattatggag ttattataat caagggggaaat ttaaagatgtt ggttcttgc当地 caagatgtt 29580
atgtctctgt tcttgc当地 ttccatatttgc当地 gaaatagaat ttgtttaaag atgtgtt 29640
cattcaacag aagtttcttgc当地 agggcccatttataaggctt当地 attataacttc当地 caccacaa 29700
gtttaatttgc当地 catttgc当地 tccggc当地 gattgtatcat gtttgc当地 ttccatatttgc当地 29760
ctagacagat cccaaatggaa tttgttgc当地 gtagatctt gtttgc当地 ttccatatttgc当地 29820
tcttgc当地 atacaaggta ttaatatttgc当地 aaacaaggtaat ttccatatttgc当地 29880
aaaaaataact tcttgc当地 ttccatatttgc当地 tccacttgc当地 tttgttcttacttcttgc当地 29940
tccatctgg attttacttgc当地 aaaaaaaggc当地 tacttgc当地 tagacaat gtttggattt 29980
aaaatggaaat gtctgaaacg atggagacct gtttgc当地 ttccatatttgc当地 30000
taaaacttgc当地 aaaaacaata cggaaatccaaatgaaat gtttatttttgc当地 ttccatatttgc当地 30060
actgtgttgc当地 gcatcaggat tttgttgc当地 acaaataaaa ttccatatttgc当地 ttccatatttgc当地 30120

tttcatgggg atgaccgact ttaaataaat aattacatga acaggccaag cacagtggct 30180
catgcctgtt atccccagcac tttggggaggc tgaggcggat ggatcacttg aggtcaggag 30240
ttcgagacca gcctggccaa catggtgaaa ccccatctgt actaaaaata caaaaattag 30300
cagggtgtcgt ggcatgcacc ttagtctca gttactttgg aggctgaggc aggagaatcg 30360
cttgaacctg gagggtggag gttgcagtga gcggagatcg caccactgta ttccagctg 30420
ggtgcacagaa cgagactctg tctcaaaaaaaa aaaaaaaaaaa aaattgcagg aacaaactat 30480
ggtcagagct gtgaaaggaa agcaatggca tggagagaaa tggaaacgcgg ggtgaggcga 30540
ggtttctctg gggtcacagt tgggggagg cctgatggat gatggggcac agagcagtgg 30600
gtgcttaggtg gaaggaaggg cgtatgagaa gttaaagatg gaaaaggtga tggaaaagtt 30660
cgagaacaga cagaagagtg tggcttgcgt gtcacatggag ggggcaca gtccatgag 30720
atgaggatgc tgagggaggc aggggcctcc tcatttggca cttataggc catttaaggg 30780
ctttttgttt ttgtggaaatg caaagggttg ctgttggagg gttcagcaa cagagagaca 30840
tggccagact cagtttcat ccctctgggt gtcacatggat tcatacttgcg gatggggga 30900
agagaggaag tggggatcca gttaacgggg tactgctatg gcctaattggaa agcatggact 30960
ggggtgaaga tgggggaggc agggaaaagg ggggtggatac cagcaatgtg ttttggaggt 31020
agaattgaca ggtcttaatg atggaaacacg aagcttgagg gagaagagaa aaccaagtag 31080
aaaccttaggc aggcttagag cgtatgccc ttctctttat aaaagcttga tgatagtagc 31140
tgtggagcac aatatacgac ttcccttgcgt cattttgtat ttgtgatagg attttataca 31200
tggctttttt tttttttttt tttttttctg tttttttttagt atggagttc 31260
attcttgcg cccaggctgg agtgcagtgg tggatcttg gtcactgca acctctgcct 31320
cccagattca agcaattctc ctgcctcagc cttcaagta gctgggatta caggcactcg 31380
ccaccacacc tgctaattt tttttttttagt agtagagacg gggtttccacc atgttggcca 31440
ggctggctt gaaactcctga ctccaggtga tccacctgccc ttggcctcct gaagtgcgtt 31500
tattacgggc atgagccatg gcacctggac ttatcatgac ttttggaaaag ccaggagtt 31560
actgtgactg cctgggggtga tatgttacgt tagacttgcctt ctggggaggag tgagaggact 31620
actctttgtg agtcaagagt ttctgccaag tggatcttgc ttattcagaa ggagagaatc 31680
aaatttgttt tattgtccat ttccacaatgt acattaaagg gaaaggagtg gggaggcggg 31740
ggggtggggg ttgagcatga aatgtcaaaa taacagtggg ttttatctt aagggttggc 31800
atggattta aagaaataga attaattggc tcaggtggat ttggccaagt ttccaaagca 31860
aaacacagaa ttgacggaaa gacttacgtt attaaacgtt taaaatataa taacgagtaa 31920
gtagtaatg ttacatttt tttgaatggc aaggtaacgtt gaatctgca tattttttt 31980
tatgcttctc ttttctttat tagggatca ttatcttctt tctgatcctc attaaacatt 32040
tcattctacc aagaggagtt tggcttactc cgagatgatc tcactttact gttgttattt 32100
caataaaaaat ggatatacca ttgatcatcc ttttgggtgt atcttcagaa ctgaagctat 32160
agagtcattt gctttaaagt gacatgcaaa ttcatgaaat gtcctgtt taaaaaccg 32220
tggcaccaga tagaacctat cattaccac aaaataggtg atcttggaa tggcttagtc 32280
ttaccttctt attttataga tgagggaaact aagatccaga gatgtgaatg gattttgtct 32340
aagataaaaag cttagatggta attgttctt ggttgcgtt tatttataa ggcactgctc 32400
caaaatgcag tgctaaaaaa cagcaatttta ttgttgcgtt taatgggtcc atgggttgc 32460
tgtgctcattc tgacaatttca tcacttgggg tctcagaggg atttgcagtc agtagtcatc 32520
tgaaaccttg actacagcct atcttaggtt ggatatccaa gctggctagc agttgacacc 32580
ggctgtggc tggaaagttca gctgggactg tcaatcgaaa tacctccaca tggcctccct 32640
atggggattt ggccttcttac aacttgggttgc ctgggttca agaaggattt tccccagaac 32700
aagtcatcca aaagatcagg agtggatggc aaggcttctt ttgacctaattt ctgaggagtt 32760
ccagaacgctc actaccatca agttatattt gttaaacaag tcactgaagc cagcttagat 32820
tcaaggggag gccaaatagg ccctaccccg taatttgcgtt ttcttagggta tgagttctaa 32880
gaatattatt tagggactgg tggatgtggc tcacgcctgt aatcccagca ctttgggagg 32940
ccgtggcagg cgatcacct gaggtcagga gttcgagacc agcctcacca acatggagaa 33000
acccctctct actgaaaata caaaatttgc tgggtgtat ggccatgc tggatctca 33060
gcttctcgag aggtcgatc agaagaatttgc cttgaaccccg ggaggcggag cttgtgggtga 33120
gcccagatca tggcatttgc ctccagcctg ggcaacaaaaa gcaactcc ctctcaaaaaa 33180
aaaataaaaaa taaaataataaaataa ctattttaggg aggctgaggat ggtggatca 33240
cttgagccca ggagtttgcgtt acttagcctgg gcaacatgg caaaacttca cctctacaaa 33300
aaatacagta attaggccgg tggatgtggc acgcctgttag tctcagctac ttcaagact 33360
gagggtggag gaccatttgc gcccagtagg tggaggctgc agtggatccat ggtcacacca 33420
ctgcactaca gcttgggtga cagatgaga ccctatctcc aaaaaaaaaaa aaagaatgtt 33480
attcaatttca tggatattata tccaaagaaga tataaattcac agtgcatttca attaacagta 33540
aaaagtttaga acaaacaaaaa tatccagcag taaaagaaatg agtataatata ttttggcttctg 33600
tccctqatc gatggctgtt ttgcagccat taaaatgac tggctggcc aggcatgggt 33660

gctcacgcct gtaatcccag cactttggga ggccaagaca ggcagatcac gaggtcaaga 33720
 gactgaggcc atctggccaa catggtgaaa ctctgtctc actaaaaata caaaaattag 33780
 ctgggcattgg cagcgatcg ctgtatccc agctactgg gaggctgagg caggagaatc 33840
 gcttgaaccc aggaggcgga gtttcgtgt agccaagatc gcggcattgc actccagcct 33900
 gggcgacaaa gcaagactct tctcaaaaaa aatgactggc tgggtgcagt ggctcaggcc 33960
 tgtaatccta ccactttgag aggccaaggc tgggtggatca cttgaggtca ggagtgcgag 34020
 accaacctgg gcaacatgga gaaaccctgt ctctacaaaa aatataaaaaa ctagccaagt 34080
 gtgggtgtgt gtgcctgtgg tcctagctac tagggagct gaggtaggag gatcgctga 34140
 gcccctagggg tggaggttgc agtgcggca cattgcaact gcactccagc ctgggtgaca 34200
 gagtgagacc ctgtctcaaa aaaaaaagga agaatctaaa ataacattat tttaggattg 34260
 tcaaagtatac agtaattttt tttatTTTg caaatttgc tcatataactt taaaacttct 34320
 tgcattaaaa aataaaaattt taaaatgatt attcttcctc atctttgaaa tctccaattt 34380
 atttactgca cttagcatgg aattttctta ggtcttgc acacatccct gtaaaggcctt 34440
 ccaccatttc accttctctg cataagttat cctctttgt tatatttgcc acacattgaa 34500
 aatccctgaat taggtacttc acactgcctg gtttacctag cttgctgcc taaatgtgg 34560
 ttgtttgtga aatacaaaga ttttaacaca aatctaagca aaacataatg tatgatttag 34620
 ctatgaaaaa ttgcactggc tgggtccatt ggctcatgtc tgcaatccca gcactttggg 34680
 aggctgagggc aggtggattt ctagatccca ggagtttgc accagcatgg gcagcgcc 34740
 aaaaccccat ctctacagaa aatagaaaaa attagatggg tgggtgggt tgctccctgt 34800
 gtcccagcta ctcaggagac tgagggtggga gaattgttt aggttagaaag gttgaggctg 34860
 caatgagccca agattgtgcc actgcactcc aacctgggt acagagcaag actctgtctc 34920
 aataaaataa ataaattaat taaaatgaca tcactggcat ttcaagagta ctacagatga 34980
 tttttaaatt gtctgtatgtc tggcattaag tgcgtgcct ttatTTTattt attttttgag 35040
 acagagtctt gctctttgc ccaggctggc gtgcagttgt gcaatcttgc ctcactgcaa 35100
 cctccgcctc ctggatttcaa gcgattctcc tgccctagcc tcccaagtag ctgggattac 35160
 agacatgcgc cactgtgccc agctaaattt tttgtatTTT tagtagagat ggggttcac 35220
 catgttggtc aggctggctc tgaactccctg acctcgatcc ccccccaccc tcgcctccca 35280
 aagtgtggg attacaggcc tgagccaccg cggccggcca ctgcctttta ttttatctt 35340
 agagtgagaa ctgtatgtt tttttcagt atgttcaattt tttcttttgc aatgtctgg 35400
 cttccattct aaaactatgt gagaaccaca gcaatggtt aataaggaa ttagacagt 35460
 tgtctattac atgagggtgtt ttgtgggtgt tatgaggat gtacactgac actgcctatgt 35520
 tccctgttcc ttttaactag gaaggcggag cgtgaagta aagcattggc aaaactgtatgt 35580
 catgtaaata ttgttcaacta caatggctgt tggatggat ttgattatga tcctgagacc 35640
 agtgtatgatt ctcttgagag cagtgattat gatcctgaga acagaaaaaa tagttcaagg 35700
 taactaaaaa taaattctca tagccataat aggatggaa gaaattgtta tttactatgt 35760
 atggccact ggataagct attaatcatc acgattaattt atcacaattc cctctgagag 35820
 acactgttat ctctccatcc cgaaggtaag gagaaggtaa aaatcttgc cttgctcc 35880
 ctctgtgc agacttgctc tcacaaccct ctgttacatc ctcagctgtc tgcaaaatct 35940
 caggttcagc ttccctgact ccattgtttc atggagagcc ttgttcacgt gccggcttca 36000
 gcgaggctg ttttaagtgtt gtcttgcggaa gaggttttta acatataatg gctgcatttg 36060
 ggggctccct ctcagctac caacactttt ctgtccctt cttaggtgt gattgggtgt 36120
 gtgcgtcag agggctcttt tggaaatgtaa ctataaccact tatgtctgggg tgggtggggag 36180
 tggaaatatt ttttaagacca caagctgaga tggggccacc ctcatgtttt atgtcagtt 36240
 agccattgcc aaacaactgg agatcctaaa gagctggcat ctgttttgc aagtccacca 36300
 acctattatg gggacagttcc tctcaactt atcctgaggc caatgggtc ccattcattc 36360
 attttctctt gccccaccc catctccatg tcgtgttaatg gagaacatttca tcatcatttc 36420
 aggagttatt gaccgtcagc atacaggact tcagctttca gcaatttctt ggctacctct 36480
 tcctgttttca aagctgacat atatacaaag aatataaaatg aatattgggg ctaacttaat 36540
 tcagaaaaaa aataaaaacgt ggttagcaaa aaaaaaaaaa aaaaaaaatca agcctccaaat 36600
 ttatgtatct tagtaatttgc tggcacttc tcttagagta cttcccttat ttttttaggt 36660
 ttgtttccctt tttactcttctt cctatttagac tattatcccc gtgacggccaa ggatataatgt 36720
 tctaactgtat tttctcatct cttaggtgcctt tcctatgttta gtagatcaat ggtgaattaa 36780
 aaggtttcaa agttacttta tataataatg aaatttagtt tcctgcattt tattcatgtt 36840
 cctatttcttca tctgttagca atggtgattt cagatcttca gcaatgaaga atgggtggct 36900
 cattttttttt ttcttctctt tttttttttt ttgtttttttt ttgagacgggt gtctcgact 36960
 gtcgcacagg ctggagtgcgt gtggtgcaat ctgggtcact tgcaagctct gctcccgga 37020
 ttcacagtat tctccctgcct cagttctctg agtagctggg actacaggcc cccggccacca 37080
 cggccggctt atttttgtt ttttagtag agacgggatt tcaccgtt agccaggatg 37140
 gtcttgatct ctcgacccatcg tgatccaccc gcctcgccct cccaaagtgc tgggattaca 37200

tgctgtgagcc accgcgccccg gcctttttttttt tgagacagag tcttactcta 37260
 tcgctcatgc gggagcacaa tggcgtgatc tcagcttact gcaatctctg ccttctgggt 37320
 tcaaatgatt ctcgtgcctc atcccccga gtagctgaga ctacaggtgc cgccgcacca 37380
 cacccagcta atttttgtgt ttttagtaga gatgggggtt cgccatgctg cccaggctgg 37440
 tctcaaaactc ctgagctcaa gcaatccgccc agtctcgccc tcccaaggtg ctaggattat 37500
 aggcgtgagc caccgtgc c acccgagtc atattttata aattagctaa acaaataaaag 37560
 ctctggacat ccgggaactt atgattgaaa taaaaaatgg cctattatat ttgattcaa 37620
 atttgttat tatatttaga tttctat tttt gtgacatgtt ttgggggtt tttttttct 37680
 tttttttt tttttgtga gacggaatct cgctctgtca cccaggctgg agtgcagtgg 37740
 cgtgtctcg gctcaactgca agctccgcct accgggttca cgccattctc ttgcctcagc 37800
 ctccccggag tagctggac tacaggcgcc cgccaccacg cctggctaat tttttgtatt 37860
 ttttagtagag acgggggttc accgtggctc cgatctcctg acctcggtat ccggccgcct 37920
 cggccccc aagtgtttt ggggttctt agaagataag gtataagctt taaaaagtt 37980
 atgaaaaact taaaaaagtt ataaaaattt ttttataat ttatattat tttttttttt 38040
 aacatactgt gaattttata cccaggtcaa agactaagt ccttttcatc caaatggaa 38100
 tctgtataa agggacctg gaacaatggg ttgaaaaaag aagaggcgag aaactagaca 38160
 aagtttggc ttggaaactc tttgaacaaa taacaaaagg ggtggattat atacattcaa 38220
 aaaaattat tcatagagat cttaaaggtaa gtggaaaatg tacttttata attgatata 38280
 atataatata gtaattttaa aatataatctt ctcagctggg cacagtggct cacgcctata 38340
 atctcaacac tttgggagc tgaggcaggc agatcatctg aggtcatgag ttgaaaccca 38400
 gtctggccaa catggtaaa ccgtgtctc actaaaaata caaaaattag ctgggcatgg 38460
 tggcgtgcgc ctgtaatccc agctactcg gaggctgagg caggagattc gcttgaacct 38520
 gggaggtgga gtttgcagtg agccaagattt gtgccactgc actccagctt aggtgaagag 38580
 tgagacttgt ctcaaaaaaaa aaaattatata atatataaa aataagatag atagatata 38640
 atttttttctt ctatgtttttt aatagtggttt gattgatagt tatgagaaaa ttgtatctga 38700
 acattttccat gcaaataattt actgtgactg gcacagccaa ctggctgctc tgcccctgtt 38760
 cctccctgcct cctctaagtg actcagctt atttgagagg cagaggggac tctgttact 38820
 gttgttttagt gaatatgggtt ccctaatttc tcagtcattt ctgcgcaggc ctgtcacagc 38880
 tactgggtcc agagtctaat actgtcttgg ttaagcattt caaccccatg attggaaaat 38940
 tgcggtaatc ccggacttggg aaagtgttac atcccttagt attttcattt tcctctggct 39000
 tttatgttcc ggacaaggag tttccctatt ttttacttctt cattaaaatg acagaagggt 39060
 agagacagaa tagcccttca cagccttcc tccattccctt attccctgtg acttgcctaa 39120
 gcctgtcaca agctggccgt cctgaatccctt gtcctggac ctttgctcat gttcttctct 39180
 ctcatggac actttctgc ctgccttctt tgggttgaat tccttactg agcctttctt 39240
 gatcaactctg gaactgcctt tttctgttctt aggcagaagt accttattta tggcttgc 39300
 tgcttatccc accccctctaa aacagcaagg aataaggaat gaaacaaaaa aattccttga 39360
 gagaaaaataag ttcccatata cacagttgtt tattgggttc agagaggaat gaggtagccct 39420
 taaaaggat tgcctccgtg gtctgcccag gggctggatg tctgtatgc tgggtttttt 39480
 agtctgtctg gttccaatata tgcctttctt caatatctga agttgttctt tgaagggtg 39540
 acattgtcag aactatttca aaaggataaa tttttttttt gttatgtttt cactttggg 39600
 taaatcatac atatagttaa ataacaaaata agcacaattt tttctatata aaataattt 39660
 caaataaaatg cagaagtgtt ggcattaaagc tccttagtctt cagaatgaat tagaaaaatt 39720
 ctgactgggtt ctttccactt tacctgccaa ctatgccccca caccgtgtt gcccctgttc 39780
 atggactgtat cttttttttt tgcattttgc agagaatttt tactctggct gcagttgtc 39840
 aagggtcaga ctttattttt cttttttttt tttttttttt tttttttttt tgagacaagg 39900
 tcttgcctttt ttggccaggc tggagtgcag tggcacaatc acggcttattt acaggcttga 39960
 cttccctggc tcaaggagtc ctcccacccctt agcctccctt atagctgggaa ccacagggt 40020
 acaccaccac acctggccat tttttttttt tagagacagg gtctcaccat 40080
 gtttccgagg ctggcttcaa actttttttt tttttttttt tttttttttt tttttttttt 40140
 aagtgttggc attccaggtt tgccttactg caccggccctt caagctttga tactgagact 40200
 tctttcatct tctataactt ttcaggctctt cactactaca gttttttttt tttttttttt 40260
 aagaaaaagat acaatgaagg tttttttttt tttttttttt tttttttttt tttttttttt 40320
 aggtgggtttt gcccggat ggtctttacc taacacagcc ccttttacaa aagtctccaa 40380
 gtgtttacca ctttctgtt gatctttagg aacttagacca aaggcgctgg gaaggacat 40440
 aggggtttttt ggggttgggg cttttttttt tttttttttt tttttttttt tttttttttt 40500
 cttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 40560
 aggtgaagtt tgcattccctt ttatatgtatc tacagccctt tttttttttt tttttttttt 40620
 taactgatta gacaaaatgtt ggcattttttt tttttttttt tttttttttt tttttttttt 40680
 cactctgttg cccaggctgg agtgcagttt tttttttttt tttttttttt tttttttttt 40740

cctaggctca agcaatccctc ccacacctggc ccccccacata gctgggacta caggtgcagg 40800
 ctaccaaggc aggctaattt ttgacatattt gtggagacag gatttgcca tggccctg 40860
 gttggtctcg aactcctgag ctcaagtgtat ctggccacct tggttccca aagtgttggg 40920
 attacaggca tgagccacca taccagctt cttttctt tcttttttc tttttctt 40980
 tttttttt tttgagacag agtctccctt gttgccagg ctggagtgcgt gtggagtgat 41040
 ctcgctcac tgcagccctt gactctggg ttcacagat tctccctgcgt cagccctcg 41100
 agtatctggg attacaggcg cctgccatga tgcccagata atttttgtt ttttagtag 41160
 agacagggtt tcaccatgtt ggcaagggtt gccttggact gatggggcca cgctgtctgc 41220
 ccgcttcagc ctcccaaagt gctgggatta caggtgtac tcaccacgccc ctgcccactt 41280
 tttctttga atgaactaca aaaagtgtatc tgatatttc actagatagc ctcatccagc 41340
 ttagatattt acacggcttc acaaattcaa ttttctgtt ctttaggtca ggtgatagcc 41400
 ttatgtggga cttagcgttt cacttgcattt cctgacatat tcctacacat tgcaacttga 41460
 acatagcata ggaatgtttt ctctccacat ccactccaca tctgtctaca gctttccatc 41520
 tgtattactg gtgttaggtt ccaatctgac tggtaatgtt attctaatcc aactgcta 41580
 tgctgtatga gccgtcatct caagctggct tctcgaaagc tcctccctca gccttccctg 41640
 ggcttatggt ctctccctc ttaggtcctt actaggtagg ccctctcata agtgtttat 41700
 cccgttagt ctgtgtgtt agcctaagat tggtaataaa gtcagccctt ttcaaaaata 41760
 gcaaaatattt aattttctca tcaactaccc tccctgtttt gtgtcttta gaatattgt 41820
 cagtagagct ggggtgtgggt gcctgtggc ccagctactt gggaggctga ggtgggagga 41880
 tcgcttgagc tgaggaagtc aaggctgcag tgagccatga tcacgtccact gaaatccatc 41940
 ctggataaca aaatgagaca ctgtctcaaa aacaaacaaa aataatattt gtcataacct 42000
 cctatgggct gggcgtgggt gctcatgcct gtaacctcag cactttggga ggctgaggtg 42060
 agcagattgc tttaggttcag gagtttgaga ccaatctggc caacatgggtt aaaatctgtc 42120
 tctactaaaa atacaaaaaaa attagccaaat cgttggca catgcctgtt atccctagtc 42180
 ctcgggaggc tgaggcagga gaatttgcattt aacccagggaa gcagagggtt tggtagggcg 42240
 agatcatgcc actacactcc atcctgggtt acagagcggag gctccatctt acaaaacaaa 42300
 acaaaacaaa acacccctt taaaaaaaaaa aatctgtttt aaagaatttgc atggataaaa 42360
 atatttcaga gcttagttt agcttccagt taacttggta tgctttcatg gtggaaaggga 42420
 tgtgtttgtt aagaagtgtt cagaggctt gggaaaagac ccccaagaga aattctgcac 42480
 aggctaattt gcaactattgt tggaaatggc cccattccga gaatctcaaa gttggaaagg 42540
 atcttaagga tggctgttcc agtccctatc agatcatggc tcataattttt caacatttcc 42600
 tcaagtgggtt gttcagccctt atcttgggtt ggggaactgt ctaactccca ttctttggac 42660
 aacactattt ggtatattttt atattttttt gtaatctttt aggtcatttc caccctatag 42720
 tcctggatct tttcccttgg accatgcaga gtgaatccac ttgcacgtg acagctttc 42780
 agatattcga gggcagctgt gcccagagcc acctctgggt tcaagctttaa aatcctact 42840
 tctgtccagg cgtgggtggc catgcctgtt atccctggcac tttgggaggg caaggtgggt 42900
 ggatcatgag gtcaggagat cgagaccatc ctggcttaaca cggtaaaacc ctgtctctac 42960
 taaaaaaaaaaa aaaaaaaaaaaa aaaaaaaaaaa ctggccgggc atgggtggcgg gtgcctgttag 43020
 tcccagctac tcgggaggtt gaggcaggag aatggcatga acccaggagg cggagcttgc 43080
 agtgaaccga gatagcacca ctgcacttca gcttgggtt cagagcgaga ctccggccca 43140
 aaagaaaaaaa aaaaaaaaaaa aatccctgac ttctttcagc tggcattttt aagacgagtc 43200
 atattaaattt ccctgatattt ggcttccatgt gtaagggtaa aggtcttata aataatataa 43260
 aaatagtctt ttctgtatataa aatggatataa tggtaataa gatgttaag ttgttacatg 43320
 taagttaaat tttttttt cataggcaag taatattttt ttagtagata caaaacaagt 43380
 aaagatttggc gactttggac ttgttacatc tctggaaaaat gatggaaagc gaacaaggag 43440
 taagggaaact ttgcgatatac tgagcccaaga acaggtttaagg tctctttccct gtctgtctat 43500
 attttacttc ttttttttgg aaaaattttaa aaagagtataa cactacttat ataattaaaa 43560
 ctgtacagaa gtatataacta aaaattttcc ttaccattct tttcttacccc tattctctt 43620
 atcagtttat tctttatccct ttttagataat ttctgtgtt ataaaaacat acaaacacaa 43680
 atatacaccc agatttttt tacagaaaca tatatatgtt tacattttt caaggactta 43740
 ttttggattt ttgtgactat atagcataat ttctccatat tagttcaaat agatctgcca 43800
 cattttttt ttaacaactg tattatattt caaaatatgg agataccata atttaactat 43860
 ttttttaaat ttaatatttt ttgttgggtt tctttagttt ttttagagac agggtcttgc 43920
 tctgtcaccc aggctggagt gcagtagtat gattttgtt cactgcagcc tcaaaatctt 43980
 gggctcaaggc aatcttccca cctcagccctc ctggatgtt cactgcagcc tcaaaatctt 44040
 cactgtgccc agctaattttt tttttttt attaattttt tattttactt ttttttttgg ttttttttgg 44100
 agacaaggc tcactatgtt tcccaggtt tattttactt ttttttttgc gaagggtt 44160
 tcttttaggtt gtttacaact tcataactt agacatttccctt ctttttttgg ggtcccaaga 44220
 acaaataattt ctgtgataat ctgtgttaga ctttttttgg taaagtgtt 44280

accagtgcatttcaactta attgctgttt aattgtcatt ctaaaaaaaag tgattctaa 44340
aatactgtcc cgtaaaaatg tatgagaata ctgcatcatc atactctcca gtgatcagg 44400
ttgggtatgt tggtgaatta ggagtatctt gctattttag tttgtatccc ccagatccc 44460
agtaaggat gcccctttt catatatttta cttaaacatt ttctgcaaat tctctactca 44520
taccccttcc caatttctca taattaagtt ctcattttct tggatctg taaggaatct 44580
tgatctatat tgggtgttga tcccgatctt gttactata ttatagaatt ttctccctt 44640
atgttactt cttgtttat aatgacattt gtggtaactgc agctttttt tttttttttt 44700
tttttgaga tggagtttttgccttgcac caaggctgga gtgcaatggc atgatctcag 44760
ctcaactgcaaa cacccctgc ctcgggtt caagcaattt tcctgcctca gtctcccaag 44820
tagctgggat tatagggtcc caccaccatg cccagctaa gtttgtatccc tttagaaaga 44880
cggtttcac catgctggcc aggctggctt cttaaactcctg acctcaggta atccacccac 44940
cttggcctcc caaagtgcg ggattacaga cgtgagccac cttaaacccagc actgcagctt 45000
ttaaattgtc atatttatca atacggctgc taggtttctc atttttatccc tggaggctt 45060
tattacaaga ttatggaaat atttttgtt ttactaaca taaaattaa ctgcaattt 45120
aattaactt tggatgttga tgagaaagga atctaactt gtttccccgg tttttttttt 45180
cagttgttca atcaactacgt gttaaagcgt taattatcc aatgtatccc taaggaaaat 45240
tcatagagac agaaaagtgga acagaggta tctggaaagaa gggaggaatg ggaacttctt 45300
gtttaatggg tatagtttctt gtttgggtt gttttttttt atgaaaagtt ctggaaatag atagtggta 45360
tggttatataca acattgtgaa ggttagttat gccactgaat tgtaggcata aaaatggta 45420
aaagggtaaa tttatgtt gttctatccc accacaataa aatattatccc tttttttttt 45480
aaaattccca cacattcata gatgtgttcc tggacttttgc tctggatccc taatttattt 45540
tatatttctc tctttatatac tttttttttt agattatttgc agcattataa actaggctt 45600
agtatttgcgaa cagcaggacc tgccacattt ttcttcattt taaaatgtt ctcagctt 45660
cacatttaca attccaaatg aactctgttca tcacattgtc atcttcata actgggtttt 45720
agggttttgcgat agcaatttgc tttttttttt gttttttttt gttttttttt gttttttttt 45780
tatatttgcgat atttctccaa aatttgcgat ttcttcact tttttttttt tttttttttt 45840
cagttttgcgat cagactatgc tttttttttt gttttttttt gttttttttt gttttttttt 45900
ataccaagggtt tttttttttt gttttttttt gttttttttt gttttttttt gttttttttt 45960
tttgcctctga gtttgccttcaat cttttttttt gttttttttt gttttttttt gttttttttt 46020
caactggccgc tttttttttt gttttttttt gttttttttt gttttttttt gttttttttt 46080
gcttcagactt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt 46140
caaggcaatgg tttttttttt gttttttttt gttttttttt gttttttttt gttttttttt 46200
gcaatcatac aacccatccatc agaggccattt ttatatactt gttttttttt gttttttttt 46260
atatacgatgg agaggatggatg agattttttt gttttttttt gttttttttt gttttttttt 46320
atataattttt tttttttttt gttttttttt gttttttttt gttttttttt gttttttttt 46380
gtggcacaat catagcttccatc cactggccgc tttttttttt gttttttttt gttttttttt 46440
tgcctcagcc ccttcagttt gttttttttt gttttttttt gttttttttt gttttttttt 46500
ttttttttt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt 46560
tgggtttttt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt 46620
acggcccttgc gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt 46680
tgcttataaa atgagatttcc atgcttgcac cttttttttt gttttttttt gttttttttt 46740
tcggccattt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt 46800
aaaaaaagaaa agaaaatttccatc tttttttttt gttttttttt gttttttttt gttttttttt 46860
atataatctt tttttttttt gttttttttt gttttttttt gttttttttt gttttttttt 46920
catttttaag tttttttttt gttttttttt gttttttttt gttttttttt gttttttttt 46980
caccatacat ccacagattt tttttttttt gttttttttt gttttttttt gttttttttt 47040
aactccattt tttttttttt gttttttttt gttttttttt gttttttttt gttttttttt 47100
tttgcattttt tttttttttt gttttttttt gttttttttt gttttttttt gttttttttt 47160
ggcttattttt tttttttttt gttttttttt gttttttttt gttttttttt gttttttttt 47220
tctttttttt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt 47280
ttatccatca atggacactt tttttttttt gttttttttt gttttttttt gttttttttt 47340
gatgaacatg gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt 47400
tttgaatgtt tttttttttt gttttttttt gttttttttt gttttttttt gttttttttt 47460
cctattttt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt 47520
ttcattttt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt 47580
tgagacttca gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt 47640
aaatatagaa cacaataggc tttttttttt gttttttttt gttttttttt gttttttttt 47700
tgcattctgtt atgcttgcctt tttttttttt gttttttttt gttttttttt gttttttttt 47760
ttttttttt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt 47820

gtggctcatg cctgtaatcc caacactttg ggaggctgag gtgggcagat cacctcaggt 47880
 caagggttt gagaccagcc tggccaagat gttgaaactc catctccact aaaaaaaacaa 47940
 aaatacagaa atacaaaact acaaaaatga gccaggcgtg gtggcacgtg cctggagtc 48000
 cagctactct ggaggctgag gcaggagaac tgcttgaacc tgggaggtgg gggctgtgt 48060
 gagccgagac cacgccactg cattccagcc tggtgacagc gggactccgt ctcaaaaaaa 48120
 aaaaaggcaa cattttgtt aggaacaatt tatacagat aaaaatgcaca gatcttaagt 48180
 gtatatttt tcgaaaaatgcatac acctctgtaa ctatataagac tataaagata 48240
 tagaacattt tgctccctca agctcccttc cagtcagtg ctcctccca ctgatcagaa 48300
 gaaaccagca ctctgagttc tatcaccata gcttagttt tcccgaaaaa gaccctcata 48360
 tgaatggaat catacagtag gtactctttg tatttaattt cttcattcaa aataatatct 48420
 tctgaaaaa ctttggcttgc cataccagca gagaattcct ttttattgtt gaggcgttagt 48480
 ccatgtatg aatatgccac aacatgtta tccattttc tgggtggc ctttgagttg 48540
 ttccagttt tggatattt tgaataaata cgctatgaac agttgcaatg caagccgcct 48600
 actgggtgct attttactg ctttacactgc tgcacatcttac ttcacaaatc aaactctgtg 48660
 gttgatactg ttgttatcct tgggttataa ctgagattt tccatgttg atcgtaatt 48720
 tacacagagg attcagctat tcggcggtac agatttgaac ctggcgttc agactccaca 48780
 gattttgtca ataaaatagac attgttttggt ggtgttaagat gtttggtca aataactttt 48840
 ttggcttta gaaggctgga tatttatgtt agggacataa caaaggtaaa tctattttgg 48900
 tctctttaga tttcttcgca agactatggaa aaggaagtgg acctctacgc tttggggcta 48960
 attcttgctg aacttcttca tggatgttgc actgcttttgg aacatcaaa gtaaaaattt 49020
 tctcaaaagaa agaattaaac aagaaaaattt actgactacc accttcagag tgctgctgca 49080
 gacagtttcc gcccacgt gaggatgggc ttgagcatat tagatctga ctgcaaatga 49140
 aatatgaatt ttctgtctt caaggtttgg cagagaccaa acactttttt aaagacaaaa 49200
 aactttgatc ttccctgaa ggtgttacat ctcataagac ttgttaagact tgcagtcag 49260
 taacattttt ttgattgttgc gctttgttgc agacactgtg ctaagtgttgc taagggttgc 49320
 aaaaataaaac aagccttggc tggcgccgtt ggctcacccc tgaatccca gctttgagag 49380
 gccaaggcag gcagatcaact tgaagtcagg tggatgttgc cagcctggcc aacgtgtga 49440
 aatctcatct ctactaaaaa tacaaaaattt agctgggtgtt ggtgttgcac acctgtatc 49500
 ccaactactc agggggctga ggcaggagaa tgccttgcac ctgggaggcggc gaggttgcag 49560
 tgagccaaga tcacaccact gcactccagc ctgggtgaca gagtgacatt ccattctcaa 49620
 ataaaataat gaataaagcc ttgttcttca ggagcttattt ttctaaaagg gaagataata 49680
 taagagaatg ccataagcat tttaggagaa ggcatgaagt ctgttgcac agctgggagg 49740
 gagatcttc cagctgttgc gacttaggtt tcatggagac atctaagctg ggctctgaag 49800
 gatctgttgg ctcttaatag tccaaaacag aaaagttgtat tctagcatgg aggccggaaat 49860
 gtacagagtg tattttggc cagcaggcgtt tgaatgttgc attggagtttataagtaca 49920
 aggaagtagt ggttgggttgc gctagaaaga taggttggc taacttgagg aaaaatgtg 49980
 gaccccttg cttagacagt gggagtcac taaaggcagt aggcaagtgg atatccact 50040
 cttttttttt ttttttttga gatagagttt cacttttattt gcccaggctg gagtgcaatg 50100
 gcgcgatctt ggctcaactgt aacttcttgc tcccaagggttca aagcaatttct cctgcctcag 50160
 cctcccaagt aactgggactt acaggcgttgc accaccatgc ctggtaattt tttttgttatt 50220
 tagtagagat ggggtttcac catgttggc aggctggctt cgaactcctg acctctggca 50280
 atccacccgc ctcggccctcc cagagtgttgc ggattacagg tggatgttgc tgcaccaggc 50340
 tggatattctt actcttacgc tcaggaaagg gaacttttctt ggagtcaata accttacct 50400
 ctgtaaaaca tttagaaatgttgc cttatcttgc agggttccaa aatgcatgaa gggagattgt 50460
 aaagatgttgc cacttaacac ttcatgttgc ttttttttttgc aatgcaagga tggatgttgc 50520
 gtgttaggaga gaggaaatcc tgcttgcattt ttggctaaag agactttccc aaaaatctg 50580
 gaaatatccctt acatttcagg tatttcttgc cttttagtttgc ttttttttttgc cccaaatgttgc 50640
 taatttccctt atatacaccatc atcattttttt tttccatgttgc ttcacagacc tacggatgg 50700
 catcatctca gatataatttgc ataaaaaaaaga agtaagact tggatgttgc ttttttttttgc cagaatttttgc 50760
 tttatttccctt ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 50820
 acagaaaattt ctctcaaaaga aaccttgcatttgc ttttttttttgc ttttttttttgc ttttttttttgc 50880
 ctgtactgttgc tggaaagaaaa gcccaggagaa aatgaaacga cacacatgtt agagcccttc 50940
 tgaaaaatgttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 51000
 aatataatgttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 51060
 taatcttttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 51120
 ttacttttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 51180
 ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 51240
 gtttggatgttgc aatgacacacatgttgc ttttttttttgc ttttttttttgc ttttttttttgc 51300
 gtttggatgttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 51360

-22-

ctc当地actcc tgacctcaag taatccacact gcctcgccct cccaaagtgc tgggattaca 51420
 gggatgagcc accgcgcccgc cctcatctc tttgttctaa agatggaaaa accacccca 51480
 aattttctt ttatactatt aatgaatcaa tcaattcata tctatttatt aaatttctac 51540
 cgcttttagg ccaaaaaat gtaagatcgt tctctgcctc acatagctt caagccagct 51600
 ggagaaaat ggtactcatt aaaaaaaaaaaa aaaaaaagtga tgtacaacca cttcggaaaa 51660
 caatttggca ttatcttagta aagttgaatc catgtataacc cacatagcta tcaattctat 51720
 tcctacatac gtgcttacaa gaatgtccat aaaaccctgt ttataatagc caaaagaaca 51780
 gggacaaccataatgcaca tcaaaaagaag aatggattaa aaaaattata ttcacacaca 51840
 ggagtactat atagtattga aaacaattga agtacagcta aatgtataaa cgtaacacaa 51900
 tacaactctc agaaacataa tgtaagcga acaaaggcagg ttttcagaaa atatatgcag 51960
 aataattcca tttatataaa gttccagac atgaaaaact aaatcatttt gtataaaaaa 52020
 cccaaacaaat gtgatgagac aataatggga aggaaggaa tgagaaatat taaattctgg 52080
 atgggtggtt tctttgaggg aggggaatga tggatggact ttcaaaaggtt 52140
 atggtaactt ccttaagctg gatggtaggt ccactagtgt ttgtcgtata gttataaccc 52200
 ttatcttaaa tacatttgtt atctattgtt acaaccat taaagacaac cgtgctgtaa 52260
 ggcagtagct aaaaaacagaa aatagtccat cgggaagggt aagatggctt tctgctgagc 52320
 acaggggctag aagtgcacagc ccagtgggccc ttccaactat atgccagggt gttagatgag 52380
 tagagaggag accacccagg aagtctggac aaggggctg gcatgagctc tggagaagat 52440
 atatttgggg aacatggggg atgcttagttt gttgtcctga attgctgttag agaagataat 52500
 ttaaattgca tcttagaaga cgaccctgag ggtgaatttc aacttagggc aattgtttta 52560
 gtttgggtt tattgggttta aatggatact tgaagctgga taatttataa gggaaaagaga 52620
 tttatatgac ttacagtctgcaggctgttca aagaaaacat ggcaccagca tctgcttctt 52680
 ccccccggctgc ttccactcat ggtggaaagggt gaagggggagc cggatgtgca gagatcatat 52740
 ggcaagagag gaagcaagag agcgaggagg aagggtgcag gctttttta aataaccggc 52800
 tcttgaggga actaatagat tgagaactcc ttgttctcc tccccagcac accccaccccc 52860
 cagggacggc attaatgtat tcatgagggg tcttccccca tgacccaaac acctcccatc 52920
 aggccccacc tccaacactg ggatcaaatt tcaacatgag atttggggg acaaacatgc 52980
 aaactatagc agcaaccaggc 53000

<210> 11
 <211> 508
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (1)...(508)
 <223> n = A,T,C or G

<400> 11
 aggatacgg aagaagaaaat ggctgggtat ctttcagcag gtttcttcat ggaggaactt 60
 aatacataacc gtcagaagca gggagtagta cttaaatatc aaganctgcc taattcagga 120
 cctccacatg ataggaggta ggttgcata aaaaatgata tggcagccat aaanaatgat 180
 gagttcatgt cctttgttagg gacatggat aagctggaaa ccattattct cagcaaacta 240
 tcgcaaggac aaaaaaacc aacaccgcattt gttctcaactc ataggtgaga actgagcaat 300
 gagaacacat ggacacagga aggggaacat cacacaccag ggactgttgtt ggggtggggg 360
 gaggggggag ggatagcatt aggagatata cctaatgcta aatgacgagt taatgggtgc 420
 agcacaccaa catggcacat gtatacatat gtaacctgca cgttgcac atgtacccta 480
 aaacttaag tataataata ataaaatt 508

<210> 12
 <211> 492
 <212> DNA
 <213> Homo sapiens

<220>

- 23 -

```
<400> 12
accagtttct ggagcaaatt cagttgcct tcctggattc gtaaattgta atgacacctaa 60
agcttttagca gttcttccat ctgactcagg tttccttttc tggcggtctt cagtatcaac 120
atccacaccc ttccatgttgc tttggacaa agcttccaac caggtacaag 180
ctgtcttcca aatttagcac tcagaaaagt ggcatcatct aagtcaatta catgcaaatt 240
ttttggctaa tttcttgtgt atgttaaatg ggtcacaaca tgacttctgt aaatcctcaa 300
atctgtcaat gtaaattttt acatgatgaa agcaaattgt attgttccca gaaagtgtca 360
ttccagttct aagttgaagt aaaagcatac catttgcatttgc caattcttgc aaagtcttaa 420
aacctgtgtg acgagtatag taggttttat ggcactcatt tgttagtacga agctggactc 480
caactqaaca tg 492
```

```
<210> 13
<211> 458
<212> DNA
<213> Homo sapiens
```

<220>

```
<210> 14
<211> 20
<212> DNA
<213> Artificial Sequence
```

<220>

<223> Antisense Oligonucleotide

<400> 14
caagtgtgga gctgaatgcc

-24-

<210> 15
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 15
ctgtggttctt accaagtgtg

20

<210> 16
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 16
cgtgcctgtg gttctaccaa

20

<210> 17
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 17
tctatgcttg tcgtgcctgt

20

<210> 18
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 18
gacctcgatg cctcgatgaa

20

<210> 19
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

- 25 -

<223> Antisense Oligonucleotide

<400> 19

tatgatagcc agggtctcct

20

<210> 20

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 20

ccagcgaaga ctaaggtcta

20

<210> 21

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 21

ataccagcga agactaaggt

20

<210> 22

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 22

gctccagaaa ctggtaaaag

20

<210> 23

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 23

caaatccagg aaggcaaact

20

<210> 24

-26-

<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 24
cagagaagca aacctgagtc

20

<210> 25
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 25
aaatgcacgc agataatcac

20

<210> 26
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 26
tccaaaatgc acgcagataa

20

<210> 27
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 27
ttcccgatc ctgggtggaa

20

<210> 28
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 28
atcaccagcc atttcttctt 20

<210> 29
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 29
gcagttcttg atatttaagt 20

<210> 30
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 30
aggtcctgaa ttaggcagtt 20

<210> 31
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 31
ataacttgaa atgtaaacct 20

<210> 32
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 32
tctattataa cttgaaatgt 20

<210> 33
<211> 20

-28-

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 33

ccttcacacctt ctggaaatc

20

<210> 34

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 34

tgatctacct tcacaccttg

20

<210> 35

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 35

agctaatttg gctgcggcat

20

<210> 36

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 36

tcaacagcta atttggctgc

20

<210> 37

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

-29-

<400> 37
gaattcgttg ttgtcaataa 20

<210> 38
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 38
gataatcctt ctgaagaatt 20

<210> 39
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 39
acactgttca taatttacag 20

<210> 40
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 40
ataatgaaat ccttctggcc 20

<210> 41
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 41
cctgtaccaa tactatattc 20

<210> 42
<211> 20
<212> DNA

-30-

<213> Artificial Sequence
<220>
<223> Antisense Oligonucleotide
<400> 42
tagtagaacc tgtaccaata

20

<210> 43
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide
<400> 43
cctgttttagt agaacacctgta

20

<210> 44
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide
<400> 44
tgcttcctgt ttagtagaac

20

<210> 45
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide
<400> 45
taaagagttg ctttgggact

20

<210> 46
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide
<400> 46

ttcagaagcg agtgtgctgg

20

<210> 47
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 47
ccttcagatg atgattcaga

20

<210> 48
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 48
gtcactgtta gaatttatct

20

<210> 49
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 49
gaactgttta aactgtcact

20

<210> 50
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 50
tgccaaagat cttttgcct

20

<210> 51
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 51

tctttcatgt caggaaggtc

20

<210> 52

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 52

aaaacttggc caaatccacc

20

<210> 53

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 53

ttgcttgaa aacttggcca

20

<210> 54

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 54

ctgtgtttg ctttggaaac

20

<210> 55

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 55

gtttaataac gtaagtcttt

20

<210> 56
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 56
ctccgccttc tcgttattat 20

<210> 57
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 57
tttatacag aattccattt 20

<210> 58
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 58
tgttccaagg tccctttatc 20

<210> 59
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 59
agatctctat gaattaattt 20

<210> 60
<211> 20
<212> DNA
<213> Artificial Sequence

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 60

tattacttgg cttaagatct

20

<210> 61

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 61

tactaagaat atattacttg

20

<210> 62

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 62

gcgaagaaaat ctgttctggg

20

<210> 63

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 63

acttccttcc catagtcttg

20

<210> 64

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

-35-

<400> 64
aattagcccc aaagcgtaga 20

<210> 65
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 65
gatgttcaa aagcagtgtc 20

<210> 66
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 66
aactttgatg tttcaaaagc 20

<210> 67
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 67
ctgtaaaaaa ctttgatgtt 20

<210> 68
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 68
gagtaatttc tgtagaagag 20

<210> 69
<211> 20
<212> DNA

-36-

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 69

tgagagtaat ttctgttagaa

20

<210> 70

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 70

gcttttcttc cacacagtca

20

<210> 71

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 71

gaaggggctct aacatgtgtg

20

<210> 72

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 72

gatacttttt cagaagggt

20

<210> 73

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 73

aaggtaaata tctattgata

20

<210> 74
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 74
ctgtttctgc agaaagatta

20

<210> 75
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 75
atgttttga agcaaaaaga

20

<210> 76
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 76
ttgattcatt aatagtataa

20

<210> 77
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 77
gcggtagaaa tttaataaaat

20

<210> 78
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 78

ccagctggct tgtaagctat

20

<210> 79

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 79

tttaatgagt accatatttc

20

<210> 80

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 80

tatgagcaaa ctgaaaattga

20

<210> 81

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 81

attgacttag atgatgccac

20

<210> 82

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 82

gttgaatgta aaactcaaat

20

<210> 83
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 83
cttggattgg gagcaggcag 20

<210> 84
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 84
aactcctgac ctcaggtgat 20

<210> 85
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 85
ctcaagtcca tcatctccca 20

<210> 86
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 86
ttgtccttgc gatagttgc 20

<210> 87
<211> 20
<212> DNA
<213> Artificial Sequence

-40-

<220>

<223> Antisense Oligonucleotide

<400> 87

ccttcctgtg tccatgtgtt

20

<210> 88

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 88

tgcacccatt aactcgtcat

20

<210> 89

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 89

tctggaaaca atacaatttg

20

<210> 90

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 90

caaatgagtg ccataaaacc

20

<210> 91

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 91

aatgccaaat tgtttccga

20

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
20 March 2003 (20.03.2003)

PCT

(10) International Publication Number
WO 2003/022222 A3

(51) International Patent Classification⁷: A01N 43/04, C12Q 1/68, C12P 19/34, C12N 15/63, 15/88, C07H 21/02, 21/04

(21) International Application Number:
PCT/US2002/028870

(22) International Filing Date:
11 September 2002 (11.09.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/953,611 13 September 2001 (13.09.2001) US

(71) Applicant: ISIS PHARMACEUTICALS, INC. [US/US]; 2292 Faraday Avenue, Carlsbad, CA 92008 (US).

(72) Inventors: WARD, Donna, T.; 41349 Magnolia Street, Murrieta, CA 92562 (US). WATT, Andrew, T.; 1500 Shadowridge Drive, Apartment 154, Vista, CA 92083 (US).

(74) Agents: LICATA, Jane, Massey et al.; Licata & Tyrrel P.C., 66 E. Main Street, Marlton, NJ 08053 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CI, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, IU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:
3 February 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2003/022222 A3

(54) Title: ANTISENSE MODULATION OF PROTEIN KINASE R EXPRESSION

(57) Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Protein Kinase R. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Protein Kinase R. Methods of using these compounds for modulation of Protein Kinase R expression and for treatment of diseases associated with expression of Protein Kinase R are provided.